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ABSTRACT  
PRECLINICAL EVALUATION OF GOLD-BASED CHEMOTHERAPEUTIC CANDIDATES 
FOR THE TREATMENT OF METASTATIC RENAL CANCER  
by  
Benelita Tina Elie 
 Advisor: Dr. Maria Contel, Ph.D. 
Renal cell carcinomas (RCCs) remain a significant health concern in the United States 
because of a lack of effective treatment. To date, RCCs account for 2.4% of all cancer deaths in 
the United States, and about 14,970 people will die from the disease in 2018, mostly of advanced 
or metastasized RCCs1,2. Mutations in metabolic pathways are characteristics of RCCs, including 
changes in redox metabolism, deregulation of proteolytic factor expression, and inflammation. 
These molecular events promote tumor vascularization, growth, invasion, and metastasis, which 
often correlate with a poor prognosis. Many pharmaceutical avenues have been explored, including 
cytotoxic chemotherapeutics, biologics targeting cellular pathways, and immune therapies 
administered as mono- or combination therapies; all with very modest success in treatment of the 
advanced disease, and most are associated with significant adverse events3,4.   
The absence of viable treatment options has led to a resurgence of interest in 
unconventional metal-based drugs that have shown some potential in the treatment of RCCs5–8. 
The conception of molecules containing two different metals with known anticancer properties to 
potentiate their cytotoxic effect is recent, and studies suggest that this approach may be 
v 
successful9,10. In our group, a series of heterobimetallic compounds containing gold-titanium or 
gold-ruthenium were synthesized and progressively modified to optimize their stability,  
bioavailability, and cytotoxicity 11–13. After screening a series of novel bimetallic complexes and 
their monometallic moieties against an array of cancerous cell lines, we were able to substantiate 
our assertion that gold drives the potent efficacy of the complexes. From these screens, three 
promising candidates emerged: (gold-titanium) Titanocref and Titanofin and (gold-ruthenium) 
RANCE-1. For those compounds, mechanistic and efficacy studies were carried out in vitro and 
in a mouse model of RCC. We found that our novel gold-titanium and gold-ruthenium compounds 
were highly cytotoxic to ccRCC cells, were selective for tumor cells, and inhibited molecular 
markers associated with advanced ccRCC malignancies such as invasion and angiogenesis at 
subtoxic concentrations. In vivo the complexes induced significant tumor shrinkage in the case of 
Titanocref and Titanofin or exhibited chemo-static effects in the case of RANCE-1. We also 
obtained pharmacokinetic and pathology reports indicating that the compounds were deposited in 
tumors and that they caused no chronic systemic toxicity. This body of work from my doctoral 
research, indicates that these three novel metallodrug complexes are viable candidates for further 
preclinical development.   
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CHAPTER 1 
BACKGROUND AND SIGNIFICANCE 
1.1 Kidney cancer 
There are multiple types of kidney cancer. In adults, renal cell carcinoma (RCC) is the most 
common, making up about 85% of diagnoses, and in that population, 70% clear cell RCC (ccRCC) 
phenotype; papillary, chromophobe, ductal, and medullary kidney cancers make up less than 15% 
of adult diagnoses 1–4. Approximately 15000 people (10,000 men and 5,000 women) are expected 
to succumb to kidney cancer in 2018, and an approximate 63,340 new cases will be diagnosed, 
largely in individuals over 64 years of age or with known risk factors (Table 1.2); in about 30% of 
new diagnoses, the cancer will have already metastasized 2,4. ccRCC are renal cortical tumors 
distinguishable by hyperproliferating cancerous epithelial cells with clear cytoplasms in a compact 
mass enlaced by an extensive vasculature network. These cancers develop in the proximal renal 
tubules of  the kidney, through which blood is filtered 5. Clear cells are stratified by rate of growth 
from slow growing (grade 1) to fast growing (grade 4), as well as their location relative to the 
kidneys boundary (Figure 1.1) 1,5. 
Table 1.1. Kidney cancer 
x Lifetime risk of kidney cancer is approximately 1:48 for men, 1:83 for women. 
x Projected deaths due to kidney cancer for 2018 is 14 970 people (10 010 men and 4 960 women) 
x Predicted kidney cancer diagnosis for 2018 is 63 340 (42680 in men and 22 660 in women) 
x RCC death rates dropped by about 1% annually due to early detection because of advanced imaging tests 
including CAT scans and MRI, which detect cancers that would have previously not been detected. 
x The most common kind of kidney cancer is the ccRCC which form in the cells lining the small ducts in 
the kidney which filter the blood and produce urine. 
x There are two subtypes of renal cell carcinoma, clear cell carcinoma the most common type representing 
approximately 92 percent of renal cell carcinoma and papillary carcinoma which accounts for about 8 
percent of cases.4 
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            6,7 
 
Figure 1.1. Diagram of the kidney indicating stages of disease progression and treatment 
options.   
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Table 1.2 Risk factors  
 
 
 
 
 
 
1.1.1 Treatment options  
When detected early, most cases of kidney cancer can be cured with an approximate 5-year 
disease-free survival (DFS) rate of about 95 percent 4,8,9. However, because efficient treatment 
options for advanced stage and metastatic RCC (mRCC) are lacking, the rates of 5-year DFS is 
about 12 percent when the cancer has spread beyond the kidney capsule and into surrounding and 
distal tissues 4,10,11. Hence, the recommended courses of treatment are stage specific. Surgery is 
usually the preferred intervention for small and localized tumors3. The introduction of 
pharmacological interventions such as chemotherapy, targeted therapy, or immunotherapy is most 
often reserved for advanced stages of ccRCC (Figure 1.1). Also, participation in clinical trials is 
greatly encouraged for patient with metastatic disease 12. 
 
 
 
Risk factors 
x Old age. The incidence of kidney cancer is highest in individual 64 year and older.  
x Tobacco Smoking.  
x Obesity. 
x Hypertension.  
x Treatment for kidney failure such as chronic dialysis. 
x Inherited genetic syndromes such as von Hippel-Lindau disease, Birt-Hogg-Dube 
syndrome, hereditary papillary renal cell carcinoma or a family history of renal cancer. 
x Family history of kidney cancer. Unrelated to genetically inherited syndrome. 
x Ethnicity. In the United States, African Americans and American Indians/Alaska Natives 
have higher rates of kidney cancer than whites. 
x Occupational exposure such as exposure to asbestos, cadmium, or certain herbicides. 
x Chronic misusing  of some pain medicines prescribed or over the counter.                     2,4 
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1.1.2 HIF-α, VEGF, and the PI3K/Akt/mTOR pathway 
Initially, tumors are not vascularized and thus rely only on the diffusion of oxygen from 
the surrounding healthy blood vessels. Angiogenesis, the emergence of de novo vasculature from 
adjacent blood vessels, is an adaptive trait in response to low oxygen conditions, which is promoted 
by cancer cells to initiate oxygen supply essential for the continued growth of solid tumors 13. 
Hypoxia-inducible factors (HIFs) are principal regulators of angiogenesis by controlling the 
expression of genes associated with angiogenic signaling, amongst which VEGF-A, angiopoietin, 
placental growth factor (PGF), and platelet-derived growth factor (PDFF). 14,15.  The synthesis of 
cell cycle proteins such as cyclin D and HIF-α are increased when their upstream regulator, mTOR, 
is activated 16. In this context, the activation state of mTOR determines whether the tumor 
undergoes proliferation, survival, and angiogenesis. Because the activation of HIF-α, VEGF, and 
the PI3K/Akt/mTOR pathways consists of multiple diverging yet interconnected kinase cascades, 
they present a target-rich druggable therapeutic ecosystem that has driven RCC therapy 
development for the past twenty years. 
 
1.2 Pharmacological interventions 
1.2.1 Chemotherapy  
Chemotherapy broadly serves to kill tumor cells through cytotoxic arrest of growth or 
division, thus priming the cells for apoptotic death. however, healthy cells are also affected 
indiscriminately. While cytotoxic chemotherapy is usually the standard of care for cases of renal 
sarcoma and ductal renal cell carcinoma, it has limited efficacy against ccRCC 17. In the last two 
decades, treatment of advanced ccRCC has undergone a shift, distancing from non‐ specific 
therapies such as cytotoxic chemotherapies in favor of therapies that target cancer-specific or 
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tumor microenvironment-specific markers, or activate the immune system in the tumor 
microenvironment, or a combination therein 18.  
Though ccRCC is often characterized by resistance to most chemotherapy, we know now 
that there is merit to each form of intervention and most often, combining agents from each of 
those classes potentiates treatment efficacy. The United States Food and Drug Administration 
(FDA) has a list of drugs approved for the treatment of RCC (Table 1.3) and the rationale behind 
each treatment choice lies in the etiopathology of ccRCC 19. 
 
Table 1.3. FDA Approved Drugs for Kidney Cancer Treatment 
June 2018, NCI : https://www.cancer.gov/about-cancer/treatment/drugs/kidney 
Immunotherapy Lenvima (Lenvatinib Mesylate) Bevacizumab (Avastin®) 
Yervoy (Ipilimumab) Inlyta (Axitinib) Pazopanib (Votrient®) 
Opdivo® (Nivolumab) Nexavar (Sorafenib Tosylate) Chemotherapy 
Avastin (Bevacizumab) Pazopanib Hydrochloride Gemcitabine (Gemzar) 
Proleukin/Interleukin-
2/IL-2(Aldesleukin) Sorafenib Tosylate Doxorubicin 
Afinitor (Everolimus) Sutent (Sunitinib Malate) Capecitabine (Xeloda) 
Torisel (Temsirolimus) Cabometyx (Cabozantinib-S-Malate) fluorouracil (5-FU, Adrucil) 
Votrient (Pazopanib 
Hydrochloride) Angiogenesis Inhibitors Vinblastine 
  Axitinib (Inlyta®)   
 
Thus far, clinical chemotherapy regimens are administered as mono- or combination 
therapies.  The most extensively studied monotherapies (single organic agent chemotherapies) for 
ccRCC include vinblastine, gemcitabine, capecitabine, floxuridine, and 5-fluorouracil (5-FU) 20. 
Vinblastine in monotherapy did not yield promising results; However, responses to vinblastine 
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were not improved with the addition of p-glycoprotein efflux channels inhibitors which aim at 
prevent the cancerous cells from expelling the chemotherapeutic agents from the cytoplasm 21. 
Gemcitabine, with a response rate of only ~10%, demonstrated modest activity in monotherapy 
with a progression free survival period of about four months and a 12 month average 
overall survival 22,23. 5-FU was the most effective monotherapy, with a response rate of ~20%, and 
a 15 months average overall survival. Monotherapy response to the pro-drug capecitabine was 
similar to that of 5-FU 22. Thus, 5-FU and capecitabine are the most effective monotherapies within 
their limited spectrum. 
Although chemotherapy is effective against many cancers, ccRCC are often chemoresistant 
17. To circumvent resistance, combinations of chemotherapeutic agents have often been used in the 
clinic. In some patients, the combination of standard of care cytotoxic chemotherapeutic agents 
such as gemcitabine with capecitabine or 5-FU has temporarily shrunk tumors 22. A combination 
of a prodrug 5-FU called Tegafur, along with an inhibitor of dihydropyrimidine dehydrogenase, a 
prognostic marker for 5-FU therapy response, yielded a response rate of 24%, and a 2-year DFS 
in 67% of patients 24. The moderate response rates observed following fluoropyrimidine treatment 
prompted investigation of the efficacy of a combination of fluoropyrimidine with  gemcitabine and 
5-FU in individuals with metastasized ccRCC (mccRCC) 22. The combination of capecitabine and 
gemcitabine led to similar results 22 in that  no increase in disease free survival (DFS) was 
observed. In an attempt to increase response Taxol/taxanes, thalidomide, or metal based 
chemotherapeutics such as cisplatin, oxaliplatin, were then added to the combination of 
gemcitabine and 5-FU, however, all failed to improve outcomes and resulted in significantly 
increased toxicity and side-effects/ adverse effect (AEs) 22,25. Though we must note that AEs of 
chemotherapy are often dose dependent, and do not outlast the treatment; they include increased 
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risk of infection, gastrointestinal distress, and hair loss. In sum, both mono- and combination 
therapies of cytotoxic chemotherapy agents have proven only modestly effective with mccRCC 26–
29 and currently do not represent a viable treatment option for most patients.  
 
1.2.2 Immunotherapy 
1.2.2.1 Interferons (IFN-α) and interleukins (e.g. IL-2) 
Immunotherapy seeks to exploit natural immune-modulating agents to potentiate the anti-
cancer immune response of the patient 30. The cytokines interleukin-2 (IL-2) and interferon-α  
(IFN-α) are two such agents that are intimately associated with ccRCC therapy 7. IL-2 also called 
T-cell growth factor, is a cytokine produced by activated T cells known to increase proliferation 
and activate cytotoxic T-cells, natural killer (NK) cells, and monocytes, as well as stimulating 
hematopoiesis 31. IL-2 also promotes B cell proliferation and antibody production  to further assault  
cancer cells 32. The antitumor activity of IFN-α is mediated by a series of mechanisms including 
immunomodulation, promoting anti-proliferation signals, inhibition of angiogenic signaling, 
regulation of differentiation, crosstalk with growth factors, and other gene expression modulation 
33. IL-2 and IFN-α have been the most evaluated immunotherapies for treatment of ccRCC, but 
have yielded very modest overall response rates and low DFS advantages, and are coupled with 
significant toxicity, which renders them less than ideal for clinical use 7.  
 
1.2.2.2 Additional immunomodulators 
In addition to cytokines, there are cell-surface modulators of immune activation that can 
affect anti-cancer response. For example, the programmed death-1/programmed death-ligand-1 
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(PD-1/PD-L1) pathway,  is involved in the interaction between the immune system (specifically T 
cells) and tumor cells, and has been found to be a key player in the ability of tumor cells ability to 
avoid host immune responses 34. The approach of immune checkpoint blockade is to reestablish 
natural tumor-specific T-cell-mediated immunity. The immune checkpoint inhibition rationale for 
anti-PD-1 therapeutics such as nivolumab in ccRCC is that the tumor antigens will be presented 
by MHC Class I  to T cells, resulting in their activation and the successful  killing of the tumor cell 
35 . The FDA has approved nivolumab in combination with ipilimumab and immunostimulatory 
monoclonal antibody, as a first-line treatment in cases of advanced ccRCC whose disease have 
poor prognosis 36.  
One of the most appealing features of immunotheraphy is the ability to enhance the 
patient's natural antitumor response. This relies on blocking the tumorigenic immunoregulatory 
apparatus. One such critical inhibitory checkpoint is cytotoxic T lymphocyte antigen-4 (CTLA-4), 
which is a crucial in the negative regulation of the antitumor T-cell response36. 35,37. Ipilimumab is 
an immunotherapeutic agent  that exhibits potent immune-related anti-cancer toxicities, and 
functions by blocking CTLA--4, The average overall survival in response to PDL-1 and 
ipilimumab is between ten and 20 months 38.  
Finally, Bbevacizumab is a recombinant humanized monoclonal antibody (mAb) proposed 
as an immunotherapeutic that blocks angiogenesis by inhibiting VEGF-A 10,39. Bevacizumab 
combined with IFN-D is now approved to treat of naïve ccRCC 10. Its average overall survival of 
nine to ten months is comparable to the clinical first-line multityrosine kinase inhibitors that is 
sunitinib and pazopanib 40. 
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1.2.3 Chemotherapy in combination with immunotherapy 
Traditional chemotherapy in combination with immunotherapy has yielded a modest 
improvement in patients treated with immunotherapy such as IL-2 or IFN- α 27,32,41. However, this 
course of treatment induces significant AEs and is rarely used in the clinic. There are very few 
trials reporting studies of combination between chemotherapeutic agents and the new wave of 
immunotherapy.  
 
1.2.4 Targeted therapies 
A paradigm shift away from non-specific chemotherapy, towards tumor specific 
therapeutics has led to the advent of targeted therapy, that is the design of agents to specifically 
identify and disable cancer cells without harming healthy cells. Because ccRCC are a highly 
vascularized cancer due to overactivated VEGF signaling and mTOR deregulation, the these 
pathways have been identified as therapeutically druggable targets 42. Current clinical guidelines 
for ccRCC patients with poor prognoses recommend targeted therapies with FDA approved multi-
targeted receptor tyrosine kinase (RTK) inhibitor agents such as sunitinib, pazopanib, or the 
mTOR-specific inhibitor temsirolimus as the standard of care for first‐ line treatment 10. Sunitinib, 
similar to other multi-targeted RTK inhibitors, inhibits cellular signaling by targeting several 
RTKs, including the PDGF receptors (PDGFRs) and VEGF receptor (VEGFRs) known to drive 
tumor proliferation and angiogenesis 17,43. The simultaneous inhibition of these targets curbs tumor 
vascularization and apoptosis and has been reported to lead to tumor shrinkage. Sunitinib also 
inhibits CD117, a RTK, which drives the malignant progression of many gastrointestinal tumors 
when dysregulated 10,44 . One of the downsides of sunitinib is that it also binds other receptors 
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which leads to AEs such as advanced dermatologic toxicities 10,27. Pazopanib is a potent and 
selective RTK inhibitor that hinders tumor growth and inhibits angiogenesis. Its main targets are 
c-KIT, fibroblast growth factor receptor (FGFR), PDGFR, and VEGFR 26,40. Temsirolimus is a 
clinically used mTOR-specific inhibitor that modulates proliferation, growth and survival 
regulating proteins in tumor cells. Temsirolimus leads to G1 cell cycle arrest, and inhibits tumor 
angiogenesis by downregulating VEG.  
While targeted therapeutics for mRCC constitute two different mechanistic classes, they 
often have overlapping  functions 17, in particular the inhibition of VEGF upregulation.   Anti-
VEGF agents such as bevacizumab (directed against the ligand with mAb) or, sunitinib, sorafenib 
or pazopanib (directed at the receptor, TKI). On the other hand, temsirolimus and everolimus act 
through inhibition of intracellular mTOR kinase signaling, leading to cell-cycle arrest, enhanced 
apoptosis, and angiogenic inhibition 17,42. To enhance the efficacy of the targeted approach to 
ccRCC therapy, a combination of agents capable of targeting different points in the VHL–hypoxia-
inducible gene pathway has been proposed.  
Though it has been determined that the VEGF and mTOR pathways are up-regulated by 
various tumor specific factors such as hypoxia, select cytokines, the inactivation of tumor-
suppressor genes, and angiogenic enhancement, their targeted inhibitors exhibit different 
antitumor activities and dissimilar AEs. These differences are important in composing the best 
clinical intervention regiment limited outcome improvement.  
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1.2.5 Chemotherapy in combination with targeted therapies  
A deepening of our understanding of the molecular biology of ccRCC and great progress 
in rational drug design have rendered metastasized ccRCC amenable to treatment with targeted 
therapies using multi-TKI inhibitors, mTOR inhibitors, and VEGF targeting agents as the current 
standard of care for mccRCC. In monotherapy, mTOR inhibitors such as everolimus and 
temsirolimus are reported to slow tumor growth, but clinical response to such therapy is very 
modest, and most cases, the tumor does progress and necessitates second, or thirst line therapies 
17. As with other chemo- and immune-therapies, combination of several agents or agents from 
different classes have been studied in attempts to improve efficacy. The hypothesis being that there 
might be synergy that would potentiate each agent against their distinct targets while avoiding 
resistance and reducing AEs. Combination therapy using cytotoxic chemotherapy with targeted 
therapy have shown promising results in ccRCC clinical trials 36,45,46.  For example, the VEGF 
inhibitor antibody bevacizumab combined with capecitabine and gemcitabine yielded modest 
overall survival rate improvement with no significant side effects in ccRCC. Other antiangiogenics 
agents such as thalidomide were tested in combination with gemcitabine and 5-FU but cause 
significant AEs while yielding little clinical outcome improvements 47,48.  
 
1.2.6 The proposed biology of cytotoxic chemotherapy resistance in ccRCC  
The mechanisms of chemoresistance in ccRCC are not completely understood. The 
mechanism most frequently proposed postulates that the overexpression of an ATP-binding 
cassette group of transporter efflux pumps drives resistance by limiting the intracellular 
accumulation of the cytotoxic agent. The permeability glycoprotein (Pgp) is an example of such 
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an efflux pump system. However, the use of Pgp antagonists in clinical trials yielded modest 
results,  challenging the assertion that Pgp is an essential mediator of chemo-resistance 49,50. It has 
also been proposed that there might be alterations in the efflux pumps characteristic of ccRCC due 
to mutations of the VHL gene. The disabling of VHL results in  intracellular accumulation of HIF, 
a microtubule dependent transcription factor involved in angiogenesis, thereby deregulating/ 
removing the breaks on  tumor cell proliferation and survival 51. It has been suggested that VHL, 
HIF, and the cytoskeletal microtubules are druggable targets that are key to the pathogenesis of 
ccRCC. However, notwithstanding the fact that there are no observed mutations in the taxane 
binding site, the use of taxanes which is an anti-microtubule chemotherapeutic has been 
unsuccessful in the treatment of ccRCC, although very effective in treating other solid tumors such 
as breast cancers 51. Taxanes are anti-mitotic agents that work by suppressing the dynamic of 
microtubules therein preventing proliferation and killing tumor cells51,52.. This suggests that anti-
microtubule therapy resistance might rely on the expression of non-standard tubulin isoforms. 
Finally, it has also been proposed that low levels of tumor suppressor phosphatase and tensin in 
ccRCC contributes to chemoresistance by activation of the key regulator of the tumor suppressor 
signaling pathway Akt/HDM2 53.  
 
1.2.7 In defense of chemotherapy 
The clinical advantage of targeted multi-kinase inhibitors, mTOR inhibitors, and VEGF 
specific agents has fueled the expansion of therapeutic options for advanced and mccRCC. 
However, these advantages have only provided modest increases in the DFS window. 
Immunotherapy has also provided only modest improvements in clinical outcome, and causes 
significant toxicity and AEs, however, it still plays a central role in the treatment of metastasized 
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ccRCC. FDA approved antibodies such as bevacizumab have been shown to slow tumor growth 
in patients mccRCC; and in combination with IFN-α, slow tumor growth and metastasis but are 
not curative 29. Axitinib, cabozantinib, pazopanib , sorafenib, and sunitinib are also FDA approved 
TKIs for the treatment of ccRCC; but their efficacy is similarly limited 17,40,54. Often, patients must 
discontinue immunotherapy treatment  because of drug related toxicity or because the treatment 
fails to hinder disease progression 27,55. Also, about a quarter of patients with advanced ccRCC 
treated with targeted therapies have VEGF refractory disease, requiring second- and third-line 
therapies, and even with these multiple therapies and have poor prognosis 17,56,57. However, it has 
been reported that for some patients with tumors refractory to anti-VEGF there is a response 
cytotoxic chemotherapy regiments, more specifically with treatment regimens of gemcitabine and 
capecitabine after a failed targeted therapies regimen 57. Several chemotherapy regimens have 
yielded modest efficacies in patients whose tumors grow following treatment with cytokines or 
targeted therapy, suggesting that the first treatment course might have sensitized the tumor 58,59. 
Combination therapy using cytotoxic chemotherapy and targeted therapy have shown promising 
results in clinical trials 45,57,58. These results make a case that cytotoxic chemotherapy may be 
beneficial in patients with ccRCC refractory to standard therapy. Consequently, given the 
relatively high prevalence of metastatic ccRCC that do not respond to immunotherapy or targeted 
therapies, there is an urgent need for novel effective, non-toxic clinical alternatives to the currently 
available pharmaceutical arsenal to extend survival and improve quality of life.  
For the sake of over 14,000 patients whose lives will be lost due to our pharmaceutical 
shortcomings, we must rethink how we treat and ccRCC and perhaps consider going back to basics. 
Harnessing the benefits of chemotherapies and improving on their success. Such efforts are underway, and 
the use of organometallic compounds has recently been proposed to meet that critical need with great 
preclinical success.  
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1.3 Chemotherapy beyond cytotoxicity 
1.3.1 Context of novel metal-based approach.  
Organometallic compounds have been offered as a potential chemotherapeutic alternative 
or complementary option to the current clinical regimens in the treatment of ccRCC 60–64.  While 
many cancer chemotherapeutics are highly toxic to both cancerous and normal cells, and cause 
debilitating AEs, there are now reports of metallodrugs, specifically titanium-based and gold-based 
complexes, that are highly selective for tumor cells while minimally toxic to healthy cells at low 
doses. Some such compounds are also reported to inhibit growth factors, cytokines, and proteases 
key to the malignant progression of ccRCC. Molecules made of two different metal centers 
(heterobimetallic), each with distinct known chemotherapeutic properties, are proposed as a novel 
single-drug approach to multi-targeted anticancer therapy 65–68.  
 
1.3.2 Metallodrugs 
The platinum based drug cisplatin (CPPD in Chart 1.1) was the first metallodrug oncotherapy 
approved by the FDA in 197869. To date, cisplatin is still the first line of treatment for many ovarian 
and testicular carcinomas, small cell lung cancer, bladder, and cervical cancers. However once 
metastasized, most cancers do not respond to cisplatin 69–71. Despite tremendous successes, the 
coordination compound cisplatin and its offshoot compounds carboplatin and oxaliplatin face 
three main obstacles 1) existence of cisplatin-resistant tumors, 2) severe secondary effects such as 
neuropathy, myelotoxicity, and nephrotoxicity, and 3) lack of specificity as conventional platinum 
anticancer drugs target DNA, which is ubiquitous among normal and cancerous cells 72–74. 
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Therefore there is a need for alternative metal compounds with greater efficacy and lower non-
specific-toxicity than cisplatin 74.  
Organometallics offer great structural variety, along with greater stereochemical diversity 
than organic compounds 74–76. Furthermore, organometallic compounds allow for rational ligand 
design, providing control over electrochemical properties and important kinetic properties, 
specifically their rate of ligand hydrolysis.  Many organometallic drugs are lipophilic, are most 
uncharged, and are contain a kinetically stable metal atom in low oxidative state 77. Because of 
these assets not found in classical (inorganic) coordination metal complexes, organometallics offer 
a large area for the design of a novel realm of chemotherapeutics characterized by their metal 
specific biological properties. 
 Organometallics containing different metals [e.g. titanium (Ti), gold (Au) and ruthenium 
(Ru)] such as metallocenes, containing arene-, NHC-carbene-, or phosphine ligands are among the 
most reported for medicinal applications 74,78,79. For example, Ti complexes such as titanocene 
dichloride (TDC) and Titanocene-Y (Ti-Y) have exhibited significant antitumor activity. Gold 
coordination and organometallic complexes such as Au-NHC-carbenes and Au-phosphines, have 
demonstrated outstanding cytotoxic and chemosensitizing properties against many cisplatin 
resistant tumors.  Recently, ruthenium-based compounds, including Ru-arene, have shown great 
promise in animal models and in the clinical setting in the treatment of metastatic tumors 72,80,81.   
 
1.3.3 Titanium                             
In the late 1980’s, titanocene dichloride (Cp2TiCl2 also known as TDC, Chart 1.1) was 
shown to have potential cancer- chemotherapeutic properties both in vitro and in mouse models 82. 
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TDC’s cytotoxicity was credited to interactions with the iron transport protein, transferrin, via 
which it is shuttled into the cell 83.   
 
 
Chart 1.1. Platinum, titanium, gold and ruthenium metallodrugs that have entered clinical trials, 
or that have been part of advanced preclinical studies (Titanocene Y and RAPTA-C).  
 
One notable asset of TDC and many subsequent (monometallic) titanocenes, is that it does 
not affect bone marrow proliferation (key to immune health), a frequent dose-limiting secondary-
effect of organic drugs 64. Owing to promising preclinical success, in 1993 TDC became the first 
non-platinum coordination complex and the first organometallic drug to enter clinical trials84. 
However, TDC clinical trials against breast and renal-cell carcinoma (RCC) were unsuccessful 
due to poor aqueous solubility and hydrolytic instability 64,84. Ti-Y (Chart 1.1) was a more stable 
and more lipophilic descendent of TDC, and like TDC, it is highly cytotoxic to cisplatin resistant 
cancers 85. The proposed mechanism of Ti-Y activity suggests that it diffuses via serum albumin 
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to the cancer cells where it is internalized through interaction with transferrin. Titanocene activity 
requires pH dependent hydrolysis of the Ti-Cp ligands. Ti(IV) species can be kept in a lipophilic 
milieu long enough to permit uptake of Ti by transferrin due to its slow hydrolysis 86.  We must 
mention that cytotoxic Ti derivatives, with more stable Cp-Ti bonds, may exhibit distinct 
biochemical interaction than TDC. Over the last decade, new cytotoxic Cp-derived and diverse 
coordination Ti complexes have been shown to be active against breast, prostate, and kidney 
cancers that are refractory to cisplatin, though much is still to be optimized in their design to 
increase stability and efficacy 62,64,66,79,87,88. 
 
1.3.4 Gold 
Gold (Au) complexes were found to be highly antiproliferative, a property for which 
Au-complexes have garnered great attention 74,89. Au complexes comprise a large variety of 
different ligands (i.e. thiolates, phosphines, heterocyclic NHC-carbenes, and aryl-containing 
moieties) attached to Au in the oxidation state I or III. The inhibition of tumor growth by Au 
complexes has been linked to a potent and specific inhibition of the mitochondrial enzymes 
thioredoxin (Trx) and thioredoxin reductase (TrxR). Trx is upregulated in many malignant solid 
tumors and high levels of expression correlate to chemoresistance and aggressive tumor 
invasion and metastasis 90–92. It has   been reported that Trx mediates hormesis against oxidative 
stress-induced apoptosis. The pharmacodynamics and pharmacokinetics of Au based 
metallodrugs is distinct from that of cisplatin. One key point of dissimilarity with cisplatin is 
that Au(I) compounds only weakly bind to DNA, thus are unlikely to cause DNA damage 88,93. 
Because of the great structural diversity of ligands, and the unlikelihood of a single biochemical 
or pharmacological profile for all gold complexes, it is expected that not all pharmacodynamic 
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effects of Au-complexes are based on TrxR inhibition. Very recently, the phosphine-gold(I)-
thiolate compound auranofin (AF) (Chart 1.1), an FDA approved anti-arthritic drug in use for 
over 25 years, has entered clinical trials as an anticancer agent 94,95.  AF is undergoing trials for 
the treatment of leukemia, small cell lung cancer and ovarian cancer 94,96. AF has also proven very 
efficacious against bacterial and parasitic infections. AF’s efficacy in killing bacteria, parasites, 
and cancer cells, was also correlated to a strong inhibition of TrxR 97.  
 
1.3.5 Ruthenium 
In the last three decades, numerous ruthenium (Ru) containing complexes have been 
evaluated with notable success against primary and metastatic breast cancers, and are therefore 
being studied and developed as building blocks for new antiproliferative and antimetastatic 
metallodrugs 98. Though Ru is a transition metal in the Pt group, Ru compounds’ means of 
efficacy against cancer differ from that of Pt drugs.80,99. Ru(III) drugs can accumulate in cancer 
cells with limited accrual in healthy tissue, which curbs one of the main shortcomings of 
cisplatin 87,100. Such selectivity may be explained in part by Ru’s use of transferrin to enter 
tumors 80,101. Also, Ru(III) is a fairly inactive oxidation state prior to its reduction to the active 
Ru(II) form. Such activation is driven by a reduction pH and occurs most likely inside cells or 
in the tumor microenvironment, where it may be stimulated by hypoxia 79,80,98,99,101,102. The 
oxidative mechanism was suggested to account in part for the innoxiousness of Ru(III) drugs 
NAMI-A, and KP1019 (Chart 1.1) to healthy cells; perhaps a key feature for their entry into 
clinical trials 79,103–105. Ru(II) organometallic complexes such as RAPTA-C (Chart 1.1) or 
RAPTA-T were reported to inhibit metastatic invasion, proliferation, and angiogenesis, though 
the complexes were inactive against primary tumors 99,106. NAMI-A, and RAPTA-C have also 
 
 
19 
 
been reported to drive down the expression of TGF‑ β and VEGF, and inhibit vascular cell 
assembly into blood vessel precursor tubes 80,81. 
 Recently, two Ru(II) polypyridyl complexes TLD-1433 and RuPOP have garnered great 
interest;  in 2016, TLD-1433 entered phase I clinical trials against non-muscle invasive bladder 
cancers 102,107, and RuPOP, which was reported to inhibit growth and metastasis of triple negative 
breast cancer cells while enhancing apoptosis, is being evaluated in vivo in animal models 108. The 
selective intracellular uptake and cytotoxicity of TLD-1433 and RuPOP is associated with either 
transferrin receptor, or integrin mediated endocytosis receptor activity 109. Moreover, RuPOP was 
reported to induce remedial alteration in the expression of proteins that regulate metastasis such 
as urokinase-type plasminogen activator (uPA) or MMP-2/-9, while inhibiting VEGF 109–111. 
The oxidative properties of some Ru-arenes result in complex interactions with double helical 
DNA, which was demonstrated to induce radio-sensitization of cancer cells otherwise refractory 
to irradiation therapy79,112,113. Thus, Ru-based complexes are evidently a promising line of 
antitumor and antimetastatic therapeutics. However, notwithstanding the data gathered in the 
past decade, the causal mechanisms of the antitumorigenic potential of Ru-based oncotherapies 
are not fully understood.  
 
1.3.6 Heterobimetallic compounds 
Not many polymetallic complexes (homometallic: a complex with one species of metal centers;  
heterometallic: a complex with two or more different species of metal centers) with anticancer 
potential have been evaluated, in contrast with monometallic complexes.  
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Chart 1.2. Some heterometallic Ti-Au and Ru-Au compounds with anticancer activities reported 
by the Contel group88,111. 
 
In 2011, the Contel research group and the  Casini group reported on titanocene-gold(I) 
complexes with cyclopentadienyl-phosphine linkers that showed a synergistic effect in ovarian 
and prostate cancer cell lines88,111. However, like titanocene dichloride (TDC), the compounds 
were not very stable at physiological pH (7.4). In 2015, the Contel group reported on the first 
arene Ru(II)-Au(I) compounds based on the structure of RAPTA-C and gold(I)-thiolate or chloro-
phosphines similar to auranofin (Chart 1.2). These new complexes displayed more promising 
activity toward colon cancer cells in vitro than the individual Ru and Au species, these bimetallic 
compounds were also more cytotoxic or more selective. The Ru(II)-Au(I) compounds showed no 
interaction with plasmid (pBR322) DNA, but did induce inhibition of TrxR, which may be 
attributed to the gold moiety. Ru(II)-Au(I)  compounds also inhibited cysteine proteases cathepsin 
B (CtsB), known to be inhibited by Ru-containing compounds111. CtsB is a poor prognostic marker 
in many cancers and is associated with the recruitment of blood-vessels as well as protumorigenic 
immune cell recruitment  to the tumor microenvironment114–116. It has therefore become evident 
that heterometallic compounds possess multifunctional features, all valuable assets for cancer 
treatment.111   
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There seems to be no conserved narrative of how a set of given metals affect cancer cell 
behavior, in part because there has not been systematic study of the phenotypes and pathways 
involved. Our limited understanding of the mechanisms of the antitumorigenic potential of Ti, 
Au-, and Ru-based compounds has hindered rational design of novel compounds and hampers 
their clinical application. There is empirical evidence that some Ti-Au and Ru-Au compounds 
are highly toxic to ccRCC while minimally toxic to healthy cells, there are also some broad 
indications of the molecular pathways affected in response to treatment with some of the Contel 
Research Group Ti-Au and Ru-Au compounds. 89,117.  
 
1.4 Molecular signaling and drug efficacy (Markers of interest) 
Tumor progression impinges on both inherent tumor characteristics and crosstalk between 
tumor cells and stromal1 cells in the tumor microenvironment.  Fibroblasts, macrophages, and 
adipocytes are central components of the tumor microenvironment. A variety of soluble factors 
serve to connect stromal cells and tumor cells. Those factors include pro-inflammatory cytokines 
and chemokines secreted by stromal and tumor cells as well as growth factors. It is therefore 
critical to validate in vitro findings obtained from cancer cells in mono culture, to in vivo data 
obtained from a mammalian animal models since, the protein expression profile observed in vitro 
in cancer cell monoculture might not reflect the signaling complexity and expression profile of in 
vivo tumor samples. To this end, to gain essential mechanistic insights as to how the Titanocref, 
                                                          
1 In immunology stromal cells are defined as non-hematopoietic cells, for our purposes this term will be 
used to refer to all non-cancerous cells of the tumor microenvironment. 
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Titanofin and RANCE-1 achieve their efficacies, we interrogated, key pathways in vitro and in 
vivo known to drive proliferation, angiogenesis, migration, metastasis, cell death and death 
resistance.   
 
1.4.1 Inflammation  
1.4.1.1 Inflammation at the intersection between immunity and angiogenesis  
The link between cancer and inflammation has been extensively studied, and cytokines are 
known to be important mediators of many cancers and inflammatory diseases 118,119. In fact, as 
previously noted, the FDA approved Au-organometallic drug Auranofin (AF) is prescribed to treat 
rheumatoid arthritis, a chronic inflammatory disease, is now also being tested for cancer treatment 
120,121. The efficacy of Au complexes in palliating inflammation is credited to their effects on the 
signal transduction of immune cells, specifically macrophages, and the inhibition of inflammation 
promoting cytokines, including interleukin-6 (IL-6), Cyclooxygenase-2 (Cox-2), and focal 
adhesion kinase (FAK) 96,119,122.  Several Ru compounds that inhibit angiogenesis have also been 
observed to either inhibit or lessen the expression of IL-6 or VEGF. AF has been reported to 
inhibit angiogenesis via cytotoxic effects on endothelial cells and by decreasing proangiogenic 
factor secretion (e.g. IL-6) by cancer cells 123–125. p38 MAP kinases, which were shown to be 
inhibited by some Ti-Au complexes, were also found to promote inflammatory cytokines such 
as IL-4, IL-6, and tumor necrosis factor-α (TNF-α) 122. It has also been reported that treating 
cancer cells with p38 MAPK inhibitors diminished the expression of both uPA and its receptor 
uPAR through which tumor invasion and metastasis was shunted 126.  
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COX-2 is a membrane bound enzymes that serves as the catalysis of the synthesis of the 
inflammatory mediator prostanoid 127. Its expression is intimately regulated by inflammatory 
modulators such as growth factors, cytokines, and endotoxins 128. AF has been shown to shunt 
pro-inflammatory eicosanoid formation (in particular prostaglandins, leukotrienes, and eoxins) 
in human serum via the inhibition of COX-1/2 129. It was shown that AF inhibits the synthesis 
of the COX-1 baseline enzyme product prostaglandin E-2 (PGE2) in human synovial fibroblast-
like (FLS) cells through the inhibition of TrxR, while also suppressing COX-2 expression, 
which produces PGE2 through inflammatory stimulation 130.  
 TrxR activity is  also known to increase inflammation in  lung and joint tissue, is 
significantly inhibited by several gold complexes 131. Trx may induce the expression of hypoxia-
induced factor 1 (HIF-1α) and upregulate expression of VEGF, promoting neoangiogenesis in 
tumors 132. Finally, the antiangiogenic properties of Ru-based compounds have also been linked 
to the inhibition of zinc-containing and calcium-dependent endopeptidases matrix 
metalloproteinases (MMPs) and the inhibition of HIF-1α 108,133,. We note that HIFs also 
participate in the modulation of proliferation and metastasis.  
What is evident in this pathologic orchestra, is that many players such as HIF, TrxR, 
MMPs, and IL-s to name a few, are promiscuous and contribute to multiple disease phenotypes 
depending in their interaction partner(s) or environmental factors.  
 
1.4.2 Angiogenesis 
Angiogenesis, the sprouting of neovasculature a budding pre-existing blood vessels, plays 
a key role in tumorigenesis and in cancer treatment 134. To initiate angiogenesis, emerging solid 
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tumors secrete factors that induce the production and chemotaxis of endothelial cells (ECs) 135.  
The oxygen-poor environment of the inner tumor induces the expression of HIF-1α, which then 
activates the expression of an angiogenic gene cascade that includes VEGF and Fibroblast Growth 
Factor (FGF) basic that respectively stimulate vascular permeability and EC growth 136. FGF 
drives angiogenic branching morphogenesis, which is critical for the proper outlay of vasculature 
in healthy tissue, but in tumors can serve to fulfil the vascular promoting functions much like 
VEGF 137.  While VEGFs is the most studied and most discussed angiogenesis promoting protein 
family, the initiation of angiogenesis by the EC can be triggered via several other growth factors 
such as angiopoietins, FGF, TGFs, and PDGF, thereby enabling resistance to anti-VEGF therapy 
137–139.  In response, tumor cells can bypass VEGF’s contribution to angiogenesis by up-regulating 
FGF-2   
In addition to angiogenesis, FGF basic signaling regulates cell growth, differentiation, and 
wound healing, and in those capacities to promote to proliferation of vascular cells has been 
proposed to play a central role in the resistance to anti-VEGF therapy 137,140. PDGF and 
angiopoietin-1 facilitate chemotaxis, while ephrin guides newly formed blood vessels and 
maintains cell-cell separation and together they also compensate for the absence of VEGF.  
Considering the VEGF compensatory response by FGF, agents targeting FGF signaling are being 
explored as an additional target of antiangiogenic therapies.  Targeting both VEGF and FGF 
pathways has great potential and may translate into improved patient outcomes. 
Trx has also been reported to play a role in HIF mediated angiogenesis 91. Trx and TrxR 
are of interest because they have been reported to be significantly inhibited by gold compounds. 
Trx is overexpressed in a variety of cancers, and correlate enhances vascular networks and 
increases VEGF levels 91,123,141,142. The Trx inhibitor AW464 is reported to impair Trx1 as well as 
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HIF1 activity and lessen EC which contributes to hypoxia-driven vascular remodeling that 
facilitates tumor extravasation 143,144. Other Trx1 signaling inhibitors such as pleurotin and PX-12, 
decrease Trx1 expression and activity, thereby decreasing HIF1α, and reducing VEGF levels, 
leading to the formation of poorly perfused vasculature 145–148. Blockade of Trx1 using PX-12 has 
shown promise in clinical trials as it induces a significant  decrease in plasma concentrations of 
VEGF 148  
Equally important to the vascular dynamic of the tumor microenvironment are the 
negative regulator of angiogenesis such as Tie2 (a tyrosine kinase receptor) and endogenous 
inhibitors such as endostatin and thrombospondin-1. The signaling promiscuity extend to 
angiogenic proteins as well, such as angiopoietins which can regulate the survival and apoptosis 
of endothelial cells through interactions with their receptor, Tie2 (a tyrosine kinase receptor) 149,150. 
Tie2 activation in turn enhances the normalization of tumor vessels and decreases angiopoietin 
expression and facilitates local drug delivery as blood vessels with more integrity will best deliver 
to the tumor 151.   Endostatin, inhibits angiogenesis by down regulating many signaling cascades 
like ephrin, inflammatory cytokine TNF-α, and NFκB signaling, as well as coagulation and 
adhesion cascades that are involved in angiogenic initiation and local recruitment of vascular cells 
152,153. Thrombospondin-1 is an antiangiogenic factor that is enhanced by IL-18. Therefore, in 
designing novel therapeutic agents, the potentiation of those antiangiogenic factors, while also 
blocking their natural inhibitor remains of interest. 
 
 
 
 
 
26 
 
1.4.3 Immunomodulators 
1.4.3.1 CCl-7, M-CSF and GMCSF 
The immune system can be a powerful weapon against cancer, however is can also be 
coopted by the tumor microenvironment as a tumor promoting phenotype 154,155. Upon the 
acquisition of pro-tumorigenic phenotype, macrophages are known to play a key role in the 
malignant progression of tumors via a large orchestra of signaling molecules. In this molecular 
arsenal are chemokine (C-C motif) ligands (CCLs), CCL-7 [also known as macrophage 
chemotactic protein-3 (MCP3)] and macrophage colony stimulating factor (M-CSF). CCL-7 is a 
key regulator of the interplay between stroma and tumor, an increase in CCL7 expression recruits 
monocytes to the tumor periphery and establishes a protumorigenic ecosystem. M-CSF is the chief 
regulator of macrophage differentiation, proliferation, and survival. It is also critical to 
macrophage-related functions such as vascular development and maintenance, and innate 
immunity. Both M-CSF and its receptor can be expressed by tumor cells, thus M-CSF may serve 
as an autocrine growth factor for cancer cells. An increase in CCL7 or M-CSF in the tumor 
microenvironment fosters the recruitment of tumor associated macrophages which provide 
proteolytic factors to the tumors cells, thereby allowing them to extravasate into the vasculature or 
degrade the ECM to promote angiogenesis.  
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is much higher in many 
primary tumors than healthy tissue. Along with its receptor in RCC and cancerous intestinal tissues 
high GM-CSF levels modulated by IL-3 and IL-5 correlate with greater survival 156. Recent clinical 
studies demonstrated that first line therapy combining inhibition of cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and GM-CSF-based immunotherapies can potentiate  the antitumor 
efficacy 157. 
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1.4.3.2 ICAM-1 
Adhesion is critical to immune cell to tumor cell as well at immune cell to immune cells 
communication. The intercellular cell adhesion molecule-1 (ICAM-1) plays an important role in 
both acute and chronic inflammatory responses 158–160. ICAM-1 is a transmembrane signal 
transducer, and modulates leukocyte-leukocyte, leukocyte-endothelial cell, and leukocyte-
epithelial cell interactions, as well as cell motility and adhesion 161. ICAM-1 expression can help 
determine the malignant potential of cancer and is positively correlated with metastatic potential 
and is therefore of therapeutic interest. 
 
1.4.4 Metastasis 
Tumor metastasis is a sequential process in which cancer cells migrate from the primary 
tumor site (extravasation), survive vascular or lymphatic dissemination, relocate in distant 
secondary niches (intravasation), and continuously divide 162,163. Communication between 
intracellular signaling proteins and the extracellular matrix (ECM) is a critical axis in driving 
successful metastasis. Cell-ECM communication is a critical process that regulates cell 
morphological dynamics, survival, differentiation, proliferation, and migration. The activation of 
MMPs is regulated through the serine protease uPA and its receptor uPAR 108,115 uPA 
dysregulation leads to overexpression of MMP-2 and MMP-9, which are linked with the 
initiation of metastasis of many types of solid tumors 108,110,164–167. Importantly, Ru compounds 
have been reported to be inhibited by MMP-9 74,105,108,168,169.  
In fibroblasts and macrophages, MMP-9 is upregulated by transforming growth factor 
β1 (TGFβ1), TNF-α, FGFbasic, IL-1β, and lymphotoxin (LT) 170–172. TNF-α serves as an 
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endogenous tumor promoter that enhanced tumor invasion, while FGF overexpression correlates 
with poor prognosis 173,174. Following upregulating MMP-9 production in fibroblasts and 
macrophages, these cells then contribute to the peritumoral proteolytic activity that cuts through 
the ECM and creates a path for the tumor cells to invade 175–177., Blocking the FGF receptor has 
been reported to inhibit tumor growth, lymphangiogenesis, and metastasis 137,178. IL-17A can also 
increase tumor cell motility by upregulating MMP-2 and MMP-9 via activation of NF-κB 166,179,180. 
IL-17A is associated with and hormone receptor negative breast tumor hyper proliferation and 
poor prognosis. IL-17 has been reported to induces a HIF-1α-dependent invasive phenotype in 
both tumor cells as well as synoviocytes. This is noteworthy because IL-17 in part regulates 
migration and invasion of synoviocytes in joints affected by rheumatoid arthritis,  plays a key role 
in the malignant development of this inflammatory disease for which Auranofin is already a 
clinically approved treatment 179,181,182.  
A disintegrin and metalloproteinases (ADAM) (ADAM-8 and ADAM9 in particular) are 
also modulated by MMPs, and are known to be expressed in in breast or lung cancers that have 
metastasized to the brain 183–185. The apparent brain homing metastatic phenotypes suggest that 
there may be a zip-code like property to ADAM-8 and ADAM-9. Also it has been reported to 
serve as a metastatic disease progression marker 184–188. Also ADAM9 expression is used in the 
clinic as  prognostic relapse in prostate cancer189. The ability to block ADAM expression holds a 
great deal of therapeutic potential. Another protein with metastatic site-specific features is the 
macrophage-capping protein (CAPG). It serves as a predictive biomarker for the metastasis of 
breast cancer to the bone, and in that capacity is used to guide therapeutic interventions 190,191. 
Forkhead Box C2 (FOXC2) can also induce the migration of ccRCC by upregulating  
MMP-2 and MMP-9 192,193. However, FOXC2’s contribution to metastasis is not only associated 
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with MMP activity. Independently of MMPs, FOXC2 expression is induced when ECs undergo 
EMT and take on a which protects the cells from immune detection and facilitates the metastatic 
process. Overexpression of FOXC2 is a  feature of many highly metastatic breast cancers 194,195. 
E-cadherin is a transmembrane protein that facilitates homophilic cell–cell critical in cell 
motility. Not unlike FOXC2, E-cadherin contribute to tumor through its ability to modulate EMT. 
Tumor progression is often accompanied by the loss of E-cadherin function and the transition to a 
more invasive phenotype 196,197. When E-Cadherin levels decrease, tumor cells undergo the 
pathological EMT process and migrate. E-cadherin is released as a soluble factor that augments 
cancer cell motility and EGFR-dependent survival and proliferation 197. Finally, E-cadherin has 
been reported to interact with FOXC2 in the process of tumor EMT 198 
CCL8, like CCL7, plays an important role in tumor-stroma, tumor-immune cell and tumor-
tumor cross-talk. It is most important in the early stages of metastasis when dermal fibroblasts 
increase the production of CCL8 to facilitate proteolysis by stimulating the production of pro-
metastatic proteolytic factors such as MMP-9 and MMP-2 by tumor cells and peritumoral stromal 
cells 199–201.  The levels of CCL8 in the periphery tumor microenvironment modulate the initial 
protrusion of the tumor cells and the initiation of metastasis 199. 
1.4.5 Survival  
Cell survival relies on the activation of inhibition of apoptosis (IAP) proteins, which is 
occurs through the expression of pro-apoptotic factors and the enhanced expression of anti-
apoptotic factors. Survivin is a member of the IAP family 202. Increased survivin expression in 
fully differentiated  tissues, often leads to  unregulated cell survival, resulting in cancer 203. 
Survivin has been reported to shield cells from caspase-induced apoptosis activated in mitosis 
 
 
30 
 
through Caspase3, 7, or 9 binding 202,204.  If overexpressed in ccRCC and other solid tumors, 
survivin is of prognostic relevance as its expression has been significantly associated with poorly 
differentiated, advanced stage and more aggressive ccRCCs 202,203,205,206. Bcl-2 is critical to 
mitochondrial mediated apoptosis. Bcl-2 family members down-regulate apoptosis by directing 
mitochondrial permeability following death signaling, Bc-l2 promotes the release of cytochrome 
c resulting in apoptosis 207,208.  Lastly, in addition to all the functions of Trx previously discussed, 
it also serves to evade cell death. In its capacity as a ROS scavenger, Trx is overexpressed in 
cancer cells in order to escape oxidative damage induced apoptosis, thereby overcoming 
cytotoxic assault 148,209. 
 
1.5 Therapy resistance  
Cancers are characterized by their ability to evade death and develop chemoresistance. 
There are several known markers of chemoresistance, and knowing if they are expressed or not in 
a given tumor type can help inform treatment decisions 210,211. The drug resistance process can be 
regulated by an increase in the apoptotic threshold through a variety of cytokines and growth 
factors, hypoxia levels and high activity of drug-efflux transporters 52,212,213. Recent reports have 
suggested that the emergence of drug resistance may be caused during the EMT stage in which the 
differentiated tumor cells gain stem-cell like molecular signatures. Most drug-resistant cancers 
have populations with stem-cell like phenotypes that are resistant to chemotherapy 214,215. For 
example, CD31 is an immunoglobulin member expressed on the surfaces of circulating platelets, 
neutrophils, and lymphocytes and is involved in cell-cell contact. When CD31 expression is low 
or lacking cells lose part of their endothelial properties, undergo EMT,  and are more tumorigenic 
and chemoresistant 216. FOXC2 also contributes to chemoresistance by activating EMT, and by 
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eliminating the epithelial phenotype of tumor cells. Furthermore, the inhibition of FOXC2 
reinstates epithelial phenotype and drug sensitivity 195. 
HIF-1 enhances the expression of IL-6, IL-8, and multidrug resistance (MDR)-1, and in so 
doing, mediates the cellular efflux of chemotherapeutic agents thus increasing cell survival 217–219. 
It has been shown that co-administration of HIF inhibitors, like digoxin or acriflavine, countered 
paclitaxel- or gemcitabine-dependent initiation of IL-6, IL-8, and MDR-1 expression and led to 
tumor resorption 212,220,221. It’s been shown that acriflavine also prevents acquired chemoresistance 
by inhibiting EMT 212. 
The mitochondria isoform of TrxR is a target of several gold containing drugs including 
the Au(I)-thiolate AF 130,131,222,223. TrxR and its substrate, Trx, are overexpressed in many 
malignant carcinomas, and are known to protect cells from ROS induced apoptosis. 
Upregulation of Trx expression contributes to malignant cell growth, tumor proliferation, as 
well as chemoresistance 121,130,224. It has been reported that upon inhibition of Trx, cancer cells 
regain their chemosensitivity to agent such as cisplatin for instance 225. Au-containing 
complexes inhibit TrxR in mitochondria which causes a reduction in membrane potential that 
initiates the caspase-9 and caspase-3 dependent apoptotic cascade 91,96,123,130,226.  
 
1.6  In search of pathways 
The markers of oncological interest discussed here were selected for analysis guided by 
our own preliminary work and insights from the literature. The behaviors that are modulated by 
those factors are critical to several aspects of tumor malignancy, therefore compounds capable of 
modulating their function hold therapeutic benefits.  We utilized these markers to investigate the 
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mechanism by which novel heterobimetallic potential chemotherapeutic agents achieve their 
anticancer efficacy in vitro and in mouse models.  
Understanding which compounds affect which factor can be informative for several aspects 
of therapy. First, such knowledge can inform further rational design of novel gold-based 
compounds aimed at a malignant phenotype or marker pathway by providing some indications of 
how design affect function. Second, a better mechanistic understanding of the compounds’ effects 
can be invaluable in determining potential responsiveness to treatment, in planning treatment 
regiments in monotherapy or the optimal combination therapy partner drug. Third, because so little 
is known on the mechanism of nontraditional metallodrugs, we chose a broad array as to explore 
members of many families of malignant phenotype markers.  
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CHAPTER 2 
THE GENESIS OF THE PRECLINICAL EVALUATION OF GOLD-BASED 
CHEMOTHERAPEUTIC AGAINST ccRCC 
 
This dissertation is centered on the preclinical evaluations of three gold containing 
heterobimetallic compounds as anti-renal cancer chemotherapeutic candidates, the gold-titanium 
compounds Titanocref and Titanofin, and the gold-ruthenium compound RANCE-1. This chapter 
will serve first, to briefly position the compounds in the current landscape of heterobimetallic 
chemotherapeutic candidates (2.1). Second, it will serve to present the experimental genesis of this 
work and what led to the choice of those three compounds (2.2). Third, this chapter will serve to 
state the aims of this body of work (2.3).  
 
2.1 Positioning Titanocref, Titanofin, and RANCE-1 in the current landscape of 
heterobimetallic chemotherapeutic candidates. 
 
2.1.1 Heterometallic Compounds Containing Titanocenes 
The heterometallic compounds gold- titanium complexes discussed here have a titanocene 
motif (that is a titanium (IV) metallic center attached to two cyclopentadienyl Cp rings). Titanocene 
dichloride (TDC, [C5H5)2TiCl2]) was the first organometallic compound to undergo clinical 
assessment for the treatment of breast and renal cancers, following significant preclinical success 
in vitro and in vivo 1–4.  In phase II clinical trials patients exhibited modest reduction in tumor size, 
or the inhibition of metastatic proliferation of RCC or breast cancer 1–4. Since this trial, titanocene 
derivatives have been developed with varied degrees of efficacy in vivo against RCC 1–4.   
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Chart 2.1 Structures of three generation of novel Ti-Au compounds and their predecessors. 
 
2.1.1.1. Titanocene-Ruthenium Compounds 
The first heterometallic complexes based on titanocene dichloride (TDC) and the Ru-p-
cymene derivative RAPTA-C, were developed by the Casini laboratory in 20105,6.  RAPTA-C is a 
highly selective antimetastatic compound with no systemic toxicity when tested in vivo 6. The 
Casini research group described a series of neutral (like compounds 1 and 2 in Chart 2.1) and 
cationic bimetallic complexes (titanocene(IV)-ruthenium(II)) that were selectively cytotoxic in 
vitro to human ovarian cancer cell lines. The novel bimetallic Ti-Ru complexes displayed strikingly 
improved efficacy over TDC and RAPTA-C, their monometallic counterparts 6.  
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2.1.1.2 Titanocene-Gold Compounds  
In 2011, the Contel and Casini research groups developed gold (I) titanocene compounds 
containing gold-phosphane (titanocene(IV)-gold(I) compounds) 7–9(Chart 2.1). The 
cyclopentadienyl rings in TDC can be modified to contain phosphane ligands able to coordinate 
gold(I) fragments such as gold-chloride 7,8. Such modification lead to an increased efficacy against 
ovarian and/or prostate cancer cell lines with respect to TDC, in particular cationic compound 3 7 
and neutral compound 4 8.  Compounds of that class, referred to as zero generation in Chart 2.1, 
showed synergistic effects between the two metal fragments on the same molecule 7,8. Because 
these compounds did not bind to DNA (plasmid DNA; pBR322) 7, or exhibited only weak 
electrostatic interactions with DNA (calf thymus DNA) 8, their mode of action was evidently 
different from that of cisplatin which achieves efficacy by creating DNA covalent adducts. The 
difference between these compounds interaction with DNA and that of cisplatin was attributed to 
their gold(I) fragments (known not to interact with DNA but affect other biomolecular  targets such 
as mitochondrial TrRx) 8. Though the complexes were more suitable for potential medicinal 
application as they are more stable in physiological pH and less acidic than TDC, their stability was 
still suboptimal 8. This may be because TDC breaks down at neutral pH (hydrolysis) providing 
titanium oxo species and cyclopentadiene. If that hypothesis hold true, zero generation Ti-Au 
compounds would break into distinct titanium and gold monometallic species in physiological 
media or in vivo before reaching the tumor site, thereby failing to function as a single mutimetallic 
molecule. We hypothesized that incorporating the second metal to a ligand strongly bound to the 
titanium (IV) center would ensure that heterometallic Ti-M species remain after the Ti-Cp 
hydrolysis takes place under physiological pH conditions. Since Ti-O bonds are considerably 
stronger ('Hf298 = 662(16) KJ/mol) than Ti-C ('Hf298 = 439 KJ/mol) or Ti-Cl ('Hf298 = 494 
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KJ/mol) bonds we envisioned a carboxylate as the ideal group to bind titanium(IV) centers.8 This 
gave rise to first generation compounds8 that were subsequently modified and that we will describe 
in sections 2.2.2-2.2.4). 
 
2.1.2 Ruthenium-Gold Compounds 
The Contel research group in collaboration with that of Dr. Messori (in Florence, Italy) 
reported on the first, non-ferrocene-basedheterometallic complexes bearing a p-cymene 
ruthenium(II) motif (Chart 2.2) 10.  Arene-ruthenium(II)-gold(I) complexes such as compounds 10 
and 11, which are neutral and incorporate a [Ru(p-cymene)Cl2(dppm-kP)] fragment (R) with known 
cytotoxic and potential antimetastatic attributes, and a gold(I) chloride or a thiolate moiety were 
synthesized and exhibited cytotoxic activity in vitro against the colon cancer cell line, HCT116 10 . 
These novel complexes were more cytotoxic and more selective to cancerous cell lines than 
individual ruthenium and gold species. Additionally, DNA (plasmid DNA, pBR322) was 
determined not to be their primary target, unlike cisplatin. Micromolar quantities of compound 11 
inhibited the cysteine protease CtsB, known to play a critical role in the malignant progression of 
many solid tumors, specifically in the formation of new tumor vasculature and facilitation of 
metastasis 10. Our group improved on the design and efficacy of those compounds by developing  
second generation cationic complexes such as 12-14 and RANCE1 (Chart 2.2), which incorporate 
gold(I)-N-heterocyclic (NHC) carbene ligands 11 because cationic gold NHC complexes possess 
antimitochondrial and anti TrxR properties 1. Indeed, the combination of the ruthenium 
monometallic compound (R) with the [Au(NHC)]+ fragment, resulted in highly physiologically 
stabile cationic Ru-Au complexes with selective cytotoxicity towards  renal and colon cancer cell 
lines. We were able to demonstrate the synergistic potentiation of the bimetallic complex, as the 
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co-administration of the two monometallic moieties did not achieve the efficacy of the 
monometallic structures 11. These compounds achieve efficacy by similar means to other Au(I) 
derivatives containing phosphane (such as Auranofin) and NHC ligands, and are unlike cisplatin in 
their mechanism of action 1. The compounds did not interact with DNA and inhibited mitochondrial 
TrxR in the metastatic human clear cell renal carcinoma cell line (Caki-1) 11. 
 
 
Chart 2.2 Structures of first and second generation ruthenium-gold compounds with selected 
bimetallic compound RANCE-1 and monometallic compounds rutehium (R) and gold (ANCE-1). 
 
2.2.1. Preliminary studies 
The ultimate goal of my doctoral work was to identify the tumor-malignancy phenotypes 
affected by a selected set of novel titanium-gold (Ti-Au) and ruthenium-gold (Ru-Au) compounds, 
and to elucidate some of the underlying mechanisms of their efficacies. In order to identify viable 
candidates for mechanistic and eventual in vivo preclinical evaluation, a series of approximately 
thirty compounds were tested against several tumor cell types (breast, colon, kidney, and prostate) 
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from which three promising compounds were identified with activity against renal cancer: two 
titanocene-gold Titanocref and Titanofin (Chapter 3) and one ruthenium-gold RANCE-1 (Chapter 
4) compounds. The preliminary studies described here gave rise to four publications and one patent 
(years 2014-2017).8,10-12 These studies, and the follow-up investigation contained a synthetic 
component (with synthesis, characterization, and stability studies of new compounds) conducted 
by members of the Contel lab and a biological component (in vitro and in vivo evaluation of the 
compounds and preliminary mechanistic studies) conducted by me.  
We first evaluated a series of bimetallic compounds focusing on Ti-Au titanocene(IV)-
gold(I) and on Ru-Au arene-ruthenium(II)-gold(I) derivatives as well as their monometallic 
counterparts, which were used as control compounds (Chart 2.1 and 2.2). In addition, a few 
published reference compounds such as cisplatin, titanocene dichloride (TDC), titanocene Y (Ti-
Y), auranofin, or ruthenium dimer starting material (Ru-d) were also evaluated for comparative 
purposes 9,11–13.  
 
2.2.2 First Generation Organometallic Titanocene-Gold Compounds as Potential 
Chemotherapeutics in Renal Cancer. 
We first assessed the antitumor potency of a class of Ti-Au compounds with a carboxylate-
phosphane ligand 13,14, which we named “first generation” (Chart 2.1),  as they were improved and 
more stable versions of the compounds previously described by our group (zero generation or 
compounds 3 and 4 in Chart 2.1.)7. From this work, we observed that compound 5 and compound 
6 (Charts 2.1 and 2.3) were more stable in physiological media and more cytotoxic than the 
previously reported zero generation Ti-Au-Phosphane 8.   Compounds 5 and 6 were found to be 
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highly cytotoxic to renal cancer cell lines with IC50 values in the low micro- and nano-molar-range 
(Table 2.1).  
 
 
 
Chart 2.3. Structures of heterometallic first generation titanocene−gold complexes 5 and 6 and 
corresponding gold monometallic complexes 19 and 18. 
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Table 2.1. IC50 (μM) of Heterometallic TiAu2 Compounds 5 and 6 (Chart 2.1), Monometallic Au 
18 and 19, Cisplatin, Titanocene Dichloride, and Titanocene Y in Human Cell Lines.a All 
compounds were dissolved in 1% of DMSO and diluted with water before addition to cell culture medium 
for a 24 or 72 h incubation period. Cisplatin and titanocene dichloride were dissolved in H2O. 
 A498 UO31 Caki-1 HEK-293T PC3 DU145 
[Cp2Ti{OC(O)CH2PPh2AuCl}2] 
5 
8.7 ± 1.7  
(24 h) 
3.2 ± 0.38 
 (72h) 
6.3 ± 1.1 
 (24 h) 
1.4 ± 0.1 
 (72h) 
6.0 ± 1.8 
 (24 h) 
2.2 ± 0.99  
(72h) 
24 ± 0.73 
 (24 h) 
6.9 ± 2.4 
 (72h) 
51.7  ±  4.2 
 (24 h) 
27.1 ± 4 
(72h) 
38.6  ± 5.5 
 (24 h) 
35.5  ±  1.4 
(72h) 
[HOC(O)CH2PPh2AuCl] 
18 
58 ± 11.0 
 (24 h) 
43 ± 4.9 
 (72h) 
27.3 ± 2.7 
 (24 h) 
5.2 ±  1.6 
(72h) 
33.8 ± 2.1  
(24 h) 
23.0 ± 4.1  
(72h) 
36.5 ± 3.3 
 (24 h) 
9.7 ± 2.5 
(72h) 
38.2 ± 2.2 
 (24 h) 
30.2 ± 4.2 
(72h) 
34.7  ±  1.8 
 (24 h) 
31.3  ±  3.1 
(72h) 
[Cp2Ti{OC(O)-4-
C6H4PPh2AuCl}2] 
6 
28 ± 3.4 
(24 h) 
6.9 ± 2.2  
(72h) 
6.8 ± 0.2 
 (24 h) 
0.3 ± 0.06 
(72h) 
10.3 ± 4.1 
 (24 h) 
1.0 ± 0.29 
(72h) 
39 ± 4.1 
 (24 h) 
20.1 ± 1.6 
(72h) 
51 ± 4.2 
 (24 h) 
37.7 ± 7.1 
(72h) 
33.4 ± 1.8 
 (24 h) 
6.6 ± 1.8 
(72h) 
[HOC(O)-4-C6H4PPh2AuCl] 
19 
36.1 ± 6.3  
(24 h) 
21 ± 2.5  
 (72h) 
38.3 ± 4.1 
 (24 h) 
1.2 ± 0.8 
(72h) 
28.4 + 5.9  
(24 h) 
19.2 ± 2.9  
(72h) 
34.2 ± 3.7 
 (24 h) 
31 ± 0.9 
(72h) 
>  200  
(24 h) 
78 ± 18.1 
(72h) 
32 ± 2.7  
(24 h) 
39 ± 5.7 
(72h) 
Cisplatin 
74.7 ± 6.0  
(24 h) 
37.2 ±  4.6 
(72h) 
>  100 
 (24 h) 
8.9 ± 2.7 
(72h) 
68.8 ± 0.14  
(24 h) 
29 ± 4.1  
(72h) 
64.4 ± 7.9 
 (24 h) 
3.2 ±  0.13 
(72h) 
92 ± 18 
 (24 h) 
14 ± 2.3 
 (72h) 
44.5 ± 0.33 
 (24 h) 
12.1 ± 3.9 
 (72h) 
[Cp2TiCl2] 
titanocene dichloride 
>  200 (24 h) 
>  200  (72h) 
>  200 (24 h) 
>  200  (72h) 
>  200 (24 h) 
>  200 (72h) 
>  200 (24 h) 
>  200  (72h) 
>  200 (24 h) 
>  200  (72h) 
>  200 (24 h) 
>  200  (72h) 
Titanocene Y 
>  200 (24 h) 
> 29.6 ± 2.8 
  (72h) 
>  200 (24 h) 
>  200  (72h) 
>  200  (24 h) 
29.4 ± 4.2 
 (72h) 
>  200 (24 h) 
>  200  (72h) 
>  200 (24 h) 
58.1 ± 11.2 
 (72h) 
>  200 (24 h) 
55.2 ± 7.9 
  (72h) 
aData are expressed as mean ± SD (n =3). 
 
Compound 6 was on average 20-fold more potent than cisplatin and over 20-fold more 
cytotoxic than Ti-Y against ccRCC cells (Caki-1, UO-31) after 72 hours of incubation (Table 2.1) 
8 .Two specific aspects of the cytotoxic evaluation are salient for this investigation: 1) the 
heterobimetallic compounds were far more toxic to tumor cells than they were to healthy human 
embryonic kidney cells transformed (HEK-293T) which indicates that these Ti-Au compounds 
were highly selective; 2) the monometallic Ti fragment (TDC)  and Au fragments (compounds 18 
and 19) of the bimetallic compounds were significantly less cytotoxic than in their bimetallic 
forms. Even when both monometallic fragments were added to the cells together (1:1 ratio), they 
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were still significantly less cytotoxic than the heterobimetallic compound; this finding points to 
cytotoxic synergism between the metals 8 . 
Compound 5 induced necrotic cell death and no binding to DNA, while compound 6 
induced apoptotic cell death while also exhibiting no interaction with plasmid (pBR322) DNA 
(Figures 2.1 and 2.2), suggesting that primary target(s) implicated in cell death was not DNA 8. 
 
 
Figure 2.1. Cell death assays on Caki-1 cells induced by 5 and 6 (10 μM) measured by using 
two-color flow cytometric analysis, after 6 h of incubation. 1% DMSO is vehicle alone control, 
and staurosporine is a known inducer of apoptosis as positive control. 
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Figure 2.2 Electrophoresis mobility shift assays for cisplatin, titanocene dichloride, 
heterometallic compounds 5 and 6. DNA refers to untreated plasmid pBR322. Letters a, b, c, and 
d correspond to metal/DNAbp ratios of 0.25, 0.5, 1.0, and 2.0, respectively. 
 
In our study of the organometallic titanocene-gold compounds as potential 
chemotherapeutic agents in ccRC, we also evaluated their protein kinase inhibitory properties 9. 
From a study of the inhibition of kinases with oncological interest, it was observed that this set of 
compounds includes strong inhibitors of molecules key to tumor migration such as Akt(s) and 
MAPKAPKs in the p38 pathway, with a higher inhibitory selectivity towards MAPKAPK3, with 
IC50 values of 91 nM and117 nM for compounds 5 and compound 6 respectively (Figure 2.3).  
While titanocene dichloride inhibits exclusively protein kinases of the PI3 kinase family at 
nanomolar concentrations  Compounds 5 and 6 inhibited protein kinases Akt and MAPKAPK2 at 
nanomolar concentrations  9.  
To further investigate the ability of these compounds to impair MAPKAPK2/3 activity in 
cancer cells in vitro, we examined the ability of the heterometallic compound 5 and compound 6 
to inhibit IL6 secretion, which can be activated by MAPKAPK2/3 8 .  
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Figure 2.3. IC50 (μM values) for compound 5, and compound 6 against selected protein kinases 
of the AKT and MAKPAPK families.  
.  
We found that compounds 5 and 6 significantly reduced secretion of pro-migratory and 
proangiogenic IL-6 in Caki-1cells (Figure 2.4). Inhibition of MAPKAPK2/3 and IL-6 is likely to 
play a role in the onco-efficacy of the compounds. This study additionally provided clues for 
further rational design of novel Ti-Au compounds with greater target specificity by rational 
modification of the ligand scaffolds 8 .   
 
Figure 2.4. Compounds 5 and 6 may affect downstream targets of MAPKAP2/3 in renal cancer 
cells. Inhibition of IL6 secretion over the course of 6 h in Caki-1 cells treated with compound 3 
or 5 (10 μM). Analysis was done using a capture ELISA approach (human IL-6 ELISA kit). 
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2.2.3 Second Generation Titanocene-Gold Compounds as Potential Chemotherapeutics in 
Renal Cancer: Preliminary in vivo studies 
We then set out to demonstrate that other heterometallic titanium-gold complexes inhibit renal 
cancer cell growth in vitro and in vivo 13. Therefore, we evaluated a series of compounds containing 
titanocene(IV)-methyl fragments and gold(I)-phosphine fragments linked by a dual carboxylate-
thiolate ligand where one carboxylate group is attached to the titanium center and the thiolate is 
attached to the gold center (“second generation” of Ti-Au compounds, seeking to model AF like 
Titanocref and compound 7 in Chart 2.4). We chose the most active first generation compound 5 
and second generation Titanocref for further studies since second generation compound 7 with the 
phoshane DPPF was less active and selective.  
 
Chart 2.4. Structures of heterometallic second generation titanocene−gold complexes Titanocref 
and 7. 
 
 
Compound Titanocref, closely related to first generation compound 5, was more cytotoxic than 
compound 5 and yet still selective. We found that one compound in particular, titanocref, was able 
to block ccRCC growth both in vitro (with an IC50 of 0.12 µM ± 0.003 after 72 hours) (Table 2.2) 
by pathway(s) that involve the inhibition of TrxR (Figure 2.5), and that it exhibited notable anti-
invasive properties (Figure 2.6).  
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Table 2.2. IC50 values (µM) in human cell lines were determined with heterometallic Ti-Au 
compounds 5 and Titanocref , cisplatin, TDC, and titanocene Y. All compounds were dissolved in 
1% of DMSO and diluted with cell culture media before addition to cell culture for a 72 h 
incubation period. Cisplatin and titanocene dichloride were dissolved in H2O. 
 
 
 
Figure 2.5. Comparison of thioredoxin reductase activity in compound 5, Titanocref or 
auranofin treated Caki-1 cells. Activity of Caki-1 thioredoxin reductase from soluble whole cell 
lysates following incubation with 5 μM of compound 5, Titanocref, or auranofin for 5 hours. 
 
 
 Caki-1 HEK-293T 
Compound 5 1.0 ± 0.29 20.1 ± 1.6 
Titanocref 0.12 ± 0.003 0.49 ± 0.008 
Cisplatin 29 ± 4.11 3.27 ±  0.13 
[(η-
C5H5)2TiCl2] 
>  200 >  200 
Titanocene Y 29.42 ± 4.18 >  200 
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Figure 2.6. A. Scratch assay showing that compounds 5 and Titanocref interfere with Caki-1 
migration. Panels show representative images of control (0.1%DMSO treated) cells at time points 
up to 12 hours (top row), or cells treated with 5 (middle row), and Titanocref (bottom row). The 
left column shows a representative image of untreated Caki-1 cells immediately post-scratch (t=0 
h). B. Migration assay showing that 5 and Titanocref interfere with Caki-1migration. The bar graph 
shows the percentage of the wound healed surface. Each bar represents one treatment group, 0.1% 
DMSO control treated cells blue bar), 5 treated cells (blue bar) and Titanocref treated cells (red 
bar). The graph represents results from measurements of the area of the scratch from 4 separate 
and random fields of view. 
 
Compound 5 and Titanocref also downregulated protein kinases implicated in modulating 
cell migration such as p90-RSK, AKT, and MAPKAPK-3 (Figure 2.7). Furthermore, we 
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demonstrated in the case of Titanocref that both metals were localized inside Caki-1 cells, with Ti 
and Au metals at a 1:1 ratio in a dose dependent manner (Figure 2.8).  
 
 
Figure 2.7. Decreased expression of p90-RSK, AKT, and MAPKAPK-3 in Caki-1 cells in 
response to compounds Titanocref and 5. Cells were incubated with either Titanocref or 5 or 0.1% 
DMSO for the indicated times, followed by cell lysis, and western blot analysis. Blots were probed 
with anti-β-Actin antibody as a control for protein loading. Samples from cells treated with second 
generation Titanocref are shown in panel A, and samples from cells treated with first generation 
compound 5 are shown in panel B. 
From these two studies, we determined that heterometallic titanium-gold compound first 
generation 5 and second generation Titanocref inhibit ccRCC growth in vitro and in vivo with 
some mechanistic difference. As we had done previously with first generation compound 5 8, 
Titanocref was then tested for activity against 35 protein kinases commonly associated with cancer 
12. 
Titanocref 5
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Figure 2.8. Cellular uptake of Titanocref in CAKI-1 cells. The concentration of Titanocref was 
calculated based on Ti and Au content in the cell lysates was similar suggesting that the compound 
was robust and that both elements were co-localized within in the cell. 
 
We found that compound 5, and Titanocref inhibited MAPKAPK3, kinases regulated 
through direct phosphorylation by p38 MAP kinase 8,13. p38 kinases are known to be pivotal to 
many cellular processes including inflammatory responses, gene expression regulation and cell 
proliferation, and are highly expressed in cancerous cells. From immunoblotting experiments, we 
also found that both compounds exhibited strong inhibition of MAPKAPK 3 activity, and given 
that MAPKAPK 3 expression in increased in certain cancers, novel inhibitors such as compound 
5 and Titanocref are therefore of particular interest 8,13.  
Compound 5 and Titanocref were both tested in vivo in NOD SCID mice bearing 
subcutaneous Caki-1 tumors. Following 28 days of treatment (14 doses) in mice treated with 
Titanocref (at 3mg/kg/48h), we observed a 67% reduction in tumor burden. In mice treated with 
compound 5 (5mg/kg/48h) under the same conditions, we observed 90% tumor growth, though 
the growth was 15% lower than that of control mice. Thus although modest, compound 5 may play 
an inhibitory role in tumor growth 13. (Figure 2.9) 
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.  
Figure 2.9. A. Percent reduction of tumor burden with compound 5 or Titanocref in a cohort of 
18 female NOD.CB17-Prkdc SCID/J mice inoculated subcutaneously with 8×106 Caki-1 cells. The 
treatment was initiated when tumors were palpable (6 mm diameter). 6 mice were treated with 
Compound 5 or Titanocref (red bars), and 6 were treated with the vehicle 100μl normal saline 
(0.9% NaCl) (black bars). Compound 5 was administered at 5mg/kg/48h, Titanocref was 
administered in the amount of 3 mg/kg/every other day.  
 
Such results warrant further in vivo studies to optimize effective dosage and to determine 
the compound’s pharmacokinetics. In addition, these results corroborate the notion of 
multifunctional efficacy of heterometallic Ti-Au complexes and highlight their chemotherapeutic 
potential.  
 
2.2.4 Third generation Titanocene−gold compounds as potential chemotherapeutics for 
prostate, renal and colon cancer. 
 We then proceeded to explore the inhibitory properties of titanocene−gold 
complexes containing N-Heterocyclic Carbene (NHC) ligands against prostate, renal, and colon 
cancers in vitro 12. Such modifications were made in the hopes that perhaps replacing the 
phosphane with a carbene might improve efficacy as recent publications had suggested N-
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herocyclic carbenes confer an anticancer advantage 12. We therefore tested Ti-Au compounds 
containing gold(I)–N-heterocyclic carbene moieties (instead of Au(I)-phosphane fragments) (9a-
d in Chart 2.1 and Chart 2.5). The design of this “third generation” of Ti-Au compounds was 
intended to improve or modify the pharmacological profile of the described “second generation” 
compounds 12-.  
 
Chart 2.5. Structures of heterometallic third generation titanocene−gold complexes 9a-d and 
corresponding gold monometallic complexes 8a-d.   
 
 
 Monometallic NHC–Au(I) complexes are usually more stable than Au(I)–
phosphane compounds and allow for further synthetic modification of the ligand (to for instance 
improve hydropilicity, luminescence, etc.). However, the cytotoxicity of the new compounds in 
renal cancer cell lines was found to be much lower than the “second generation” Ti-Au compounds 
containing phosphanes as ligands. Their greatest cytotoxicity was found against prostate and colon 
cancer cells.  We also observed considerably higher selectivity (than both the first and second 
generation compounds) with respect to noncancerous cell lines (Table 2.3). Two selected 
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compounds (9a, 9b) were found to potently induce apoptosis and to inhibit TrxR in prostate PC3 
cancer cell lines (Figure 2.10) 11. Moreover, as with the previously studied Ti-Au phosphane 
compounds, both metal fragments were co-localized inside of the cells (Figure 2.11). These 
complexes also displayed strong antimigratory properties (Figure 2.12).  
 
Table 2.3. IC50 values (µM) in human cell lines were determined with heterometallic Ti-Au 
compounds 9a-d, monometallic Au compounds 8a-d and titanocene Y used as control. All 
compounds were dissolved in 1% of DMSO and diluted with water before addition to cell culture 
medium for a 72 hour incubation period. Data are expressed as mean ± SD (n =3). 
Compound PC3 DU-145 Caki-1  DLD1 MDA-MB-231 
HEK-
293T 
Ti-Y 58.1 ± 11.2 55.2 ± 7.9 29.4 ± 4.2  56.2 ±9.8 18.0 ± 3.6 >200 
9a 9.8 ± 2.2 11.8 ± 3.0 21.0 ± 1.9  13.9 ± 1.7 >100 58.8 ± 6.7 
9b 10.3 ± 2.8 18.9 ± 2.9 51.5 ± 3.7  30.4 ± 4.1 >100 >100 
9c 17.1 ± 2.9 13.76 ± 2.7 29.11 ± 4.1  19.9 ± 4.1 >100 69.7 ± 9.9 
9d 11.8 ± 1.6 16.7 ± 2.0 42.9 ± 5.8  21.5 ± 2.0 >100 77.1 ± 9.1 
8a 66.3 ± 6.4 74.8 ± 4.4 81.4 ± 2.9  78.2 ± 6 >100 >100 
8b 70.4 ± 6.8 60.9 ±5.2 79.2 ± 11.7  82.6 ± 5.9 >100 >100 
8c 57.1 ± 5.1 67.6 ± 7.1 97.2 ± 8.6  73.1 ± 9.6 >100 87.9 ± 6.4 
8d 65.1 ± 4.4 59.9± 4.7 88.9 ± 5.1  77.5 ± 8.1 >100 97.2 ± 5.1 
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Figure 2.10. Thioredoxin reductase activity in monometalic Au 8a, 8b, 9a, or bimetallic Ru-Au 
9b treated PC3 cells: (Left) activity of endogenous PC3 thioredoxin reductase from soluble whole 
cell lysates following incubation with 30 μM of 8a or 8b for 5 and 24 h (values normalized against 
DMSO control); (Right) activity of endogenous PC3 thioredoxin reductase from soluble whole 
cell lysates following incubation with 5 μM of 9a or 9b for 5 h and 24 h (values normalized to 
DMSO control). 
 
 
Figure 2.11. Cellular uptake of compound 9a in PC3 cells. The concentrations of compound 9a 
calculated on the basis of Ti and Au content in the cell lysates are similar, suggesting that the 
compound is robust and that both elements are colocalized in the cells. 
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Figure 2.12. Cell migration in 9a or 9b treated PC3 cells. Migration of PC3 cells was assessed 
using a wound-healing assay following treatment with 15 μM titanocene Y or 5 μM of 9a or 9b 
incubated for 24 h (values normalized against 0.1% DMSO control). Both mono— and bi—
metallics lead to significant reduction in migration. 
 
The focus of my research broadened to include ruthenium containing compounds because 
there was suggestion that they could confer antimetastatic properties to the complex. We thought 
that it might be a potentiating agent to the observed cytotoxic properties observed with gold based 
compounds. The Contel lab had demonstrated that indeed ruthenium-gold compounds were indeed 
more cytotoxic and more selective to cancerous cell lines than individual ruthenium and gold 
species 9. As with the third generation of Ti-Au described before, we decided to incorporate gold 
containing N-heterocyclic carbene ligands to obtain second generation compounds that we expected 
to have a better pharmacological profile. These compounds were synthesized in the Contel lab and 
evaluated against renal and colon cancers 10. 
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2.2.5 Second generation heterobimetallic ruthenium–gold compounds as potential anticancer 
agents for renal and colon cancer 
 
 As described before, we went on to evaluate new cationic heterobimetallic ruthenium-gold 
compounds containing a N-heterocyclic carbene–gold(I) fragment (second generation). Building 
on work reported by the Contel group in 2015 on neutral ruthenium-gold Ru(II)-Au(I) compounds 
(first generation 10 and 11, in Chart 2.2), improved heterobimetallic cationic Ru-Au derivatives 
were synthesized incorporating the same linker (dppm) but also incorporating NHC- carbene 
ligands coordinated to Au 10. Gold NHC-carbene complexes exhibit great antimitochondrial 
properties attributable to both their cationic nature and their lipophilicity. Joining the potential 
antimetastatic/cytotoxic properties of Ru to the TrxR inhibitory effects of Au species may give 
rise to potent cancer chemotherapeutics. 
This novel series of heterometallic compounds [second generation Ru-Au depicted in Chart 
2.2, compounds 12-14 and RANCE-1] have been shown to be highly cytotoxic to ccRCC Caki-1 
and colon cancer DLD1 cell lines while also more selective than their monometallic counterparts 
(Table 2.4), which suggests that there is synergism between the two metal moieties 10. They are 
also very stable in physiological media, more so than their Ti-Au-NHC counterparts with half lives 
of 24h to 72h. 
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Table 2.4. IC50 values (PM) in human cell lines were determined with monometallic 
[(NHC)AuCl] 115-17 and ANCE-1 monometallic [Ru(p-cymene)Cl2(dppm-κP)]  R, and new 
heterometallic Ru–Au compounds (12–14) and RANCE-1. 
aAll compounds were dissolved in 1% of DMSO and diluted with water before addition to 
cell culture medium for a 72 h incubation period. Cisplatin was dissolved in H2O.  
 
As mentioned in chapter 1, changes in cell anti-oxidant capacity are a characteristic of 
many chemo-resistant cancers, and overexpression of thioredoxin reductase (TrxR) is among the 
key defense and survival mechanisms of cisplatin-resistant cells. It has been reported that 
Auranofin, some heterometallic titanocene– gold   as well as Au–NHC compounds are inhibitors 
of TrxR, with varying degrees of potency13. We wanted to know if the addition if a Ru moiety 
would preclude or potentiate the Au-driven inhibition of TrxR (Figure 2.13) 
 
 Caki-1 HEK-293T HCT 116 
[(NHC)AuCl]    
15 27.1 ± 2.0 61.5 ± 5.1 39.7 ± 4.9 
ANCE-1 21.2 ± 1.6 >100 31.2 ±3.2 
16 58.8 ± 3.9 >100 59.1 ± 5.8 
17 17.5 ± 2.2 >100 27.7 ± 4.9 
[Ru(p-
cymene)Cl2(η1-
dppm)] R 
35.6 ± 3.7 81.6 ± 3.0 
18.2 ± 2.2 
New cationic Ru-Au    
12 5.2 ± 0.9 73.2± 2.5 8.1 ± 1.8 
RANCE-1 14.1 ± 1.9 >100 5.22 ± 0.7 
13 3.8 ± 0.6 >100 6.4 ± 1.0 
14 12.7 ± 2.7 >100 9.6± 3.1 
cisplatin 29 ± 4.11b 3.27 ±  0.13b --- 
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Figure 2.13 . Inhibition of mitochondrial protein TrxR in Caki-1 renal cancer cells by bimetallic 
Ru-Au compound 12, the monometallic ruthenium R, andgold 15 compounds and Auranofin (1 
µM) for 24h (A) and 72 h (B). The values for indicate the percentage of reduction of TrxR activity 
relative to 1% DMSO treated control. (C)Thioredoxin reductase activity of 12 treated Caki-1 cells. 
Activity of endogenous Caki-1 thioredoxin reductase from soluble whole cell lysates following 
incubation with 5 µM of compound 12 or 0.1% DMSO for 5, 12 and 24 hours.  
 
Therefore, we measured the activity of thioredoxin reductase in Caki-1 cells, following 
incubation with compounds bimetallic Ru-Au 12, its monometallic Au moiety 15, Ru moiety R 
and Auranofin as a control. We found TrxR activity to be significantly lowered in cells treated 
with 1µM of Auranofin (-61% after 24h and -85% after 72h of incubation) and 12 (-51% after 24h 
and -77% after 72h of incubation), while not significantly affected by R (-3% after 24h and -8% 
after 72h of incubation)  or 15 (-5% after 24h and -6% after 72h of incubation). It appears that the 
inhibition of TrxR is time dependent, at least for Au-containing compounds, as the activity 
increases remarkably from 24h to 72h. 12 anti TrxR activity is also dose dependent since when 
treated with 5 µM of 12, TrxR activity is reduced by 63% after 24h incubation (Figure 2.13) while 
treated with 1 µM for 24h TrxR inhibition is of 51%. 
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We have determined that the incorporation of a Au-NHC moiety and the change from 
neutral to cationic compounds seem to improve anticancer activity. From this work we identified 
RANCE-1 (containing the NHC ligand = IMes) which we went on to study further in vivo and in 
vitro (Chapter 4). We chose compound RANCE-1, because though it is less potent than other 
compounds, it is more stable, and because in later evaluations not reported in the publication at 
hand, at sub-cytotoxic doses it was most effective at reducing migration and invasion, and also a 
better inhibitor of tube formation.  
 
2.2.6 Formulation of research objectives.  
From this body of work we identified Ti-Au Titanocref and Ru-Au RANCE-1 as candidates 
worth exploring further. As mentioned in Chapter 1, after assessing the literature, one determines 
that there is no conserved narrative of how a set of given metals affect cancer cell behavior, in part 
because there has not been systematic study of the phenotypes and pathways affected. It has been 
shown that gold compounds, ours included, inhibit mitochondrial enzyme Thioredoxin reductase 
(TrxR), which in part induces chemoresistance, and this was confirmed for our compounds. There 
is little or fragmented knowledge on mode of cell death, and molecular pathways by which 
heterobimetallic complexes achieve anti-cancer efficacy.  We found that Titanocref is an excellent 
inhibitor of MAPKAPK3, and know that it leads to a reduction in tumor burden, not much else 
was known. During my thesis an analogue of Titanocref was synthesized in our lab. This analogue 
(Titanofin in Chart 2.1) contains a gold-phosphane fragment (AuPEt3) that is also present in the 
drug Auranofin (AF). As described in chapter 1, AF has been used in the clinic for the treatment 
of rheumatoid arthritis 13 but it is currently being investigated in clinical trials in cancer as a 
potential anticancer chemotherapeutic 16–19. 
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To gain essential insights we have studied the complexes effect on cellular behaviors linked 
to tumor malignancy, then interrogated protein of oncological interest, particularly those involved 
in angiogenesis, metastasis and cell death to obtain a cleared understanding of the compounds 
efficacy. These studies constitute chapters 3 and 4 of this thesis. 
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2.3. OBJECTIVES 
2.3.1 The main goal of the work described in this thesis 
 
The aim of my doctoral work has been to identify the tumor-malignancy phenotypes affected by a 
selection of novel Ti-Au and Ru-Au compounds (three in total) and to elucidate some of the 
underlying mechanisms of their in vitro and in vivo efficacies.   
 
2.3.2 Hypothesis 
 
The individual metals in Ti-Au and Ru-Au complexes contribute to multiple aspects of 
their anticancer efficacy, 1) direct cytotoxicity 2) hindrance of tumor cell malignancy phenotypes, 
and/or 3) inhibition of protumorigenic stromal cellular behavior. Furthermore, distinct 
mechanisms are engaged by these compounds to bring about these anti-cancer phenotypes. 
 
2.3.3 Specific Aims of this thesis 
 
2.3.3.1 Aim 1. To refine our understanding of the cytotoxic and antiproliferative profile of a 
series of Ti-Au and Ru-Au compounds in vitro.  This aim was designed as an exploration 
wherein novel compounds were tested for activity against multiple cell lines in order to identify 
compounds and tumor types for more in depth investigation (Chapter 2).  
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2.3.3.2 Aim 2. To evaluate the effects of Titanocref, Titanofin and their gold monometallic 
moieties on metastatic and antiangiogenic phenotypes and related pathways in vitro and in 
vivo in a mouse model of RCC. Based on the results of Aim 1, two gold-titanium compounds 
(Titanocref and Titanofin) were selected for a deeper investigation of their mechanism of action 
based on their inherent chemical characteristics, their efficacy, and an indication of synergism 
between the two metals in the compound. Their specificity, cytotoxicity, and mechanism of action 
were assessed using in vitro models, and their potential for development and clinical trials was 
assessed using an in vivo model (Chapter 3). 
 
2.3.3.3 Aim 3. To evaluate the effects of RANCE-1 and its monometallic moieties on 
metastatic and antiangiogenic phenotypes and related pathways in vitro and in vivo in a 
mouse model. Similar to Aim 2, but focused on a selected gold-ruthenium complex (RANCE-1). 
The specificity, cytotoxicity, and mechanism of action were assessed using in vitro models, and 
their potential for development and clinical trials was assessed using an in vivo model (Chapter 4). 
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CHAPTER 3 
EFICACY AND MECHANISTIC STUDIES OF GOLD-TITANOCENE COMPLEXES IN 
VITRO AND IN VIVO.  
Part 1 
Bimetallic titanocene-gold phosphane complexes inhibit invasion and metastasis-associated 
signaling molecules in renal cancer in vitro.  
 
3.1 INTRODUCTION  
 
The potential of heterometallic compounds in medicinal chemistry and particularly in 
cancer therapy has been described and discussed in the earlier chapters1. Importantly, a single 
molecule with two or more distinct biologically active metallic centers can potentiate 
oncotherapeutic efficacy 2. This may derive from synergism (combined action of the different 
metals) or cooperation (beneficial change in the physicochemical properties) between the two 
metal entities. In the past eight years a number of heterometallic compounds have been reported 
as anticancer agents 1–17. However, there are very few publications reporting the comparison of 
anticancer properties of heteronuclear compounds to that of their monometallic fragments (alone 
or in combination) 1,5,7,8,10,18–20. Our group has focused on heterometallic compounds with gold 
fragments as one of the metallic centers. Gold(I) compounds bearing lipophilic ligands such as 
phosphanes (PR3) and N-heterocyclic carbenes (NHC) have displayed significant antitumor, 
antimicrobial, and antiparasitic effects mostly mediated by inhibition of the 
thioredoxin/thioredoxin reductase Trx/TrxR systems21–23. In this context, we have recently 
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reported on the preparation of complexes containing titanocenes 7,8,19,24,25 [TiCp2] or ruthenium(II) 
arene derivatives 5,18  [Ru(p-cymene)Cl2(dppm)] and gold(I)-phosphane or gold(I)-NHC fragments 
(2, a and b in Chart 1) and their potential as chemotherapeutics against renal, colorectal and 
prostate cancers.  
 
 
Chart 3.1. Select heterometallic Ti-Au Titanocref , Ti-Au-NHC  and Ru-Au (b) compounds with 
relevant in vitro and in vivo activity reported by our group 5,7,18,25. Structure of monometallic cref, 
AF and TDC also employed in this work. 
 
Preliminary mechanistic studies indicated that these compounds achieve toxicity through 
mechanisms different than that of cisplatin, as is the case for many other metallodrugs 5,19,25. In 
this section, we report on the comparative in vitro mechanistic evaluation of the efficacy of 
bimetallic Titanocref and Titanofin  with that of AF and the monometallic gold compounds cref  
and  fin 2--. All compounds are depicted in Chart 3.1. We studied their cytotoxicity, mode of cell 
death induction, cell cycle disruption, as well as their anti-migratory and anti-angiogenic properties 
and their inhibitory effects on 84 markers of oncological interest. We have recently reported on 
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the mechanism of action of a ruthenium-gold derivative in vitro (Caki-1 cancer cells), in which we 
also used AF as control in a number of similar experiments 5. 
 
3.2 RESULTS AND DISCUSSION 
 
3.2.1 Chemical profile  
This data was obtained from Dr. Jacob Fernández-Gallardo and Dr. Natalia Curado  
Titanofin was more soluble than Titanocref in DMSO/PBS. While the half-life for 
Titanocref in neat DMSO-d6 was 8 hours, the half-life of new Titanofin was 24h (three times 
higher). In addition, Titanofin was soluble in mixtures DMSO:D2O (3:2) and the stability in these 
solutions was higher (4 days). Both Titanocref and Titanofin are soluble in DMSO:PBS (1:99) in 
the micromolar range (necessary for the biological assays). 
 
3.2.2 Cytotoxicity, Selectivity, Cell Death and Cell Cycle Arrest 
The cytotoxicity of bimetallic Titanocref (compound 2) and Titanofin (compound 4), the 
two monometallic gold derivatives, cref (compound 1) and fin (compound 4), and monometallic TDC 
were evaluated. For comparative purposes, the cytotoxic profile of AF was also determined. In this 
assay, human clear-cell renal carcinoma Caki-1 cells and non-tumorigenic human fetal lung 
fibroblasts (IRM-90) were incubated with the Titanocref, cref, Titanofin, fin, AF, or TDC for 24h 
and 72 h. The results are summarized in Tables 3.1 and 3.2. The heterometallic compounds were 
considerably more toxic to the renal cancer cell line (Caki-1 cells) than titanocene dichloride and 
AF (in the sub-micromolar range as already reported for Titanocref for different renal cancer cell 
lines) 7,25. In addition, Titanocref was far more toxic in the nanomolar range than the monometallic 
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gold compound, cref on these cells. Titanofin was three times more toxic than the monometallic 
compound PEt3 fin. This supports the hypothesis that the presence of two biologically active metals 
improves cytotoxicity.  
 
Table 3.1. Cell viability IC50 values (µM) for Caki-1 cells and IMR-90 fibroblasts treated with 
bimetallic Titanocref and Titanofin, or monometallic gold cref and fin compounds. Monometallics 
AF and TDC were used as controlsa . The IC50 are reported with the standard deviation of the 
sample mean. 
Compound Caki-1 IMR90 
Ti-Au (PPh3)  Titanocref 0.097 ± 0.019 1.6 ± 0.006 
[Au(Hmba)(PPh3)]  cref 2.70 ± 0.052 3.99 ± 0.09 
Ti-Au (Pet3)   Titanofin 0.273 ± 0.043 3.131 ± 0.07 
[Au(Hmba)(Pet3)]  fin 0.794 ± 0.002 2.991 ± 0.006 
[Au(SR)(Pet3)] AF Auranofin  2.8 ± 0.6b 3.7 ± 0.4b 
[Ti(Cp)2Cl2] TDC Titanocene dichloride  >100 >100 
 
aAll compounds were dissolved in 1% of DMSO and diluted with media before addition to cell 
culture medium for a 72 hour incubation period. Cisplatin was dissolved in H2O. Structures of the 
compounds are provided in Chart 1 b. Values reported in reference 30. 
 
 
 
 
 
81 
 
Table 3.2. Cell viability IC10, IC20, IC50 values (µM) for Caki-1 cells and IMR-90 fibroblasts 
treated with bimetallic Titanocref , Titanofin and monometallic gold cref and fin compounds for 
72h; and Cell viability IC20, IC50 values (µM) for Caki-1 cells and IMR-90 fibroblasts treated with 
bimetallic Titanocref, Titanofin and monometallic gold cref and fin  compounds for 24h.  
Monometallics AF and TDC were used as controlsa . The ICs are reported with the standard 
deviation of the sample mean. 
aAll compounds were dissolved in 1% of DMSO and diluted with media before addition to cell 
culture medium for a 24h or 72 h incubation period. Cisplatin was dissolved in H2O. Structures of 
the compounds are provided in Chart 1 b. Values previously reported5 . 
 
Importantly, both heterometallic compounds were more selective to renal cancer cells than 
AF or the monometallic gold compounds, especially Titanocref. In view these results and the very 
high concentration of TDC required to observe cytotoxic effects, we decided not to explore the 
effects of titanocene dichloride in Caki-1 cells any further. 
In addition to measuring the IC50 at 72h, we also assessed the IC50 after 24h of incubation. 
Because we sought to determine the changes in cellular behavior as well as the associated 
molecular signaling events, it was essential that the cells were viable throughout the experiment, 
therefore we used concentrations at which we know that after 72h incubation 80% (IC20) or 90% 
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(IC10) of the cells would be viable. Some assays were carried out after 24h of incubation with the 
72h IC20, which is the lowest dose at which we were able to observe detectable changes in the 
expression levels of the proteins of interest after 24h.  For changes in cellular behaviors such as 
tube formation, we reported on the IC10 at 72h since we observed changes at that concentration in 
a trial dose response experiment. Finally, the 24h IC50 evaluation was conducted to demonstrate 
that the 72h IC20 of the compound did not induce significant cytotoxicity after 24h incubation.  
Following the evaluation of the cytotoxicity of bimetallic Titanocref or Titanofin and 
monometallic gold AF, we proceeded to evaluate how the cells died. For this assay Caki-1 cells 
were incubated with the indicated compound at the IC50 concentration for 72 hours. We observed 
that all the compounds induced apoptosis to some degree at their IC50 concentration. For the Ti-
Au compounds Titanocref and Titanofin (at nanomolar concentration) 58% and 76% of cells died 
by apoptosis (Figure 3.1).  
AF and other gold (I) compounds are known to induce apoptosis in several cancer cell lines 
26,27, TDC also induces apoptosis albeit at much higher concentrations than the aforementioned 
compounds 28 . Thus the apoptotic behavior of bimetallic Titanofin and Titanocref may be due to 
the presence of both the Ti and Au fragments. We also determined the apoptotic EC50 of the 
monometallic and bimetallic compounds, and degree of necrosis in a triple assay (Figure 3.2). 
Next, we evaluated the effects of bimetallic Titanocref and Titanofin and monometallic AF 
on cell cycle arrest (Figure 3.1). Titanocref and Titanofin decreased G1/G0 by 32% and 33% 
respectively and increased the G2/M population by 38% and 36% respectively compared to the 
DMSO control. 
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Figure 3.1. Effects of Titanocref, Titanofin, and AF on apoptotic index and cell cycle distribution 
on Caki-1 cells. (A) Cell apoptosis in bimetallic Titanocref, Titanofin and monometallic AF treated 
cells was detected by Annexin V and propidium iodide (PI) labeling combined with flow 
cytometry after 72h of incubation with IC50. The level of apoptosis was measured by the percentage 
of the total PI positive cells reported in each quadrant 2 (Q1= dead cells, Q2=Apoptotic cells, Q3= 
Alive cells). Treatment with of bimetallic Titanocref, Titanofin and monometallic AF for 24h 
caused cell cycle arrest. Cell-cycle analysis was conducted by FxCycle staining and flow 
cytometry 24 h after treatment with bimetallic Titanocref, Titanofin, monometallic AF or DMSO 
(0.1%) control. Numbers in the bar-graph (C) correspond to histograms (D) show the percentage 
of cells in the Sub G1, G0-G1, S and G2-M phases of the cell cycle (values below 3% were not 
reported on the bar-graph). 
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Figure 3.2. Effects of Titanocref, Titanofin, and AF on caspase 3/7 activity. Caspase 3/7 was used 
as an indicator of caspase dependent apoptosis Apoptosis induced by Staurosporine treatment was 
used as control. Necrosis was studied by measuring dose-dependent increase in cytotoxicity in the 
absence of caspase-3/7 activation a cellular behavior associated with primary necrosis, and 
necrosis induced by Ionomycin treatment was used as control. The cells were treated with doses 
ranging from 0.001 µM to 10 µM and incubated for 72h.  
AF increased G1/G0 by 27% and induced an arrest of 76% of the cell population at G1/G0 
(as we recently reported), while also generating a peak at SubG1 in 20% of the cells arrested, 
consistent with apoptosis 5. This suggests that the AF induced complete G1/G0 arrest, as has already 
been reported for other cells lines treated with AF 28–31, or other anti-inflammatory drugs 32. The 
cell cycle shifts of Titanocref  and Titanofin were strikingly similar, and unlike that of AF, 
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suggesting that perhaps the Ti moieties account in part for the distribution in G2/M and the prevent 
the complete switch to G1/G0 observed with AF.  
 
3.2.3  Inhibition of migration and invasion  
Increased local cell migration followed by distal invasion are hallmarks of metastasis 33. 
We therefore evaluated the anti-migration and anti-invasive properties of bimetallic Titanocref and 
Titanofin and monometallic gold cref, fin, and AF. The effect of the compounds (IC20) on 
migration was determined using a wound-healing 2D scratch assay on a collagen-coated plate 
(Figure 3.3A). We chose the IC20 because it was determined that at that concentration about 80% 
of the cells (78% ± 2.31 depending on the compound) remained viable. Migration was quantified 
by measuring the space in the wound gap that is occupied by cells 24h after treatment. We observed 
that heterometallic Titanocref and Titanofinas well as AF significantly reduced migration (89%, 
83% and 81% respectively), while gold monometallic cref  and fin  inhibited migration to a lesser 
degree (40% and 33% respectively). While the cytotoxicity and apoptotic properties of AF on 
different cancer cell lines are well known, the efficacy of AF as an anti-migratory and perhaps anti-
metastatic compound has only recently been identified5,26. All the compounds studied interfered 
with invasion and followed a similar trend, with AF and Ti-Au compounds being most effective 
(Figure 3.3B). There was also a clear trend that the monometallic gold compound fin was a better 
inhibitor of invasion than cref, although their ability to inhibit of migration was similar. This may 
be because proteolysis is necessary for the cells to infiltrate though the 3D matrix, but is not needed 
for 2D migration. 
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Figure 3.3. Cell Migration and Invasion Inhibition Assays for bimetallic Ti-Au Titanocref  and 
Titanofin  and monometallic Au cref, fin,  and AF. A. Inhibition of migration (2D wound-healing 
scratch assay). Scratch assay showing that Titanocref, Titanofin,  and monometallic cref, fin, and 
AF interfere with Caki-1 migration. Panels show representative images of untreated cells at time 
points T0 (top row) when the compound is added to the assay up to 24 hours (bottom row). B. 
Inhibition of invasion (3D transwell assay Geltrex) showing that Titanocref, Titanofin  and 
monometallic cref, fin,  and AF interfere with Caki-1 invasion. The invasion assay was performed 
using an ECM-like Reduced Growth Factor Basement Membrane Matrix (Geltrex) 3:1. Panels 
show representative images of cells 24 hours after treatment with the 72h IC20 concentration at 
which we observe less than 8% cell death after 24h of incubation. The data reported in the graph 
are the mean and standard deviation of the mean from two independent trials averaging 
quantitation from five fields of view per trial. 
 
 
87 
 
 Indeed fin  which is a better inhibitor of invasion, was also a stronger inhibitor of MMP-9 and 
MMP-2 (see next sections), which are proteolytic agents known to be key players in migration and 
metastasis. As explained above, the most efficient compounds in these experiments were 
bimetallic Titanocref and Titanofin. 
3.2.4  Inhibition of angiogenesis 
Neovascularization plays an essential role in tumor malignancy.  
  
Figure 3.4. Instigation of endothelial cell reorganization into 3D vessel assembly. Human 
umbilical vein endothelial cells (HUVEC) were seeded in plates coated with Geltrex® matrix 
using complete HUVEC media and incubated at 37°C and 5% CO2. At post-seeding the 72h IC10 
of bimetallic Ti-Au Titanocrefor Titanofin,  or AF or 0.1% DMSO was added. (A) Representative 
phase-contrast images captured 24h after the compounds were added. (B) Quantitation of tube 
formation was performed using Image-J with the Angiogenesis plugin. 
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We therefore chose to measure potential effects of our compounds on neovascularization by 
examining the formation of tube-like structures by HUVEC cells in an in vitro extracellular matrix 
34.   
In this assay, the endothelial tube formation of human umbilical vein endothelial cells 
(HUVECs) on an ECM-like matrix was determined as a function of length of the uninterrupted 
tubes (TL), and number of branching point or nodes in the tubes (TN) (Figure 3.4). The number 
of tubes and nodes was counted using Image-J with the Angiogenesis plugin. The greater the 
inhibition of tube formation [lower length of tube (TL) and the lower the number of nodes (TN)], 
the higher the anti-angiogenic properties of a compound.  
Both Titanocref  and Titanofin, as well as control AF induced similar disruption in tube 
integrity with an average of 50% in disruption tube length (TL) and 45% disruption in tube node 
(TN) formation. This indicated that the three compounds are good disrupters of vascular 
formation, which is a key attribute of many antiangiogenic compounds and can prevent tumor 
growth and hinder metastasis. 
 
3.2.5  Inhibition of targets associated to cancer cisplatin resistance, metastasis and angiogenesis 
3.2.5.1 Inhibition of Thioredoxin Reductase 
Changes in intracellular oxidation states are a distinctive feature of many chemo-resistant 
cancers. We previously reported on the significant inhibition of TrxR in Caki-1 cells by AF  and 
heterometallic titanocene-Au and Ru-Au complexes 5,7,25.  Here, we measured the activity of  
(TrxR) in Caki-1 cells, following incubation with bimetallic Ti-Au and monometallic Au 
complexes (Figure 3.5). After 72h (but not at 24h) of incubation, Caki-1 TrxR activity was 
significantly reduced by AF (86%) 5,25 , After 72 h of incubation, the inhibition of TrxR by the 
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bimetallic Ti-Au Titanocref  and Titanofin  was very similar (Titanocref, 87%; Titanofin 79%) and 
was larger than the inhibition displayed by monometallic gold compounds cref  and fin  (54% and 
57% respectively).  
3.2.5.2 Inhibition of VEGF 
 
Figure 3.5. Inhibition of proangiogenic factors TrxR and VEGF in Caki-1 cells by bimetallic Ti-
Au Titanocref  , Titanofin  and monometallic Au cref  , fin  and AF occurs in a time and dose 
dependent manner. (Left) Inhibition of proangiogenic anti-apoptotic mitochondrial protein TrxR 
following treatment with IC20 concentrations of each compound for 24 h and 72h. The values 
indicate the percentage of TrxR activity relative to DMSO treated cells. (Right) Inhibition of 
proangiogenic protein VEGF, following treatment with IC20 concentrations of each compound for 
24 h and 72h. The values indicate the percentage of VEGF expression relative to DMSO treated 
cells. The data shown, and standard deviation of the sample mean, result from two independent 
trials. 
Given the key tumor promoting properties of VEGF, we set out to evaluate the inhibitory 
effects of bimetallic Ti-Au Titanocref and Titanofin and monometallic Au cref, fin  and AF on 
VEGF. We found that VEGF secretion is inhibited by both bimetallic Ti-Au Titanocref  and 
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Titanofin, and AF after 72h incubation with IC20 of each compound  (41%  , 59%  and 55% (AF) 
reduction respectively), while for monometallic Au cref  and fin  there was no significant inhibition 
of VEGF secretion (22% and 17% respectively). In this case, the strong inhibition of VEGF could 
be correlated to the anti-angiogenic effects we found since VEGF is known to be a key regulator 
of angiogenesis and its downregulation is often correlated with reduced angiogenesis. 
 
3.2.5.3 Inhibition of Cytokines (TNF-α and interleukins) 
We then investigated the inhibition of TNF-α  and interleukins (ILs) by our bimetallic and 
monometallic compounds after 72 hours of incubation at IC20 concentrations (Figure 3.6). The 72h 
timepoint was selected because no significant effect was observed after 24h of incubation at the 
same concentrations (Figure 3.6B). We found that the bimetallic compounds, gold monometallic 
compounds, and AF inhibited IL-6 expression almost completely. 
AF and Titanocref also inhibited IL-5 expression while the inhibition by Titanofin was 
more modest (89% Titanocref, 59% Titanofin and 88% AF). AF was a better inhibitor of IL-8 
while both Titanocref  and Titanofin were much stronger IL-4 and IL-17A inhibitors. Titanocref, 
Titanofin, and monometallic Au cref and fin were particularly strong inhibitors of IL-17A. Because 
IL-17A expression is associated with estrogen receptor negative (ER(−)) and triple negative tumor 
hyper proliferation and poor prognosis in breast cancer, and not only promotes tumor cell survival 
and invasiveness, but also contributes to the promotion of tumor angiogenesis, IL-17 inhibitors are 
of significant clinical interest. AF inhibited IL-6, as previously reported 5 , but we also observed 
that it also inhibited expression of IL-5 and IL-8, all key players in inflammatory signaling 5,35,36  
. 
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Figure 3.6.  Bimetallic Ti-Au Titanocref , Titanofin  and monometallic Au cref , fin  and AF 
induced changes in the expression levels of prometastatic cytokines (TNF-α, and interleukins) and 
matrix proteases (matrix metalloproteinases) in Caki-1 cells. Analysis of 150 ng of protein 
extracted from cell lysate collected from cell treated with IC20 of the compounds for 72h. The data 
shown result from two trials, the standard deviation of the sample mean is reported. 
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3.2.5.4 Inhibition of matrix metalloproteases 
We next studied the inhibition of several MMPs of oncological interest (MMP-1, MMP-2, 
MMP-3, MMP-7, MMP-8, MMP-9) by bimetallic Ti-Au Titanocref and Titanofin (4), and 
monometallic Au cref , fin,  and AF. The protein expression of all the selected MMPs was strongly 
inhibited by the bimetallic compounds except MMP-2 which was most inhibited by the 
monometallic compounds. For MMP-3, both the bimetallic and monometallic compounds 
achieved inhibition greater than 50%. The inhibition of MMP-7 was significant, and similar 
between the bimetallic compounds, while treatment with the monometallic compounds caused 
no inhibition (Figure 3.7). AF and Titanofin  (to a slightly higher degree) inhibit the expression of 
MMP-9, while Titanocref  and the monometallic cref and fin  did not have a significant effect 5.  
It is evident from the changes in expression we observed as a result of treatment with 
Titanocref , Titanofin  and monometallic cref, fin  and AF, that while bimetallic compounds are 
most often more effective inhibitors than monometallic compounds, the latter do have a non-
negligible IL and MM inhibitory profile, rendering them promising anti-cancer candidates (see 
fin). 
Because there is limited understanding of the pathways by which metallodrugs achieve 
efficacy, we performed a protein expression screen of our compounds’ effects on 84 cancer-related 
proteins for 72h at IC20. From this screen, we identified that our compounds had a significant effect 
on nine markers of oncological interest in addition to the fourteen reported earlier in this chapter. 
In an attempt to determine if there was any discernable pattern in the inhibition of expression of 
oncological proteins by bimetallic compounds, we generated a heat map (Figure 3.7) comparing 
the effects of bimetallic Ti-Au (Titanocref and Titanofin) and monometallic Au (cref and fin) as 
well as AF shown in Figures 3.5 and 3.6.  
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Figure 3.7.  Heat map visualization of protein expression data. Each row represents a protein of 
oncological interest and each column represents a specific compound incubated for 72h at IC20. 
Markers features whose levels vary significantly (p < 0.05) between at least two treatment groups 
(bimetallic Titanocref  and Titanofin , monometallic cref, fin and AF) are projected on the heat 
map and used for clustering. The scaled expression value of each feature is plotted in red-green 
color scale. The red color of the tile indicates high abundance and green indicates low abundance. 
The color gradients indicate the degree of expression relative to the DMSO control.  
Markers whose levels varied significantly (p < 0.05) between at least two treatment groups 
(Titanocref, Titanofin, cref, fin,  and AF) were projected on the heat map and used for clustering. 
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In the heat map (Figure 3.7), we included seven additional markers of interest in cancer progression 
that were inhibited by either bimetallics, monometallics, or both classes of compounds.  
One particular salient point arose from this analysis, there seems to be some stratification 
of markers that are affected by the bimetallic and not the monometallic compounds and vice versa. 
This stratification warrants future exploration.  
These findings are informative not only for guiding further rational drug design, but also 
in adding mechanistic insights to an already FDA approved drug that is actively being explored as 
a potential anticancer agent. Broadening our understanding of the mechanism by which AF 
achieves its efficacy is a valuable contribution to the study of its potential as safe, clinically 
available, and efficient anticancer agent. What has also become evident from our evaluations is 
that however effective the monometallic compounds might be, overall the bimetallic compounds 
are more potent and affect a broader spectrum of molecular targets and cellular behaviors than any 
single monometallic as observed in their inhibition of migration, invasion, and angiogenesis, as 
well as their inhibition of VEGF, MMP(s), and IL(s). 
 
3.3 CONCLUSIONS 
This study expands on the discovery of the high in vitro efficacy of bimetallic titanocene-gold 
derivatives against a human clear-cell renal carcinoma cell line . One of the compounds (Titanocref) 
had been previously described as extremely efficacious in vitro and in vivo 25. In this study, we 
report a more complete mechanistic view on Titanocref, and on a second related compound, 
Titanofin that contains the same gold-phosphane fragment as AF. Comparisons were made with 
AF as control and with the monometallic gold precursors necessary to prepare these bimetallic 
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titanocene-gold derivatives. While we have used TDC as titanocene monometallic control, the high 
concentrations (well over 100 micromolar) needed to observe effects have precluded us to use it 
for relevant comparisons in most assays. The bimetallic compounds Titanocref and Titanofin 
strongly inhibited migration, invasion, and angiogenic assembly along with molecular markers 
associated with these processes such as prometastatic IL(s), MMP(s), TNF-D, and VEGF. Bimetallic 
titanocene-gold compounds have thus emerged as potential chemotherapeutics for renal cancer as 
they hindered three of the most harmful behaviors of the tumor microenvironment, local migration 
of tumor cells, invasion into the vasculature for metastasis, and the formation of de novo blood 
vessels. We also evaluated AF and observed that it had similar effects to the bimetallic compounds 
in the renal cancer cell line Caki-1 in terms of its antiproliferative and antimetastatic properties 
and inhibited most notably VEGF and IL(s).  
These results along with those previously published for Titanocref, indicate that further 
investigations of their efficacy, pharmacokinetic (PK), and histopathological studies and 
mechanistic exploration in vivo for bimetallic titanocene-gold derivatives are warranted. In 
addition, the relevant results found for AF also warrant further exploration of this drug for renal 
cancer treatment. 
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Part 2 
Preclinical evaluation of heterobimetallic titanocene-gold complexes unveils great tumor 
suppressive and angiosuppressive efficacy in a mouse clear cell renal carcinoma xenograft 
 
3.4  INTRODUCTION 
A previous study, briefly discussed in Chapter 2, of the in vivo efficacy of Titanocref 
yielded a decrease in tumor volume of 67% after a 28 day treatment course with doses separated 
by 48h. However, that study lacked the pretrial PK study which lead to an under-dosing of the 
mice with too narrow of a window between doses. The dose range component of that study was 
performed in a different mouse strain (C57BL/6) than that used for the efficacy trial (NOD.CB17-
Prkdc SCID/J), which might also have skewed the dose choice. Therefore, despite these 
limitations, given the promising in vivo results of this first trial, and in light of the impressive in 
vitro data obtained for both Titanocref and Titanofin outlined in part 1, we chose to test both 
compounds following rigorous preclinical design parameters informed by an expert clinical 
pathologist and oncology pharmacologist. Therefore, to obtain further clinically relevant insights 
into Titanocref and Titanofin’s anticancer efficacy, the biological response, and organ distribution, 
an in vivo study was performed in NOD.CB17-Prkdc SCID/J mice bearing a subcutaneous clear 
cell renal carcinoma (Caki-1) xenograft, an established preclinical model of ccRC. We report here 
that measurements of the acute and chronic toxicity, pharmacokinetics, efficacy, and pathology of 
treatment with Titanocref and Titanofin generated promising results, and suggest that our 
compounds are viable preclinical candidates  
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3.5 RESULTS AND DISCUSSION 
3.5.1 Dose range finding study. 
First, we report the acute toxicity and maximum tolerated dose (MTD) of Titanocref and 
Titanofin in naïve NOD.CB17-Prkdc SCID/J mice. This study was carried out to assess the 
toxicological profile of Titanocref and Titanofin following 6 intraperitoneal (i.p.) doses between 
10mg/kg/48h and 30mg/kg/48h Titanocref and 30mg/kg/48h to 50mg/kg/48h for Titanofin 
followed by a two-week recovery period. Vehicle solution (0.5% DMSO + 99.5% normal saline) 
treated mice were used as controls.  Lung, liver, kidney, spleen, and  heart were collected, weighed, 
and visually evaluated during a cross necropsy. Parameters, such as mortality, bodyweight, 
posture, grooming, and clinical and gross pathologies, were monitored throughout the study. The 
acute toxicity study indicated that the median lethal dose (LD50) of Titanocref was 30mg/kg/48h 
and of Titanofin was 45mg/kg/48h (Figure 3.8) . The MTD study indicated that male and female 
mice tolerated three i.p. injections at doses of 10mg/kg/48h to 15mg/kg/48h of Titanocref and 
30mg/kg/48h to 40mg/kg/48h of Titanofin without notable signs of toxicity or changes 
pathological parameters in the treated animals (Figure 3.9). These findings informed the rationale 
for selecting the doses of 5mg/kg/48h for Titanocref and 10mg/kg/48h for Titanofin for the PK 
and histopathological analysis. It was concluded that administration of seven consecutive doses of 
5mg/kg/48h Titanocref and 10mg/kg/48h Titanofin via intraperitoneal injection in female and male 
NOD.CB17-Prkdc SCID/J mice would be well tolerated under these study conditions since no 
changes were observed in mean body weight compared to control and no signs of distress were 
observed at three times these doses. Although some residue of precipitated compound was 
observed in the peritoneal cavity, no obvious signs of local toxicity were observed. These dose 
 
 
98 
 
range finding toxicity studies demonstrate that Titanocref and Titanofin are rather safe compounds 
within a two week treatment at doses of less than 20 mg/kg i.p.  
 
Figure 3.8. Median lethal dose (LD50) was estimated by injecting i.p. five increasing doses of  
Titanocref and Titanofin into two mice (weighing between 18 and 22 g). Deaths occurring during 
the first two doses were recorded and LD50 was calculated.   
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Figure 3.9. Titanocref and Titanofin  are best tolerated at doses below 15 mg/kg/48h  and 40 
mg/kg/48h respectively  in non-tumor bearing female and male NOD.CB17-Prkdc SCID/J mice. 
A. Survival curves associated with MTD determination of Titanocref and Titanofin. B. Body 
weights at the end of the course of treatment with various doses during the MTD determination. 
Error bars represent SEM for each group.  
We then proceeded to evaluate the biodistribution and bioavailability of the compounds. 
To that end we performed a PK study in a preclinical mouse xenograft model of kidney cancer. 
 
 3.5.2  Pharmacokinetics and Biodistribution (PK analyses were performed by the Laboratory 
of Swayam Prabha, at the University of Minnesota Department of Experimental and Clinical 
Pharmacology) 
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Second, we determined the pharmacokinetics of Titanocref and Titanofin upon 
intraperitoneal (i.p.) administration of one single dose followed by time lapse blood collection and 
terminal tissue collection in xenograft Caki-1(renal cell carcinoma) tumor bearing NOD.CB17-
Prkdc SCID/J mice to provide insights into critical preclinical criterion such as absorbance time 
clearance rate. 
We observed that though the bimetallic compounds Titanocref and Titanofin are closely 
related, their kinetic profiles were quite different (Figure 3.10).  The compounds were absorbed 
slowly, as indicated by a peak plasma concentration of Ti reached at 12 h for Titanocref, and 24 h 
for Titanofin reached after dosing. Compounds were eliminated slowly from the blood 
compartment with an elimination half-life (t1/2) of 32.38h for Titanocref and 47.16h for Titanofin 
(Table 3.3). The plasma concentration of Au was not measured due to experimental constraints. 
This informed the choice of a 72h window between doses, as it allowed sufficient time for 
clearance of the compound. In our previous study of Titanocref, the doses were spaced by 48h 
which might have contributed to significant accumulation of the metals in the kidney and liver, in 
this investigation, the accumulation of Ti was in the order kidney>liver>tumor, and was 
accompanied by notable loss in body weight. In this new tissue distribution study (Figures 3.11 
and 3.12 and Tables 3.13-3.15), a significant amount of both Ti and Au were found in the tumor 
tissue for each compound, however while the accumulation of Titanocref was in the order 
liver>tumor>kidney, for Titanofin it was liver>kidney>tumor, (Figure 3.11, Table 3.5). It is 
important to note that we observed close to a 1:1 colocalization of both metals (Ti and Au) in the 
tissue, which can be reconciled with previous observation that in vitro (Figure 3.12), both metals 
colocalized inside the cells in a dose dependent manner. These data indicate that both metals in 
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the compounds are delivered to the tissue at a near 1:1 ratio, suggesting stability of the bimetallic 
compounds in the course of biodistribution.  
 
Table 3.3. Pharmacokineticb parameters of Titanocref and Titanofin after single intraperitoneal 
injection in tumor-bearing mice.  
Pharmacokinetic Parameters Titanocref Titanofin 
Tmax (h) 10.50±3.00 21.00±6.00 
Cmax (µg/mL) 57.20±1.77 29.73±7.56 
AUClast (µg.h/mL) 2473.9±223.4 1346.6±76.8 
AUCInf (µg.h/mL) 3247.04±380.50 2660.79±614.24 
ke (h-1) 0.0215±0.0031 0.0140±0.0058 
t1/2 (h) 32.73±4.44 56.02±1.58 
Vd/F (mL/Kg) 72.65±4.64 298.83±71.37 
Cl/F (mL/h/Kg) 1.55±0.19 3.93±0.93 
Cmin ss (µg/mL) 20.83±3.45 25.61±9.40 
Time to reach steady state (h) 163.6±22.2 280.1±107.9 
b Pharmacokinetic parameters determined include the maximum observed plasma 
concentration (Cmax), the time to reach Cmax (Tmax), area under the plasma concentration–time curve 
from time zero to 72 h post dose (AUC0-72h), elimination rate constant (ke), terminal elimination 
half-life (t1/2), apparent total clearance from plasma (Cl/F), and apparent volume of distribution 
(Vd/F). 
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Figure 3.10. Plasma concentration of the Ti metal of Titanocref and Titanofin at various intervals 
after single intraperitoneal injection. Data represent mean ± SD (n = 4). 
 
Table 3.4. Plasma concentration of the Ti metal of the Titanocref and Titanofin bimetallic at 
various intervals after single intraperitoneal injection. Data represent mean ± SD (n = 4). 
   
 
Titanocref Titanofin 
 
Time (h) Conc. (µg/mL) Conc. (µg/mL) 
 
1 42.51 ± 3.78  13.93 ± 1.43 
 
2 45.47 ± 4.42 13.71 ± 1.32 
 
6 49.47 ± 5.71 18.80 ± 8.07 
 
12 56.83 ± 1.70 21.62 ± 10.64 
 
24 45.26 ± 1.78 27.17 ± 5.49 
 
48 22.92 ± 10.23 19.56 ± 2.51 
 
72 16.19 ± 1.80 13.42 ± 2.10 
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Figure 3.11. Tissue distribution of both titanium and gold metals from Titanocref, Titanofin at the 
end of the PK study (72 h post-injection). Below the x-axis, Ti:Au represents the ratio of the two 
metals in each tissue. Data represent mean ± SD (n = 4). 
 
                                  
 
Figure 3.12. Cellular uptake of Titanocref in Caki-1 cells. The concentration of Titanocref 
calculated based on Ti and Au content in the cell lysates after 72h of incubation is similar 
suggesting that both the elements are co-localized in the cells. Modified from 25)  
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Table 3.5. Tissue distribution of the Ti and Au metals of the bimetallic Titanocref and Titanofin 
72h after single intraperitoneal injection. Data represent mean ± SD (n = 4). 
 
Titanocref Titanofin 
 
 Ti (µg/gm) Au (µg/gm)  Ti (µg/gm) Au (µg/gm) 
Liver 18.92 ± 3.32 15.06 ± 1.97 14.96 ± 14.9 17.16 ± 13.87 
Kidney 4.94± 1.14 6.33 ± 1.51 3.25 ± 1.29 5.28 ± 1.82 
Tumor 6.42 ± 5.60 6.36 ± 4.00 2.89 ± 1.46 4.60 ± 3.82 
 
 
Table 3.6. Ratio of Ti metal present between tissue and plasma of mice treated with Titanocref 
and Titanofin 72h after single intraperitoneal injection. Data represent mean ± SD (n = 4). 
 
Titanocref Titanofin 
 
Tissue  :  Plasma Tissue  :  Plasma 
 
Liver              1.19  :  1               1.47  :  1 
 
Kidney              0.31  :  1           0.24  :  1 
 
Tumor              0.39  :  1           0.22  :  1 
 
Table 3.7. Ratio of Ti and Au metals present in tissue of mice treated with Titanocref and Titanofin 
72h after single intraperitoneal injection. Data represent mean ± SD (n = 4). 
Metal ratio (72h) Titanocref Titanofin 
 
 
Ti  :  Au Ti  :  Au 
 
Liver              1.26  :  1               0.87  :  1 
 
Kidney              0.78  :  1           0.62  :  1 
 
Tumor              1.01  :  1           0.63  :  1 
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3.5.3  Efficacy study  
Third, we report on an intervention trial to determine the in vivo anticancer efficacies of 
Titanocref and Titanofin in xenograft Caki-1(renal cell carcinoma) tumor bearing NOD.CB17-
Prkdc SCID/J mice in response to intraperitoneal (i.p.) administration of seven doses spaced by 
72h followed by a 72h recovery period before sacrifice. The previous in vivo efficacy study of 
Titanocref performed yielded an increase in tumor volume of 67% after a 28 day treatment course 
with doses separated by 48h. However, as noted, this study did not contain an accurate PK analysis.  
Therefore, we chose to re-test the in vivo efficacy of the compound, this time following more 
rigorous preclinical design parameters. Hence, following our most recent PK study, it was 
determined that doses of one quarter of the MTD administered once every 72h would be 
appropriate to evaluate in vivo the anti-cancer efficacy of Titanocref and Titanofin.   
In mice treated with Titanocref, we observed a decrease (shrinkage) in tumor size of 51% 
from the starting tumor burden recorded at the beginning of the trial, while mice treated with 
Titanofin had a reduction in tumor burden of 60% after 21 days of treatment (a total of 7 doses) 
(Figure 3.13). This result can be reconciled with data obtained in our previous study (Chapter 2 
Figure 2.9), where after 28 days of treatment with Titanocref every 48h we observed a tumor 
shrinkage of 67%. In comparison, we observed a growth in tumor volume of 138% in the vehicle 
treated mice.  
No significant change in weight or any decline in the wellbeing of the Titanocref and 
Titanofin treated mice were observed during this trial. These results are remarkable, as they 
indicate the compounds not only prevented tumor growth, but additionally shrank the primary 
tumor.  
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Figure 3.13. Titanocref and Titanofin treatment reduces tumor growth in a xenograft renal cancer 
intervention trial (Top) Representative histological samples of tumors resected from each 
treatment group. (Bottom) The average tumor volume after 21 days of treatment was decreased by 
51% in Titanocref treated mice and 60% in the Titanofin treated mice compared to the vehicle 
(Veh) control-treated group where tumor volume increased by 138%, ** p<0.01. The progressive 
change in tumor burden became evident 7 days after the first injection.  Mice were treated with 
Titanocref (5 mg/kg/72h), Titanofin (10 mg/kg/72h), or Veh by intraperitoneal injection from for 
21 days. Titanocref :n=6 mice, Titanofin: n=6 mice, Veh: n=6 mice. 
 
We then sought to determine the biodistribution of each metal after the 21-day efficacy 
study. Using the same methods as the PK study (Figure 3.14, Table 3.8), we observed that the 
biodistribution of Titanocref was in the order liver>kidney>tumor; whereas that for Titanofin it 
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was liver>kidney>tumor. Which is a small shift from the biodistribution of observed in the PK 
analysis the Titanocref accumulated more in the tumor than in the kidney. These changes cannot 
be clearly attributed to a specific metabolic or clearance change over the course of treatment. 
 
 
Figure 3.14. Tissue distribution of Titanocref, Titanofin at the end of efficacy study (i.e. 72 h after 
the last injection of a 21day trial (Titanocref (5mg/kg/72h), Titanofin (10mg/kg/72h). Below the 
x-axis, Ti:Au represents the ratio of the two metals in each tissue. Data represent mean ± SD (n = 
4). 
 
We observed that, compared to the tissue distribution results obtained at the PK study, at 
the end of the efficacy trial, significantly less metal was retained in the tissue at the end of the PK 
study. For mice treated with Titanocref, 18.92 µg Ti/gm and 8.19 µg Ti/gm respectively were 
found in the liver. This accounted for almost half the total metal injected, suggesting that perhaps, 
during the trial, the liver adjusted to more effectively dispose of the metals (Table 3.9). The same 
is true for mice treated with Titanofin, where significantly less metal was retained in the tissue at 
the end of the PK study (14.96 µg Ti/gm, and 8.13 µg Ti/gm of liver respectively). 
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Table 3.8.  Tissue distribution of the Ti and Au metal of bimetallic Titanocref and Titanofin at the 
end of efficacy study (i.e. 72 h after the last injection of a 21day trial (Titanocref (5mg/kg/72h), 
Titanofin (10mg/kg/72h).  Data represent mean ± SD (n = 4). 
 
Titanocref Titanofin 
 
 Ti (µg/g) Au (µg/g)  Ti (µg/gm) Au (µg/g) 
Liver 8.19 ± 1.55 6.45 ±  1.26 8.13 ± 3.42 6.45 ± 2.94 
Kidney 5.12 ± 1.89 4.86 ±  1.96 2.99 ± 1.58 2.46 ± 1.72 
Tumor 3.55 ± 1.60 3.12 ±  1.36 2.79 ± 1.14 2.45 ± 1.42 
 
Au accumulation followed a similar trend. Though there is also a reduction in the amount 
of metal retained by kidney and tumor tissue at the end of the efficacy study, the decrease was less 
drastic than that of the liver. There were striking differences between the tissue accumulation of 
Titanocref and Titanofin in tissue 72h following a single dose of compound as compared to 72h 
after a 21day treatment course.  We first observed that in both Titanocref and Titanofin treated 
mice, the ratio of Ti to Au in the tissue was higher than in the PK study indicating that more Ti 
was retained in the tissues than Au during the course of treatment. Second, we observed that the 
absolute concentration of metal per tissue weight was two-fold lower in liver tissue after the 21 
day trial suggesting that over the course of treatment, the liver increased its ability to excrete the 
compounds (Table 3.9). 
We then compared the biodistribution profiles of two metallodrugs currently in clinical 
use, Cisplatin and AF, reported in the literature to our results (Figure 3.15). The available reported 
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tissue distributions for Cisplatin are 48h after 6mg/kg (i.v.) in colorectal xenograft mice 37  and for 
AFare  24h after a single oral dose of 1mg/kg in non tumor bearing mice 38. 
 
 
Figure 3.15. Tissue distribution of  A. Cisplatin 48h after 6mg/kg (i.v.) after a single dose 20mg/kg 
(i.v.) in colorectal xenograft mice. Data represent mean ± SD (n = 4) B. AF 1  mg/kg 24h after a 
single oral dose in non-tumor bearing mice. Data represent mean ± SD (n = 6), C. Titanocref mg/kg 
72h  after a single dose . Data represent mean ± SD (n = 4). D. Titanofin 10 mg/kg 72h after a 
single dose. Data represent mean ± SD (n = 4). 
 
Both studies were dissimilar to ours in dose, means of administration, and the timepoint of 
data collection. However, we may gain some insight from them as to the trend of distribution in 
the short term 24h to 72h and long term. The relative tissue concentration of AF at 24h was 0.427µg 
Au/g  in the liver and 21.1µg Au/g in the kidney. The relative tissue concentration of Cisplatin at 
48h was 1µg Pt/g in the liver and 0.5µgPt/g in the kidney. Both Titanocref and Titanofin 
accumulated at significantly higher levels than either AF or cisplatin relative to the administered 
dose. Importantly, despite the high levels of Ti accumulation in the liver and kidney, we observed 
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no signs of hepatic or renal pathology as a result of treatment, therefore it is not of critical clinical 
concern. 
 
Table 3.9.  Fold difference in tissue distribution of the Ti metal of the bimetallic Titanocref and 
Titanofin  between the PK study (i.e. 72 h after a single injection of Titanocref (5mg/kg), Titanofin 
(10mg/kg)  and the efficacy study (i.e. 72 h after the last injection of a 21day trial [Titanocref 
(5mg/kg/72h), Titanofin (10mg/kg/72h)].  Data represent mean ± SD (n = 4). 
 
Titanocref Titanofin 
Liver 2.29 1.84 
Kidney 0.97 1.10 
Tumor 1.81 1.04 
 
3.5.4  Mechanism of action in vivo 
Given the substantial reduction in tumor size in Titanocref and Titanofin treated mice, we 
next sought to determine the cellular mechanisms driving this decrease. We sought to interrogate 
the effects of Titanocref and Titanofin on the proliferating to apoptotic cell ratio in clear cell renal 
carcinoma xenograft tumors. We first examined cell proliferation profile of the tumors using the 
proliferation marker Ki67, and because tumor growth can also reflect changes by in cell death, we 
compared the proliferation rate to apoptotic rates using apoptotic marker cleaved caspase 3. The 
average of proliferating cells in individual tumors of the vehicle (Veh.) treated mice control group 
was 36%, which was reduced to 16.2% in and 17.3% in tumors treated with Titanocref and 
Titanofin respectively, while the average of apoptotic cells in individual tumors of the Veh. treated 
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mice was control group was 2%, which was increased to 6.2% in and 7.9% in tumors treated with 
Titanocref and Titanofin respectively (Figure 3.16).  
 
 
Figure 3.16. Titanocref and Titanofin treatment affects proliferation and apoptosis at the 21-day 
trial endpoint. Titanocref and Titanofin treatment reduces tumor cell proliferation by 47% and 38% 
respectively and increases apoptosis by 270% and 312% respectively in a xenograft clear cell renal 
cancer intervention trial. The tumor proliferation and apoptosis were analyzed by staining tumor 
tissue with a cell proliferation specific marker Ki67 (green) and an apoptosis specific marker 
Cleaved caspase 3 (red) (n=4 mice per group (apoptosis Titanocref and Titanofin ***p< 0.001, 
proliferation Titanocref and Titanofin **p <0.01 ). 
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Figure 3.17. Titanocref and Titanofin treatment does affect tumor angiogenesis at the 21-day trial 
endpoint. (A, B) The tumor vasculature was analyzed by intravenous perfusion with Dextran 
(Texas Red) and endothelial specific cell surface marker Lectin (n=2 mice per group). The 
percentage of Lectin-labeled blood vessels over the total tumor area is graphed in (B- green), 
showing significant decrease in blood vessel coverage between the Titanocref, Titanofin and 
vehicle treated tumors, ** p<0.01. The percentage of dextran-stained surface over the total tumor 
area is graphed in (B -red), showing significant difference in vessel leakiness (measured by dextran 
dispersion from blood vessels) between Titanocref, Titanofin and vehicle treated tumors, ** 
p<0.01. 
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We determined, as reported in Part 1 of this chapter, in vitro that both Titanocref and 
Titanofin disrupt vascular assembly and noted that they were potent inhibitors of IL-6 and VEGF 
It has been shown that inhibition or deletion of IL-6 and VEGF in mice induced a significant 
decrease in tumor invasion and angiogenesis, and thus sought to determine if the use of our 
compounds disrupted angiogenesis and VEGF and IL-6 levels were affected.  By staining tumors 
extracted from mice following the efficacy study, we observed that Titanocref and Titanofin 
treatment resulted in a 38% and 54% reduction of vascular distribution respectively as indicated 
by the decrease in lectin positive staining while also increasing vascular integrity as evidenced by 
the reduction dextran positive surface correlated to vessel leakiness (Figure 3.17).  
 
3.5.5  Proteomic analysis  
Given the significant decrease in angiogenesis in Titanocref and Titanofin treated mice, as 
well as the drastic reversal in the proliferating to apoptotic cell ratio, we next aimed to identify 
some of the molecular signaling changes that may underlie this phenotype. We interrogated the 
effects of treatment with Titanocref and Titanofin on clear cell renal carcinoma in culture as well 
xenograft tumors on an array of proteins of oncological relevance by immunoblotting (Figure 3.18) 
and compared those results to data obtained in vitro.  
We observed from the histological analysis (Figure 3.17A) that in response to Titanocref 
treatment there was a striking reduction in angiogenesis, which could be mediated by a change in 
balance of angiogenic factors. There was indeed an increase in expression of antiangiogenic 
angiopoietin-1, endostatin, thrombospondin-1, and a decreased in VEGF at the end of the efficacy 
trial which would correlate with the reduced vasculature. We also observed an increase in 
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antitumorigenic immune factors IL-2 R and GM-CSF which are clinically associated with good 
prognosis 39–41. The expression of the macrophage related CapG protein was suppressed, which 
usually correlates with reduced migration 42,43. Those antitumorigenic phenotype changes were 
observed both in vitro and in vivo. There were however, changes in protein expression observed 
in vivo that were not observed in the in vitro samples.  The in vivo efficacy was accompanied by  
a significant decreased in prometastatic factors Cathepsin S (CtsS), FoxC,2 and MMP-3 44–47 . We 
also observed a decrease in CCL7 levels upon Titanocref treatment, which could decrease the 
tumor’s ability to recruit monocytes, thus rendering the tumor ecosystem more hostile to tumor 
progression. The decrease in Tie-2 observed would be expected to indicate decrease in tumor 
vascular normalization, however, there was no evidence from the histological samples that the 
vasculature lacked integrity, suggesting that perhaps other factors were at play. Those changes 
were not observed in the in vitro samples perhaps because  in vitro monoculture the signaling 
dynamic is limited to tumor-tumor cells communication while in vivo the tumor microenvironment 
ecosystem is rich and factors can be contributed by different cell types. It was thus predictable that 
the most significant differences were in the expression of factors primarily produced by or in 
response to immune cells in vivo. Also, the 3D nature of the in vivo model lends itself to behaviors 
such at EMT which would not readily accruing in 2D monoculture. This might perhaps explain 
why we observe a decrease in FOXC2 expression which is induced when epithelial cells undergo 
EMT which  facilitates the metastatic process. 
In response to Titanofin treatment in vivo and in vitro, we observed an increase in anti 
angiogenic Angiopoietin-1, Endostatin, Thrombospondin-1 and VEGF both in vitro and in vivo 
which can be reconciled with the antiangiogenic phenotype observed both in vivo and in vitro 
following Titanofin treatment. These data suggest that the constellation of factor involved in 
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inhibiting angiogenesis in response to Titanocref is dissimilar to that of Titanofin, in vivo. The 
decrease in FGF basic, MMP-2, and u-PA can be reconciled with their compounds’ reported 
antiinvasive and antimigratory properties. What we found of great interest is that the 
antitumorigenic immune factor GM-CSF was very highly expressed which would indicate a 
positive clinical outcome. It is unsurprising given the role of immune cells in the production of 
GM-CSF that no changes in expression levels are observed in vitro. All these changes suggest a 
potent tumor inhibiting phenotype. In vivo, Titanofin significantly decreases the expression of 
Cathepsin S, CCL8, E-Cadherin, HIF-1a, ICAM, M-CSF, VE-Cadherin, all of which when 
overexpressed promote tumor progression, however, in vitro, those proteins were either unaffected 
or they are overexpressed. This difference might be due to the lack of stromal cell contribution in 
the in vitro system. For instance, CCL8 is expressed by dermal fibroblasts to modulate tumor-
stroma and tumor-tumor cross-talk in the initiation of metastasis, while ICAM and M-CSF are 
mainly produced and modulated by immune cells or in response to immune cell signal which are 
absent in 2D monoculture. Also, solid tumors are a hypoxic environment where high levels of HIF-
1a would be expected and in response to treatment that shrinks the tumor mass one would expect 
increased oxygenation thus decrease in HIF-1a, whereas hypoxia is a lesser phenomenon in 2D 
culture. Cts levels are often lowered in the absence of angiogenesis or active invasion both 
processes in which their proteolytic capacities are necessary. It is unclear if the change in Cts is 
causative of angiogenic disturbance. 
IL-6 and Survivin were inhibited in vitro in response to both Titanocref and Titanofin, but 
expression was increased in vivo, which may be due to the contribution of stromal cells 
contribution in the case of IL-6 in particular  to the overall protein levels. Survivin however is a 
member of the inhibitor of apoptosis (IAP) family which given the high level of apoptosis observed 
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in vivo, we would expect to be significantly reduced. There might be compensatory or competing  
signals driving apoptosis, despite high Survivin activity.   
It is also notable that Titanocref and Titanofin did not necessarily affect the expression 
levels of the same molecules in vivo, as we observed that Titanofin affected expression levels of 
u-PA/Urokinase, Survivin, M-CSF, ICAM-1/CD54, CCL8/MCP-2, FGF basic, and HIF-1alpha, 
while Titanocref did not. Conversely, Titanocref affected the expression levels of CCL7, FoxC2, 
Tie-2 and MMP-3, while Titanofin did not. This suggests a greater effect or reliance on immune 
factors for the efficacy of Titanofin than Titanocref, which appears to rely on other factors known 
to drive metastasis and angiogenesis. We observed no changes of systemic presence of immune 
cells from circulating blood as a percentage of blood circulating neutrophils (NEUT)lymphocytes 
(LYMPH) and monocytes (MONO) were unchanged between control and treated mice and fell 
within the normal range. This would indicate that any change in immune cell population is either 
localized to the tumor, or systemically too small to be detected in complete blood work (Table 
3.12). 
Thinking of these results in the context of potential anticancer therapeutic agents these 
results are of great interest. Both compounds promoted the expression of Angiopoietin-1, which is  
known to disrupt vascular connections while promoting vascular regression and cell death, and 
when deficient, increases tumor metastasis 48–50. Vascular Endothelial Cadherin (VE- Cadherin) a 
critical regulator of VEGF expression was downregulated in response to treatment with either 
compound, suggesting that these compounds are viable antiangiogenic candidates. We have also 
observed a significant increase in GM-CSF expression, which can inhibit cancer growth and 
metastasis by initiating an anti-angiogenic cascade in cooperation with tumor associated 
macrophages 39,40,51.  
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Figure 3.18. Titanocref and Titanofin treatment induce tumor changes in expression angiogenic 
regulators as metastasis and apoptosis modulators in vitro and in vivo. In vitro changes in 
expression levels of proteins of oncological interest, following treatment of Caki-1 cells in vitro 
with IC 20 concentrations of each compound for 72h. In vivo changes in expression levels of 
proteins of oncological interest, following a 21-day efficacy trial in Caki-1 xenograft tumor 
bearing NOD.CB17-Prkdc SCID/J mice. Analysis of 150µg of protein extracted from cell or tumor 
lysate. The values indicate the percentage of change in expression relative to DMSO treated cells.  
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Figure 3.19. Titanocref and Titanofin treatment induce changes in expression of cell stress 
markers in vivo. In vivo changes in expression levels of stress proteins, following a 21-day efficacy 
trial in Caki-1 xenograft tumor bearing NOD.CB17-Prkdc SCID/J mice. Analysis of 150µg of 
protein extracted from cell or tumor lysate. The values indicate the percentage of change in 
expression relative to DMSO treated cells. 
 
This is particularly exciting because GM-CSF, which is a potent cytokine stimulator 
myeloid cells production, is being used, in the clinic, as an immuno-adjuvant to draw 
antitumorigenic immunity. In response to treatment, we also observed a significant reduction in 
expression of factors whose overexpression is linked to metastatic progression of many solid 
tumors in vivo, such as CCL7 and CCL8.  
The protein expression analysis revealed that in most cases, proteins affected in vitro were 
also affected in vivo, and followed similar trends for both drugs. It is not unusual for in vitro and 
in vivo protein expression prolife to retain a lot of similarities but not be identical 52 . Two notable 
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exceptions being Cathepsin and Fox2, which were (decreased in vivo and increased in vitro) in 
response to Titanocref treatment, and IL6 in response (increased in vivo, decreased in vitro) to 
Titanofin treatment. These changes might be in part driven by the contribution of stromal cells to 
those protein levels.  In vivo Titanocref or Titanofin are potent inhibitors of stress markers known 
to drive tumor metastasis and drug resistance such as HIF know to drive hypoxia, Trx known to 
drive chemoresistance and Bcl2 known to inhibit apoptosis. Both complexes affected tumor 
metabolism as they substantially induced the phosphorylation of Heat shock protein 27 (Hsp27) 
and reduced the activity of two inhibitors of apoptosis HSP60, and HSP70. Though both bimetallic 
do reduced the expressions of those proteins, they did so to different degrees (Figure 3.19).  
 
3.5.6  Pathology 
Finally, we report on our study to determine any pathological effects that might be caused 
by treatment with Titanocref or Titanofin. Access to expertise in cancer histopathology is critical 
in making a definitive determination of the safety, and therefore clinical viability of a compound 
for potential use in humans. A complete pathology study was performed in collaboration with Dr. 
Adam Michel from Memorial Sloan Kettering Cancer Center. This study revealed no significant 
adverse effects related to the Titanocref or Titanofin treatment were observed after evaluation of 
the histology (Table 3.10), in clinical indicators of  liver, kidney and spleen function (Table 3.11) 
complete blood counts (Table 3.12), and clinical chemistry (Table 3.13) of all mice treated with 
either test compound when compared to vehicle treated mice. The levels of ALP <100 which is 
below normal (Table 3.13), however lowered ALP is not a critical health concern and because all 
groups included vehicle treated mice have ALP below 100, we cannot associate this pathological 
manifestation to the test compounds.   
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We found no notable difference in total weight or organ weight between the treated and 
control mice at the end of the trial, the data in Table 3.10 suggest there were no enlargements or 
atrophy as a result of treatment. From stained histological samples we can appreciate the absence 
of any lesion, or signs of pathologic tissue distension, discoloration, necrosis or structural 
abnormalities (Figure 3.20). The histological data is supported by hematologic data on the levels 
of key clinical indicators of liver, kidney through clinical chemistry (Table 11A) and spleen 
function though complete blood count (CBC) (Table 11B).  
Liver function is clinically assessed by measuring tests including aspartate 
aminotransferase (AST), Alanine transaminase (ALT), and bilirubin (BILI). The table reports total 
bilirubin (TBil) which is the sum of direct bilirubin (DBil) and indirect bilirubin (IBil) 53,54. 
Abnormal liver function are defined as AST> 100U/L, or total bilirubin level > 3 mg/dL. The liver 
function indicators are within the norm as reported by bilirubin levels for the Veh group as well as 
the Titanocref and Titanofin treated mice, there appears to be no notable difference between 
treatment group. The AST is however very elevated > 100 U/L in the Veh. Groups as well as the 
Titanocref and Titanofin treated mice. We did verify that neither DMSO nor normal saline 
administered i.p. are reported to induce increase in AST levels. Though in isolation those numbers 
are concerning, we can appreciate that the increase is not caused by the compounds since the 
vehicle treated mice seem to have as high levels as the test groups. Therefore we did not observe 
any liver pathology be associated with Titanofin or Titanocref treatment. 
 Kidney damage is often identifiable clinically by changes in creatinine (CR) clearance and 
blood urea nitrogen (BUN) 55–57. High serum creatinine levels in the blood indicate that the kidneys 
aren't functioning properly. There too, we observed that Veh group as well as the Titanocref and 
Titanofin treated mice have kidney function profiles within the healthy norm.  
 
 
121 
 
The spleen is the largest lymphoid organ in the body and is critical for immune 
homeostasis. Its rich and diverse population of immune cells such as  of T and B cells, dendritic 
cells, and macrophages 58–60. In the event of splenic dysfunction, circulating thrombocyte and 
leukocyte counts can be altered if there is enlargement or atrophy of the spleen61. Furthermore, an 
increase in abnormal circulating red blood cells is often an indicator of spleen malfunction 58. 
Again, as evident in Table 3.11B, there were no abnormal changes in immune cell levels, 
confirming that there are no detectable signs of spleen pathology in response to chronic treatment 
with either compounds.  
The most common agents causing chemotherapy-associated nephrotoxicity include 
cisplatin, methotrexate, mithramycin semustine, gemsitabin and streptozocin 56. Cisplatin and 
gemcitabine are known to cause severe nephrotoxicity, dangerously high CR levels, and induce 
debilitating decrease in red blood cell production, leading chemotherapy induced anemia 55. 
Chemotherapy is also known to reduce the production of white cells in your blood, which severely 
diminishes the immune system of patients 62. We did not observed differences between the mice 
treated with Titanocref, Titanofin, or the vehicle control in the blood count report (Table 3.12), 
and all three cohorts had complete blood count profiles that fell within the NSG MICE Reference 
ranges. Finally, we found that no differences in the clinical chemistry of the treated or control 
animals were determined (Table 3.13), indicating normal production and excretion of 
physiological fluids and metabolic markers whose deregulation are indicators of pathology or drug 
side effects.  
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Table 3.10. Summary of histological data 
 
Titanocref Titanofin DMSO 
Body weight (g) 23.78 ± 3.58 22.96  ± 2.48 22.82  ± 2.14 
Liver weight (g) 1.24 ± 0.21 1.26  ± 0.17 1.17  ± 0.28 
Spleen weight (g) 0.042 ± 0.004 0.05  ± 0.003 0.05  ± 0.01 
Heart weight (g) 0.17 ± 0.05 0.14  ± 0.02 0.13  ± 0.02 
Average Kidney weight (g) 0.19 ± 0.04 0.19  ± 0.04 0.17  ± 0.05 
 
 
Figure 3.20. Titanocref and Titanofin treatment do not induce histological changes in liver, spleen 
or kidney tissue of mice at the end of the 21 day efficacy trial. Histopathology on H&E staining of 
paraffin sections magnification 20x. Sections are representative of 3 mice of each treatment. 
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Table 3.11. Summary of key clinical indicators of  (A) liver, kidney through clinical chemistry 
and (B) spleen function though complete blood count (CBC). 
A.  
 Clinical chemistry Titanocref Titanofin DMSO 
NSG 
Reference 
Range 
K
id
ne
y 
BUN (mg/dL)  22.33 ± 1.53 21.5 ± 2.12 23 ± 2.65 5.0-28 
CREA (mg/dL)  0.17 ± 0.02 0.17 0.17 ± 0.04 0.2-0.5 
ALB (g/dL) 2.7 ± 0.1 2.95 ± 0.07 2.83 ± 0.11 2.4-4.3 
L
iv
er
 
 AST (U/L)  135.67 ± 91.31 374.5 ± 41.79 372.33 ± 27.94 54-77 
TBIL (mg/dL) 0.167 ± 0.06 0.2 0.2 ± 0.003 0.2-0.6 
DBIL (mg/dL) 0.03 ± 0.06 0.05 ± 0.07 0 - 
IBIL (mg/dL) 0.13 ± 0.06 0.15 ± 0.07 0.2 ± 0.04 - 
ALT (U/L)  36.33 ± 26.63 167 ± 198 163.33 ± 156.69 27-195 
 
B. 
 
Complete Blood Count Titanocref Titanofin DMSO NSG Reference Range 
Sp
le
en
 
RBC (M/uL) 9.02 ± 0.10 9.38 ± 0.01 8.11 ± 2.51  7.84-10.84 
WBC# (K/ul) 3.21 ± 0.98 2.3 ± 0.60 2.39 ± 0.30 0.94-4.68 
Neut# (K/uL) 2.18 ± 0.83 1.49 ± 0.48 1.37 ± 0.19 0.54-3.16 
LYMPH# (K/uL) 0.7 ± 0.22 0.52 ± 0.21 0.57 ± 0.30 0.23-1.56 
MONO# (K/uL) 0.24 ± 0.07 0.15 ± 0.11 0.36 ± 0.25 0.03-0.26 
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Table 3.12. Complete blood count report 
 
DMSO Titanocref Titanofin NSG Reference Range 
RBC (M/uL) 8.11 ± 2.51  9.02 ± 0.10 9.38 ± 0.01 7.84-10.84 
HGB (g/dL) 12.6 ± 3.81 13.83 ± 0.23 14.30 ± 0.28 11.8-17.6 
HCT (%) 40.93 ± 14.32 45.66 ± 0.67  48.35 ± 0.07 44.1-58.3 
MCV (fL) 49.93 ± 2.72 50.67 ± 0.21 51.55 ± 0.07 51.1-58.6 
MCH (pg) 15.57 ± 0.23 15.33 ± 0.15 15.25 ± 0.35 13.7-17.2 
MCHC (g/dL) 31.27 ± 2.04  30.30  ± 0.17  29.6 ± 0.57  25.1-31.3 
RDW-SD (fL) 29.77 ± 3.23 29.23 ± 0.67  30.65 ± 0.49 - 
RDW-CV (%) 21.30 ± 3.49 22.23 ± 0.15 22.5 ± 0.28 17.3-20.3 
RET# (K/uL) 440.95 ± 4.88 318.47 ± 124.46 427.55 ± 127.63 294-444 
PLT (K/uL) 626.67 ± 60.07 1244 ± 76.02 1327.5 ± 284.96 651-2055 
PDW (fL) 6.85 ± 0.49 6.67 ± 0.06 6.65 ± 0.07 - 
MPV (fL)  6.15 ± 0.35  6.10 ± 0.1 6.05 ± 0.07 4.2-6.3 
WBC# (K/ul) 2.39 ± 0.30 3.21 ± 0.98 2.3 ± 0.60 0.94-4.68 
Neut# (K/uL) 1.37 ± 0.19 2.18 ± 0.83 1.49 ± 0.48 0.54-3.16 
LYMPH# (K/uL) 0.57 ± 0.30 0.7 ± 0.22 0.52 ± 0.21 0.23-1.56 
MONO# (K/uL) 0.36 ± 0.25 0.24 ± 0.07 0.15 ± 0.11 0.03-0.26 
EO# (K/uL) 0.1 ± 0.03 0.09 ± 0.02 0.14 ± 0.03 0.00-0.39 
BASO # (K/ul) 0.01 0.007 ± 0.01 0.005 ± 0.01 0.00-0.15 
NEUT (%) 58.3 ± 14.01 66.63 ± 6.38 64.35 ± 4.03 44.21-79.92 
LYMPH (%) 22.57 ± 9.14 21.8 ± 0.87 22.05 ± 3.18 13.51-42.61 
Complete Blood Count (CBC).                            NOD scid gamma mice (NSG mice)   
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Table 3.13. Clinical chemistry 
 
Titanocref Titanofin DMSO NSG Reference Range 
BUN (mg/dL) 22.33 ± 1.53 21.5 ± 2.12 23 ± 2.65 5.0-28 
CREA (mg/dL) 0.17 ± 0.02 0.17 0.17 ± 0.04 0.2-0.5 
BUN/CREA ratio 128.99 ± 2.49 126.47 ± 12.48 143.14 ± 32.51 - 
ALP (U/L) 37 ± 14.73 42.5 ± 19.1  62 ± 19.97 105-370 
ALT (U/L) 36.33 ± 26.63 167 ± 198 163.33 ± 156.69 27-195 
AST (U/L) 135.67 ± 91.31 374.5 ± 417.90 372.33 ± 279.43 54-77 
GGT (U/L) 0 0 0 - 
TBIL (mg/dL) 0.167 ± 0.06 0.2 0.2 ± 0.003 0.2-0.6 
DBIL (mg/dL) 0.03 ± 0.06 0.05 ± 0.07 0 - 
IBIL (mg/dL) 0.13 ± 0.06 0.15 ± 0.07 0.2 ± 0.04 - 
TP (g/dL) 5.03 ± 0.12 5.3 5 4.8-7.2 
ALB (g/dL) 2.7 ± 0.1 2.95 ± 0.07 2.83 ± 0.11 2.4-4.3 
GLOB (g/dL) 2.33 ± 0.21 2.35 ± 0.07 2.17 ± 0.06 1.7-2.2 
A/G ratio 1.17 ± 0.15 1.26 ± 0.07 1.31 ± 0.08 - 
P (mg/dL) 8.87 ± 1.60 9.95 ± 1.91 10.1 ± 1.68 7.3-14.5 
Ca (mg/dL) 9.33 ± 0.21 9.6 ± 0.14 9.43 ± 0.42 9.5-12.5 
GLU (mg/dL) 166.33 ± 26.50 170 ± 4.24 190 ± 33.51 172-372 
CHOL (mg/dL) 85 ± 9.17 88 ± 11.31 82.67 ± 9.81 55-169 
TRIG (mg/dL) 109 ± 22.72 76.5 ± 19.09 93.67 ± 34.59 67-289 
CK (U/L) 278.67 ± 120.79 196.5 ± 17.68 689 ± 471 428-1609 
TCO2 (mEq/L) 22.67 ± 3.79 21.5 ± 0.71 18.67 ± 2.31 - 
Na (mEq/L) 157 ± 2 155 ± 1.41 155 ± 3.46 145-181 
K (mEq/L) 8.13 ± 1.36 9.3 ± 0.85 9.73 ± 1.96 7.3-11.1 
Cl (mEq/L) 110.67 ± 1.53 112 ± 1.41 114.33 ± 1.53 111-134 
Na/K ratio 19.66 ± 3.20 16.74 ± 1.68 16.37 ±  3.39 - 
Anion Gap 31.8 ± 1.31 30.8 ± 0.14 31.73 ± 2.1 - 
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3.5.7  Considerations about the xenograft model used for this study.  
The cells used are Caki-1 ccRC which are adherent epithelial cells. The Caki-1 cells 
express wildtype von Hippel-Lindau (VHL) tumor-suppressor protein and are known to form 
tumors in immunocompromised mice. These cells were extracted in 1971 from a metastatic site 
(skin) in a 49-year-old Caucasian male with ccRCC.  While exploring changes in immune 
populations in the tumor microenvironment might have been very informative, because the NOD 
genetic background contains alleles that reduce the function of the innate branch of the immune 
system, macrophages and dendritic cells are defective 63. Thus, readouts of immune changes in the 
immunocompromised NOD SCID model would not necessarily be highly informative as when 
studying an immune competent organism. 
 
3.5.8  CONCLUSIONS  
What we have shown is that the two heterobimetallic titanocene-gold complexes lead to 
drastic reduction in tumor burden upon seven doses administered over the course of 21 days in 
mice bearing clear cell carcinoma xenograft tumors. The reduction in tumor burden coincided with 
a significant increase in apoptotic cells and drastic decrease in the number of proliferating cells in 
the Titanocref and Titanofin treated tumors. These cellular phenotypes were accompanied by a 
remarkable reduction in tumor vascularization, and an improvement in vascular integrity, which 
are features that may hinder tumor metastasis.  
We have identified changes in expression levels of eleven factors known to modulate tumor 
growth, resistance to apoptosis, and angiogenesis, changes that may drive the in vitro and in vivo 
efficacy observed. To date, there is a relatively high prevalence of primary and metastasized 
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ccRCC that do not respond to immunotherapy and targeted therapies such as Ipilimumab, 
Vinblastine, Proleukin or Bevacizumab or current chemotherapeutic regiments of Gemcitabine, 
Capecitabin 5-FU. Those treatment options are most often associated with debilitating side effects. 
Therefore, there is an urgent need for novel effective, non-toxic clinical alternatives to the currently 
available pharmaceutical arsenal to improve survival and quality of life.  This study shows that 
two novel metallodrugs are not only efficacious at reducing a tumor type that is difficult to treat, 
but they do so without any prediction of clinical side effects as indicated by the pathology study. 
Moreover, at dose below that of cytotoxicity, the novel compounds significantly inhibit TrxR, IL-
6 and VEGF which are all key drivers of drug resistance, tumor proliferation, angiogenesis and 
metastasis. Therefore, we believe that we have done due diligence in making a case for exploration 
of those compound towards clinical trials in human.  We also conclude that the compounds’ 
synergy may be due to the simultaneous targeting of multiple non-overlapping pathways involved 
in tumor growth and progression, given our protein profiling results. We have found a distinct 
changes in expression levels specific subset of factors whose changes that can be reconciled with 
changes in cellular behavior observed such as reduction in proliferation, migration, invasion, 
angiogenesis and increased in apoptotic cell death.  
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CHAPTER 4 
 
Preclinical Study of a Second Generation Ruthenium-Gold Compound:  
RANCE-1 in Renal Cancer 
 
Part 1 
Mechanistic studies in vitro in Caki-1 clear renal cell carcinoma. 
 
4.1.1. INTRODUCTION 
From previous work briefly discussed in chapter 2, we identified several heterobimetallic 
ruthenium-gold-NHC complexes that were cytotoxic against and selective for clear Caki-1 cells in 
vitro1,2. In light of their cytotoxic potential, and because ruthenium-based complexes have been 
reported to be potent antimetastatic agents, have demonstrated antiangiogenic efficacies, and are 
suggested to act through molecular mechanisms distinct from gold alone, 1,3 we sought to further 
explore our novel Ru-Au-NHC’s effect on malignant phenotypes such as proliferation, migration, 
and angiogenesis. To that end, we chose the most selective and stable of the Ru-Au-NHC, 
RANCE-1 (Chart 4.1) and evaluated its anticancer properties in detail. We report here on the 
mechanism of RANCE-1 efficacy in ccRCC Caki-1 cells. These studies indicate that the bimetallic 
compound RANCE-1 is significantly more cytotoxic than the Ru or Au monometallic derivative 
moities.  RANCE-1 significantly inhibited migration, invasion, and angiogenesis in vitro, which are 
essential for metastasis. RANCE-1 was found to disturb pericellular proteolysis by inhibiting 
cathepsins, and the metalloproteases MMP and ADAM, which play key roles in the etiopathogenesis 
of cancer. RANCE-1 also inhibits the mitochondrial protein TrxR that is often overexpressed in cancer 
cells and facilitates apoptosis evasion. We found that while Auranofin perturbed migration and invasion 
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to similar degrees as RANCE-1 in Caki-1 renal cancer cells, RANCE-1 also inhibited antiangiogenic 
formation and VEGF expression. We further determined that Auranofin and RANCE-1 have distinct 
proteolytic profiles. In summary, RANCE-1 constitutes a very promising candidate for further 
preclinical evaluations in renal cancer. 
 
Chart 4.1. Compounds used in this study: bimetallic [Ru(p-cymene)Cl2(η1-dppm)]Au(IMes)]ClO4 
(RANCE-1) 1 , monometallic [Ru(p-cymene)Cl2(η1-dppm)] R 4 , and [AuCl(IMes)] ANCE-1 5 , and 
Auranofin. 
 
4.1.2. RESULTS AND DISCUSSION 
4.1.2.1  Cytotoxicity, Selectivity, Cell Death and Cell Cycle Arrest 
The cytotoxicity of the bimetallic Ru-Au compound RANCE-1 (Chart 4.1), and 
monometallic ruthenium R, and gold ANCE-1 compounds was evaluated. The cytotoxic profiles 
of Auranofin and cisplatin (for comparative purposes) were also determined. In this assay, human 
renal Caki-1 and non-tumorigenic human fetal lung fibroblast (IRM-90) cells were incubated with 
the individual compounds for 72 hours and compared to incubation with cisplatin or Auranofin. 
The results are summarized in Table 4.1.  
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Table 4.1. Cell viability IC50 values (µM) in Caki-1 cells and IMR-90 fibroblasts for bimetallic 
RANCE-1 and monometallic Ru R Au ANCE-1 compounds. Auranofin and cisplatin were used 
as controls.a The values are also plotted in a bar graph for a better visualization of the selectivity 
profiles. 
 
Caki-1 IMR90 
RANCE-1 8.7 ± 0.9 17.3 ± 0.8 
R  27.8 ± 2.9 35.9 ± 2.3 
ANCE-1 19.8 ± 1.6 37.6 ± 2.1 
R  + ANCE-1  16.6 ± 1.3 28.1± 3.4 
Auranofin 2.8 ± 0.6 3.7 ± 0.4 
Cisplatin  23.9 ± 2.4 3.9 ± 0.5 
 
aAll compounds were dissolved in 1% of DMSO and diluted with media before addition to cell 
culture medium for a 72 hour incubation period. Cisplatin was dissolved in H2O. 
 
RANCE-1 was more cytotoxic to the Caki-1 cells than cisplatin, monometallic ruthenium 
R, or monometallic gold ANCE-1. Also, RANCE-1 is a selective compound as it was considerably 
less toxic to the non-tumorigenic fibroblast IMR-90 cells than cisplatin, R or ANCE-1. While 
Auranofin was also cytotoxic with a low IC50 value in Caki-1 cells, it was only moderately 
selective. We then studied the effect of the combination of monometallic ruthenium R and gold 
ANCE-1 compounds (1:1 equivalents) on Caki-1 cells using the same conditions as for the 
bimetallic compounds. The resulting IC50 values of the combination treatments were larger than 
those of RANCE-1, while also remaining selective. This fact supports the idea that there is indeed 
a synergistic effect for RANCE-1 on the renal cancer cells as described for other Ru-Au and Ti-
Au compounds described by our group 2,6–8.  In view of the results obtained, we decided not to 
explore the effects of cisplatin in Caki-1 cells any further. 
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Following the evaluation of the cytotoxicity of bimetallic RANCE-1 and monometallic 
ruthenium R, gold ANCE-1, and Auranofin, we proceeded to evaluate the mechanism of cell 
killing for RANCE-1 and Auranofin. For this assay Caki-1 were incubated with the indicated 
compound at the IC50 concentration for 72 hours. We observed that RANCE-1 and Auranofin 
induced apoptosis in 82% and 86% of cells killed respectively (Figure 4.1). Auranofin and other 
gold(I) compounds are known to be apoptotic in several cancer cell lines 9,10, and p-cymene Ru 
derivatives (as the classic RAED described by Sadler and RAPTA-C described by Dyson) are also 
mainly apoptotic (ca 80%) on the ovarian cancer cell line A2780 11.  Thus the apoptotic behavior 
of bimetallic Ru-Au RANCE-1 in terms of cell death may be due to the presence of both the Ru 
and Au fragments. 
 
Figure 4.1. Cell death assays on Caki-1 cells induced by IC50 concentrations of RANCE-1, and 
Auranofin measured by using two-color flow cytometric analysis, after 24 h of incubation. (A) 
Flow cytometry histogram of RANCE-1 induced apoptosis in 32% while Auranofin induced 
apoptosis in 76% of cell population (B) Bar-graph representation of from flow cytometry 
histogram quantifying cell death. 
  
Next we evaluated the effects of the most cytotoxic compounds, which are RANCE-1 and 
Auranofin, on cell cycle arrest. We observed that cells treated with RANCE-1 had the greatest 
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percentage of cells in Sub G1 (26%) and more G1/G0 (37%) the fewest cells in S phase (16%), 
and similarly few cells in G2/M (20%). Similarly for other p-cymene Ru derivatives such as RAED 
and RAPTA-C it was reported that greatest percentage of cells were in G1/G0 (60%) and fewer 
cells in S phase (approximately 15%) and G2/M (5%) for ovarian cancer A278 cell lines 11.  
 
Figure 4.2. Cell Cycle Arrest induced by RANCE-1, and Auranofin. Cells were treated with or 
without IC20 concentrations of RANCE-1, and Auranofin for 24 h. (A) Flow cytometry histogram 
of RANCE-1 increased G1/G0 (37%) and Sub G1 (26%) population accumulation while 
Auranofin increased G1/G0 (82 %) population accumulation. (B) bar-graph representation of from 
flow cytometry histogram. 
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Auranofin treated cells were almost exclusively in G0/G1 (82%), suggesting that the compound 
induced complete G1/G0 arrest, as has already been reported for AF in other cell lines 12–15, and 
also in cancer cells treated with anti-inflammatory drugs 16 . 
 
4.1.2.2  Inhibition of migration and invasion 
Increased cell migration and invasion are hallmarks of metastasis in advanced tumors 17,18. 
We therefore evaluated the anti-invasive properties of RANCE-1, the monometallic Ru R, and Au 
ANCE-1 compounds. The effect of the compounds on migration was determined using a wound-
healing 2D scratch assay (Figure 4.3A). RANCE-1 and Auranofin significantly reduced migration 
by 82% and 88% respectively. While the cytotoxicity and apoptotic properties of Auranofin on 
different cancer cell lines are well known 10, the efficacy of Auranofin was unexpected and has not 
been previously reported. The monometallic Au compound ANCE-1 reduced migration by 26% 
while the monometallic Ru derivative R reduced migration by 68%. The antimetastatic attributes 
of R as it prevents in vitro cell invasion had been previously described for the triple-negative 
MDA-MB231 cancer cells 4, and this potential metastatic phenotype was one of the reasons we 
choose the Ru fragment of the RANCE-1 heterometallic compound.  
RANCE-1 was observed to inhibit invasion in a 3D Transwell assay fitted with 
Geltrex® matrix an extracellular matrix analogue (Figure 4.3B). RANCE-1 reduced invasion 
by 66%, and the monometallic Auranofin was also an excellent inhibitor of invasion (54% of 
invasion is inhibited).  
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Figure 4.3. Cell migration and Invasion Inhibition Assays for bimetallic Ru-Au compound 
RANCE-1, the monometallic Ru R and Au ANCE-1  compounds and Auranofin. A) Inhibition of 
migration (2D wound-healing scratch assay). Scratch assay showing that RANCE-1, R, and 
Auranofin interfere with Caki-1 migration. Panels show representative images of untreated cells 
at time points T0 (top row) when the compound is added to the assay up to 24 hours (bottom row). 
B) Inhibition of invasion (3D Transwell Assay). Cells were seeded onto a transwell migration 
chambers containing filters coated on with Geltrex® matrix, then incubated for 24h with IC20 
concentrations of RANCE-1, R, ANCE-1, or Auranofin. The transwell assay shows that RANCE-
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1, R and Auranofin interfere with Caki-1 invasion. Panels show representative images of treated 
cells at time points T24. Error bars indicate standard deviations. 
 
The inhibition of invasion by the Ru monometallic compound R at 30% was quite 
robust (as previously described for another cancer cell line) 4, higher even than that of 
RANCE-1 or Auranofin. The monometallic Au compound ANCE-1 on the other hand only 
inhibited 18% of migration in agreement with the data obtained in the 2D scratch assay.  
 
4.1.2.3 Inhibition of angiogenesis 
Neovascularization plays an essential role in the pathology of tumor growth.  
 
Figure 4.4. Induction of endothelial cell reorganization into 3D vessel structures. Human umbilical 
vein endothelial cells (HUVEC) were seeded in plate coated with Geltrex® matrix using completer 
HUVEC media and incubated at 37°C and 5% CO2. At post-seeding IC10 concentrations of 
RANCE-1, A, ANCE-1, Auranofin or 0.1% DMSO was added. (A) representative phase-contrast 
images captured 24h after the compounds were added. (B) Quantitation of tube formation. 
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We chose the formation of tube-like structures by HUVEC cells on an extracellular matrix as a 
mean to assess the effects on angiogenesis of RANCE-1, R, ANCE-1, and Auranofin.  
The assay measures the endothelial tube formation of Human umbilical vein endothelial 
cells (HUVECs) (Figure 4.4). The number of tubes and nodes was counted as described by 
DeCicco-Skinner et al 19. The greater the inhibition of tube formation results in a decrease of the 
length of tubes (TL) and a decreased number of nodes (TN), the higher the antiangiogenic 
properties of a compound.  
The ruthenium containing derivatives RANCE-1 and R were observed to inhibit all tube 
formation in a 3D assay on Geltrex® matrix an extracellular matrix analogue (Figure 4.4).  The 
gold monometallic compounds ANCE-1 and Auranofin caused mild disturbances in tube 
arrangement but there was still viable tube formation. This indicates that the ruthenium 
component of the compound may be responsible for the antiangiogenic properties. However 
RANCE-1 displayed an impressive antiangiogenic effect (higher than that of the monometallic 
compound R). 
 
4.1.2.4 Inhibition of targets associated to cancer progression, cisplatin resistance, metastasis, 
and angiogenesis 
 
4.1.2.4.1  Inhibition of Thioredoxin Reductase 
Changes in cellular anti-oxidant capacities are a characteristic of many chemo-resistant cancers. 
Overexpression of thioredoxin reductase (TrxR) is a critical component of cisplatin-resistant 
cancer cell survival, thus making this enzyme an important anti-cancer target 17,20–23. We have 
reported on the relevant inhibition of TrxR in Caki-1 cells by Auranofin and heterometallic 
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titanocene-Au 2,6 and Ru-Au complexes 1. Therefore, we measured the activity of thioredoxin 
reductase in Caki-1 cells following incubation with compounds RANCE-1 Ru R, and Au ANCE-
1. Auranofin was used as a positive control [we have already reported, after 72 h of incubation 
Caki-16 TrxR activity is significantly reduced by Auranofin (86%)] (Figure 4.5). We observed that 
inhibition of TrxR activity by all the compounds did not significantly improve between 24h and 
72h. The inhibition of TrxR by RANCE-1 and monometallic Au(I) compound ANCE-1 was almost 
identical (RANCE-1, 47%; ANCE-1 (40%). While R inhibited TrxR by less than 10% in that same 
time frame. This indicates that the Au(I) fragment present in heterometallic RANCE-1 compound 
is most likely responsible for the TrxR inhibition effect. 
 
 
 
 
 
 
 
 
Figure 4.5. Inhibition of mitochondrial protein TrxR in Caki-1 renal cancer cells by bimetallic Ru-
Au compound RANCE-1, the monometallic ruthenium R  and gold ANCE-1  compounds and 
Auranofin (1 µM) for 72 hours. The values for indicate the percentage of reduction of TrxR activity 
relative to 1% DMSO treated control. 
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4.1.2.4.2  Inhibition of VEGF 
Also, ruthenium compounds have been reported to inhibit VEGF 24. Given this, and the 
key tumor promoting properties of VEGF, we set out to evaluate the inhibitory effects of the 
RANCE-1, the monometallic ruthenium R and gold ANCE-1  compounds, and Auranofin on 
VEGF. We found that VEGF secretion was significantly inhibited by both RANCE-1 and 
Auranofin after 72h of incubation (70% and 55% reduction respectively), while R and ANCE-1 
lead to no notable inhibition of VEGF secretion (Figure 4.6). Angiogenesis is a complex process 
driven by diverse activities and an intricate sequence of factors. While VEGF is known to be a key 
regulator of angiogenesis and its downregulation is often correlated with reduced angiogenesis, 
such correlation is not absolute.  
 
Figure 4.6. Inhibition VEGF. Caki-1 cells were incubated with bimetallic Ru-Au RANCE-1, 
monometallic ruthenium R or gold ANCE-1 compounds, and Auranofin (IC 20 concentrations) for 
24 hours. The values for indicate the absolute concentration (pg/ml) of VEGF following treatment, 
0.1% DMSO control. 
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As our data indicate, while there is evident inhibition of tube formation by RANCE-1 and 
significantly less inhibition of tube formation by Auranofin, they are both potent inhibitors of 
VEGF, this suggests that there might be more at play in RANCE-1 inhibition of VEGF and its 
effect on tube formation.  
 
4.1.2.4.3  Inhibition of Interleukins  
ILs also play an important role in tumor promotion and metastasis through various proteolytic 
interaction and through control of matrix metalloproteinases (MMP) expression and the expression 
of angiogenic proteins growth factors such as VEGF 25. We studied the inhibition of ILs by our 
most active compounds, bimetallic RANCE-1 and Auranofin after 72 hour of incubation at IC20 
concentrations (Figure 4.7). We found that RANCE-1 inhibited IL-6 expression by 60%, inhibited 
IL-5 expression by 37%, had no effect on IL-13 expression, and resulted in a complete inhibition 
of IL-17A expression. The inhibition of IL-17 is of great clinical interest because increased IL-
17A expression is associated with ER (−) and triple negative tumor hyper proliferation and poor 
prognosis in breast cancer. IL-17 is also known to drives several pathogenic processes during 
breast cancer progression to metastasis, IL-17 not only promotes tumor cell survival and 
invasiveness, it also contributes to the promotion of tumor angiogenesis. Auranofin, as previously 
reported, inhibited IL-6, but also completely inhibited expression of IL-5, IL-8 and IL-13, all key 
players in inflammatory signaling pathways 26. Given the potent inhibition of IL expression 
observed upon treatment with RANCE-1, this compound might be a good candidate for 
combination therapy with a more cytotoxic agent. The great value of IL inhibitors is further 
increased because ILs are known inducer of MMPs which are critical in metastasis 25,27. 
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Figure 4.7. RANCE-1 and Auranofin induced changes in the expression levels of Interleukins in 
Caki-1 cells. Analysis of 150ng of protein extracted from cell lysate collected from RANCE-1 or 
Auranofin (IC20) treated cells. The data shown are representative of triplicates. 
 
4.1.2.4.4.  Inhibition of metalloproteases and other pro-cancer proteins 
Many members of the MMP family are involved in tumor induced inflammation signaling and 
angiogenesis in cooperation with members of the IL family including IL-6 28–30. The secretion of 
9 MMPs was significantly inhibited by RANCE-1: MMP-1 (72%) MMP-3 (74%) MMP-7 
(100%), MMP-8 (97%) MMP-9(50%), MMP-10 (100%), MMP-12 (89%), and MMP-13 
(100%) (Figure 4.8). Such inhibition is particularly robust and in combination with the VEGF and 
IL inhibition by RANCE-1, indicating that this compound presents a molecular target profile that 
would potentially make it a very efficient antimetastatic and antiangiogenic agent.  
Accumulating evidence demonstrates the crucial role of proteolytic enzymes such ADAMs, which 
are closely related to MMPs facilitate tumor cell invasion and metastasis. In particular, ADAM-9 
is reported to be highly expressed in invasive renal cell cancer while ADAM8 is considered a 
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robust hemo— histo— chemical marker for lung cancer and correlated with poor prognosis for 
patients with pancreatic ductal adenocarcinoma 31,32. 
 
Figure 4.8. RANCE-1 and Auranofin induced changes in the expression levels of matrix 
metalloproteases in Caki-1 cells. Analysis of 150ng of protein extracted from cell lysate collected 
from RANCE-1 or Auranofin (IC20) treated cells. The data shown are representative of triplicates. 
 
From our study, we observed that treatment with RANCE-1 ablated expression of ADAM-
8, and inhibited ADAM-9 expression by 37%, while Auranofin had no effect on the expression 
levels of those two proteases (Figure 4.9).  
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Figure 4.9. RANCE-1 and Auranofin induced changes in the expression levels of a disintegrin 
and metalloprotease (ADAM) family members in Caki-1 cells. Analysis of 150ng of protein 
extracted from cell lysate collected from RANCE-1 or Auranofin (IC20) treated cells. The data 
shown are representative of triplicates. 
 
Cysteine cathepsin proteases (Cts) are known regulators of cancer progression and 
therapeutic responses. We have previously reported on the inhibition of cathepsin B (purified) by 
a neutral ruthenium-gold compound 27.  Here, we observed that RANCE-1 ablated CtsB and CtsD 
expression (100% suppression), while inhibiting CtsL, CtsS and CtsX/Z by 38%, 35% an 53% 
respectively. Auranofin had no inhibitory effect on the expression of the five Cts evaluated (Figure 
4.10).  
From these studies, RANCE-1 has emerged as a potent pan-MMP and pan-cathepsin 
inhibitor with additional notable inhibition of members of the ADAM protease family. These 
observatons may explain the mechanism by which RANCE-1 inhibits tumor growth, invasion, and 
angiogenesis (Figure 4.10).  
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Figure 4.10. RANCE-1 and Auranofin induced changes in the expression levels of members of 
the cathepsin proteases family in Caki-1 cells. Analysis of 150 ng of protein extracted from cell 
lysate collected from RANCE-1 or Auranofin (IC20) treated cells. The data shown are 
representative of triplicates. 
 
 
4.1.3. CONCLUSIONS 
We have demonstrated the synergism of a heterometallic Ru-Au (RANCE-1) compound 
designed to harness the cytotoxic and apoptotic effects of Au(I) lipophilic cations as well as their 
TrxR inhibition properties with the potential antimetastatic effects of a Ru p-cymene derivative 
containing a phosphine. In addition to cytotoxicity and pro-apoptotic activity, RANCE-1 inhibited 
migration, invasion, and angiogenesis. The molecular targets inhibited include different interleukins, 
metalloproteases, and cathepsins, which are all involved in tumor metastasis and angiogenesis, and to 
an even higher degree, the angiogenic factor VEGF. It is noteworthy that the inhibition observed 
was in general higher than that of the individual monometallic fragments present in the 
heterometallic compound. In some cases, this inhibition can be correlated with a particular metallic 
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fragment of the bimetallic compound (reinforcing the idea of the positive synergistic effect caused 
by the two distinct metals). 
During this study, we also evaluated Auranofin and observed it had very similar effects to 
RANCE-1 on the renal cancer cell line Caki-1 in terms of its antiproliferative and antimetastatic 
properties as well as in some of the sets of targets inhibited. RANCE-1 however was a stronger 
VEGF inhibitor than Auranofin, and a much better pan-MMP and pan-cathepsin inhibitor. 
Moreover, RANCE-1 blocked all angiogenic formation while Auranofin merely induced branching 
disturbances of de novo angiogenesis in our in vitro model.  
These results are highly relevant in the search for multi targeted therapies that would best 
avert target specific induced resistance, and thus warrant further evaluation of the efficacy and 
mechanism of RANCE-1 in renal cancer in vivo. In addition, the relevant results found for 
Auranofin (an old anti-rheumatic drug being currently ‘repurposed’ as a chemotherapeutic for 
additional diseases, including cancer) also warrant further exploration of this agent in renal cancer 
treatment. 
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Part 2 
 
Preclinical evaluation of a heterobimetallic gold-ruthenium complex unveils great tumor 
suppressive and angiosuppressive efficacy in a mouse clear cell renal carcinoma xenograft 
 
4.2.1 INTRODUCTION 
The results obtained in vitro were very encouraging as we determined that RANCE-1 has 
anti-proliferative, anti-metastatic, and anti-angiogenic properties. We also found that RANCE-1 
was a strong inhibitor of proteolytic factors critically associated with tumor metastasis such as 
cathepsins, ADAMs, and MMPs, all markers of clinical interest. We thus sought out to further 
explore the efficacy of RANCE-1 in vivo and obtain clinically relevant insights into the biological 
response. We observed organ distribution of RANCE-1 in NOD.CB17-Prkdc SCID/J mice bearing 
a subcutaneous clear cell renal carcinoma (Caki-1) xenograft, an established preclinical model of 
ccRC. We report here on the measurements of the acute and chronic toxicities, pharmacokinetics, 
efficacy, and pathology of treatment with RANCE-1 generated interesting results. These 
experiments also demonstrated that RANCE-1 blocked all tumor growth. 
 
4.2.2 RESULTS AND DISCUSSION 
4.2.2.1. Dose range finding study. 
First, we report the acute toxicity and maximum tolerated dose (MTD) of RANCE-1 in 
naïve NOD.CB17-Prkdc SCID/J mice. This study was carried out to assess the toxicological 
profile of RANCE-1 following 6 intraperitoneal (i.p.) doses between 30mg/kg/48h and 
50mg/kg/48h followed by a two-week recovery period. Vehicle solution (0.5% DMSO + 99.5% 
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normal saline) treated mice were used as controls. Lung, liver, kidney, spleen, and heart were 
collected, weighed and visually evaluated during a gross necropsy. Parameters such as mortality, 
bodyweight, posture, grooming, and clinical and gross pathologies were monitored throughout the 
study. The acute toxicity study indicated that the lethal dose (LD50) of RANCE-1 was 45 
mg/kg/48h (Figure 4.11). The MTD study indicated that male and female mice tolerated three i.p. 
injections at doses of  30mg/kg/48h to 40mg/kg/48h of RANCE-1 without notable signs of toxicity 
or changes pathological parameters in the treated animals (Figure 4.12). These findings informed 
the rationale for selecting the doses of 10mg/kg/48h for RANCE-1 for the subsequent 
pharmacokinetic (Pk) and histopathological analyses. It was concluded that administration of 
seven consecutive doses of 10mg/kg/48h via i.p. injection in female and male NOD.CB17-Prkdc 
SCID/J mice, as we had initially envisioned for the efficacy trial, would be well tolerated under 
these study conditions since no concerning changes were observed in mean body weight compared 
to control and no signs of distress were observed at three times these doses. There were, upon 
gross-necropsy, no obvious signs of local toxicity were observed in the peritoneal cavity. This dose 
range and toxicity study demonstrates that RANCE-1 is a relatively safe compound within a two 
week treatment at doses at or below 35 mg/kg i.p.  
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Figure 4.11. Median lethal dose (LD50) was estimated by injecting i.p. five increasing doses of 
RANCE-1 into two mice (weighing between 18 and 22 g). Deaths occurring during the first two 
doses were recorded and LD50 was calculated.   
 
Figure 4.12. RANCE-1 is best tolerated at doses below 30 mg/kg/48h in non-tumor bearing female 
and male NOD.CB17-Prkdc SCID/J mice. A. Survival curves associated with MTD determination 
of RANCE-1s. B. Body weights at the end of the course of treatment with various doses during 
the MTD determination -. Error bars represent SEM for each group.  
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 4.2.2.2. Pharmacokinetics and Biodistribution 
(Pk analyses were performed by the Laboratory of Swayam Prabha, at the University of Minnesota 
Department of Experimental and Clinical Pharmacology) 
We then proceeded to evaluate the biodistribution and bioavailability of the compound as 
to obtain the optimal time between doses in preparation for an efficacy trial. To that end we 
performed a Pk study in a preclinical mouse xenograft model of kidney cancer. We determined the 
pharmacokinetics of RANCE-1 upon intraperitoneal (i.p.) administration of a single dose followed 
by time lapse blood collection and terminal tissue collection in xenograft Caki-1 tumor bearing 
NOD.CB17-Prkdc SCID/J mice to provide insights into critical preclinical criterion such as 
absorbance time clearance rate. The compound was absorbed slowly, as indicated by a peak plasma 
concentration of Ru reached at 12 h after dosing.  RANCE-1 eliminated slowly from the blood 
with an elimination half-life (t1/2) of 40.8h (Table 4.2 and Figure 4.13). The plasma concentration 
of Au was not measured due to experimental constraints. This informed the choice of a 72h 
window between doses, as this allowed sufficient time for clearance of the compound.  
We then determined the tissue distribution of RANCE-1 72h after a single i.p. injection. In 
this study, the tissue distribution of Ru and Au was in the order kidney>tumor>liver (Figure 4.14 
and Table 4.4). Notwithstanding that more compound accumulated in the kidney than in the tumor, 
there was a significant amount of both Ru and Au were found in the tumor tissue (Figure 4.14, 
Table 4.4). It is important to note that we observed close to a 1:1 colocalization of both metals (Ru 
and Au) in the tissue (Table 4.6). These data indicate that both metals in the compound are 
delivered to the tissue at a near 1:1 ratio, suggesting stability of the bimetallic compounds in the 
course of biodistribution.  
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Table 4.2 Pharmacokinetic parametersb of RANCE-1 after single intraperitoneal injection in 
tumor-bearing mice.  
Parameters RANCE-1 
Tmax (h) 10.00±3.46 
Cmax (µg/mL) 22.60±2.58 
AUClast (µg.h/mL) 792.9±270.3 
AUCInf (µg.h/mL) 1081.08±394.27 
ke (h-1) 0.0196±0.0088 
t1/2 (h) 40.77±18.67 
Vd/F (mL/Kg) 612.10±429.00 
Cl/F (mL/h/Kg) 10.00±3.15 
Cmin ss (µg/mL) 7.17±3.91 
Time to reach steady state (h) 203.8±93.4 
b Pharmacokinetic parameters determined include the maximum observed plasma concentration (Cmax), 
the time to reach Cmax (Tmax), area under the plasma concentration–time curve from time zero to 72 h post 
dose (AUC0-72h), elimination rate constant (ke), terminal elimination half-life (t1/2), apparent total clearance 
from plasma (Cl/F), and apparent volume of distribution (Vd/F). 
 
 
Figure 4.13. Plasma concentration of the Ru metal of RANCE-1 at various intervals after single 
intraperitoneal injection. Data represent mean ± SD (n = 4). 
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Table 4.3. Plasma concentration of the Ru metal of the RANCE-1 bimetallic at various intervals 
after single intraperitoneal injection. Data represent mean ± SD (n = 4). 
 
 RANCE-1 
Time (h) Conc. (µg/mL) 
1 2.15 ± 3.11 
2 1.30 ± 0.57 
6 16.53 ± 3.11 
12 21.39 ± 4.62 
24 13.88 ± 7.93 
48 8.35 ± 4.72 
72 5.16 ± 2.98 
 
 
 
Figure 4.14. Tissue distribution of both Ruthenium and gold metals from RANCE-1 at the end of 
the Pk study (72 h post-injection). Below the x-axis, Ru:Au represents the ratio of the two metals 
in each tissue. Data represent mean ± SD (n = 4). 
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Table 4.4. Tissue distribution of the Ru and Au metals of the bimetallic RANCE-1 72h after single 
intraperitoneal injection. Data represent mean ± SD (n = 4). 
 
 RANCE-1 
  Ru (µg/gm) Au (µg/gm) 
Liver 4.86 ± 3.94 3.14 ± 3.96 
Kidney 14.59 ± 10.88 15.24 ± 10.69 
Tumor 7.70 ± 5.81 9.98 ± 7.27 
 
Table 4.5. Ratio of Ru metal present between tissue and plasma of mice treated with RANCE-1 
72h after single intraperitoneal injection. Data represent mean ± SD (n = 4). 
 
RANCE-1 
Tissue :  Plasma 
Kidney Liver Tumor 
4.00 : 1 0.95 : 1 2.17 : 1 
 
Table 4.6. Ratio of Ru and Au metals present in tissue of mice treated with RANCE-1 72h after 
single intraperitoneal injection. Data represent mean ± SD (n = 4). 
 
 
 RANCE-1 
 Ru  :  Au 
Liver 1.2    :  1 
Kidney 0.98  :  1 
Tumor 0.78  :  1 
 
4.2.2.3. Efficacy study  
Third, we report on an intervention trial to determine the in vivo anticancer efficacy of 
RANCE-1 in xenograft Caki-1tumor bearing NOD.CB17-Prkdc SCID/J mice in response to 
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intraperitoneal (i.p.) administration of seven doses spaced by 72h followed by a 72h recovery 
period before sacrifice. Following our most recent Pk study, it was determined that doses of one 
quarter of the MTD (10mg/kg/72h) administered once every 72h would be appropriate to evaluate 
in vivo the anti-cancer efficacy of RANCE-1. 
In mice treated with RANCE-1, we observed neither tumor growth nor shrinkage from the 
starting tumor burden recorded at the beginning of the trial. RANCE-1 had a chemo-static effect 
on tumor growth. Mice treated with RANCE-1 had no change in tumor burden after 21 days of 
treatment (a total of 7 doses) (Figure 4.14).  
Figure 4.15. RANCE-1 treatment inhibits tumor growth in a xenograft renal cancer intervention 
trial (A) Representative histological samples of tumors resected from each treatment group. (B) 
The average tumor volume after 21 days of treatment did not significantly change  in RANCE-1 
treated mice, average tumor growth 3.87% (p=0.082) compared to the vehicle (Veh) control-
treated group where tumor volume increased by 138%, ** p<0.01. Mice were treated with 
RANCE-1 (10 mg/kg/72h), or Veh by intraperitoneal injection from for 21 days. RANCE-1: n=6 
mice, Veh: n=6 mice. 
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This result was rather unexpected given that the compound was cytotoxic in vitro. In 
contrast, we observed a growth in tumor volume of 138% in the vehicle treated mice. No 
significant change in weight or any decline in the well-being of the RANCE-1 treated mice were 
observed during this trial. These results are interesting, as they indicate the compound has growth 
inhibiting properties. 
We then sought to determine the biodistribution of each metal after the 21-day efficacy 
study. Using the same methods as the Pk study (Figure 4.15, Table 4.7), we observed that the 
biodistribution of RANCE-1 was in the order kidney>tumor>liver following a single dose, 
however the order of accumulation changed to liver> kidney > tumor at the end of the 21 day 
intervention trial. There is evidently a shift in tissue between the 72h Pk study and the 21 day 
efficacy study. Importantly, there was far less metal in the tissue after the 21 day trial, in fact, we 
observed a 30% reduction in Ru accumulation in the liver, and 80% reduction in metal 
accumulation in the kidney, but also a significant decrease in the amount of Ru accumulated in the 
tumor. These changes in metal retention cannot be clearly attributed to a specific metabolic or 
clearance change over the course of treatment. 
 
Figure 4.16. Tissue distribution of Ru and Au metal of bimetallic RANCE-1 at the end of efficacy 
study (i.e. 72 h after the last injection of a 21day trial RANCE-1 (10mg/kg/72h). Below the x-axis, 
Ru :Au represents the ratio of the two metals in each tissue. Data represent mean ± SD (n = 4). 
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Table 4.7.  Tissue distribution of the Ru and Au metal of bimetallic RANCE-1 at the end of 
efficacy study (i.e. 72 h after the last injection of a 21day trial with  RANCE-1 (10mg/kg/72h).  
Data represent mean ± SD (n = 4). 
 RANCE-1 
  Ru (µg/gm) Au (µg/gm) 
Liver 5.17 ±  0.71 4.03 ±  0.34 
Kidney 3.86 ±  1.02 3.07 ± 0.85 
Tumor 1.73 ±  0.47 1.47 ±  0.45 
 
We observed that, compared to the tissue distribution results obtained at the Pk study, at 
the end of the efficacy trial, significantly less metal was retained in the tissue at the end of the Pk 
study. We first observed that in RANCE-1 treated mice, the ratio of Ru to Au in the tissue was 
higher than in the Pk study, indicating that more Ru was retained in the tissues than Au during the 
course of treatment. Second, we observed that the absolute concentration of Ru metal per tissue 
weight was 30% and 80% lower in liver and kidney tissue respectively after the 21 day trial 
suggesting that over the course of treatment, the liver increased its ability to excrete the compound 
(Table 7). 
Table 4.8.  Percentage of change in tissue distribution of the Ru metal of the bimetallic RANCE-
1 between the Pk study (i.e. 72 h after a single injection of 10mg/kg and the efficacy study (i.e. 72 
h after the last injection of a 21day trial [RANCE-110mg/kg/72h].  Data represent mean ± SD (n 
= 4). 
 RANCE-1 (%) Change relative to Pk 
Liver 33.19 decrease 
Kidney 80.8 decrease 
Tumor 83.6 decrease  
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4.2.2.4. Mechanism of action in vivo 
Given the substantial dramatic inhibition of tumor growth in treated mice treated with 
RANCE-1, we next sought to determine the cellular mechanisms driving that static effect. We 
sought to interrogate the effects of RANCE-1 on the proliferating to apoptotic cell ratio in clear 
cell renal carcinoma xenograft tumors.  
 
Figure 4.17. RANCE-1 treatment affects the proliferation and apoptosis ratio/equilibrium at the 
21-day trial endpoint. RANCE-1 reduces tumor cell proliferation by 18 fold (from 36% for the 
veh. treated to 2% for the RANCE-1 treated) and does not significantly affect apoptosis (from 2% 
for the veh treated to 1.6% for the RANCE-1 treated- mice) in a xenograft of ccRCC in an 
intervention trial. The tumor proliferation and apoptosis were analyzed by staining tumor tissue 
with a cell proliferation specific marker Ki67 (green) and an apoptosis specific marker Cleaved 
caspase 3 (red) (n=4 mice per group (apoptosis RANCE-1 p= 0.71, proliferation RANCE-1 ***p 
<0.001 ). 
 
 
160 
 
 
We first examined cell proliferation profile of the tumors using the proliferation marker 
Ki67, and because tumor growth can also reflect changes in cell death, we compared the 
proliferation rate to apoptotic rates using the apoptotic marker cleaved caspase 3. The average of 
proliferating cells in individual tumors of the vehicle (Veh.) treated mice control group was 36%,  
We determined in vitro, as reported in Part 1 of this chapter, that RANCE-1 disturbed 
vascular assembly and RANCE-1 is a potent inhibitor of IL-6 and VEGF. It has been shown that 
inhibition or deletion of IL-6 and VEGF in mice induced a significant decrease in tumor invasion 
and angiogenesis, and thus sought to determine if the use of our compounds disrupted angiogenesis 
and VEGF and IL-6 levels were affected.  Of the mice injected with dextran and lectin the dye 
could not be detected thus we were unable to image vasculature in this treatment group. This might 
be because the tissue was significantly less dense with high presence of connective tissue and as it 
was not perfused with PFA, the tissue was fragile and retaining morphologic integrity was difficult. 
These findings are interesting because, the tumors did not seem to gain volume, as compared to 
vehicle treated mice, and this is reflected by the difference in proliferation to apoptosis ratio of the 
two treatment groups. Perhaps, as fewer cells are proliferating and more cells are dying, the cell 
density of the tumor mass is reduced, but that volume is unchanged because connective tissue fill 
in that void. One could posit that at that size there is no vasculature in the tumors. However, we 
know from another study of bimetallic compounds containing gold and titanium (Titanocref and 
Titanofin) that tumors that are even smaller than at the starting volume can be vascularized, we 
also know from those studies that smaller tumors do not necessarily have lower cells density 
(Chapter 3). Thus, the apparent lack of vasculature and tissue integrity might be a phenotype driven 
by RANCE-1 itself and later studies reported later on in this chapter seem to provide some insights 
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into the mechanism that might drive this phenotype. RANCE-1 treatment induces a significant 
decrease in growth factors involved both in the croissance of the tumor and the development of 
vasculature. 
 
4.2.2.5. Proteomic analysis  
Given the drastic decrease in proliferating in tumor tissue, we next aimed to identify some of the 
molecular signaling changes that may underlie this phenotype. We interrogated the effects of 
treatment with RANCE-1 on ccRCC in culture as well in xenograft tumors on an array of proteins 
of oncological relevance by immunoblotting (Figures 4.18-4.19). 
We observed from the histological analysis (Figure 4.17) that in response to RANCE-1 
treatment, there was a striking reduction in proliferation, which could be mediated by changes in 
balance of proliferative factors. There was indeed a decrease in expression of many growth factors 
including VEGF, PDGF, FGF, EGFR, and HGRF, all key to the proliferation of tumor cells, but 
also to the stromal cells serving protumorigenic purposes.  We noticed that while PDGF, FGF, 
EGFR, and HGRF we all significantly decreased in the in vivo sample, their expression was 
moderately increased in vitro. Perhaps the mono-culture nature of in vitro study and the lack of 
cellular diversity contributed to this difference. We also observed an increase in antitumorigenic 
immune factors IL-2R and GM-CSF, which are clinically associated with improved prognoses 33–
35. The expression of the macrophage related CapG protein was suppressed in vivo, which usually 
correlates with reduced migration 36,37. Levels of the prometastatic cytokines IL-5, IL-6 were 
increased in response to RANCE-1 treatment in vivo, though they were markedly decreased in 
vitro, which might be the result of prolonged treatment, local selection of tumor cells with robust 
production of IL-5 and IL-6, or contribution by stromal cells. We observed an increase in M-CSF 
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expression in vivo, which is the primary regulator of macrophage survival, proliferation, and 
differentiation. M-CSF is also critical to macrophage-related functions such as vascular 
development and maintenance, and innate immunity. Despite this upregulation, the tumors did not 
grow, suggesting that the depletion of key growth factors might be a main driver of the absence of 
proliferation and absence of tumor growth observed.  In vivo, RANCE-1 significantly decreased 
the expression of, HIF-1a, ICAM,  VE-Cadherin, and vascular cell adhesion molecule-1 (VCAM-
1), while in vitro, those proteins were either unaffected as was the case for VCAM, ICAM and 
VE-Cadherin, or increased as was the case with HIF-1a.  
 The in vivo efficacy was accompanied by a significant decrease in the prometastatic factors 
cathepsin B (CtsB), cathepsin S (CtsS), FoxC2, MMP-2, MMP-3, MMP-8, ADAM8, and 
ADAMP9, all of which are peritumoral proteolytic factors known to drive angiogenesis, migration, 
invasion, and metastasis 38–42. We also observed a decrease in CCL7 and CCL8 levels upon 
RANCE-1 treatment, which could decrease the tumor’s ability to recruit monocytes, thus rendering 
the tumor ecosystem more hostile to tumor progression. CCL8 is expressed by dermal fibroblasts 
to modulate tumor-stroma and tumor-tumor cross-talk in the initiation of metastasis, while ICAM 
is mainly produced and modulated by immune cells or in response to immune cell signal which 
are absent in monolayer monoculture.  
We believe the most important differences were those observed in vivo. There are multiple 
potential explanations for differences observed between in vitro and in vivo samples. Specifically, 
signaling in the in vitro monoculture is limited to tumor-tumor cell communication, while the in 
vivo tumor microenvironment is significantly more complicated and involves multiple cell types. 
However, in most cases the protein expression changes followed similar trends in vitro and in vivo, 
with the notable exception being genes involved in tumor immunity. 
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 Figure 4.18. RANCE-1 treatment induces changes in the expression of growth factors and cancer-
immune interface regulators in vivo. In vitro changes in expression levels of proteins of oncological 
interest, following treatment of Caki-1 cells in vitro with IC20 concentrations of each compound 
for 72h. In vivo changes in expression levels of proteins of oncological interest, following a 21-
day efficacy trial in Caki-1 xenograft tumor bearing NOD.CB17-Prkdc SCID/J mice. Analysis of 
150µg of protein extracted from cell or tumor lysate. The values indicate the percentage of change 
in expression relative to DMSO treated cells.  
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Figure 4.19. RANCE-1 treatment induces changes in the expression of proteolytic factors in vivo. 
In vivo changes in expression levels of pericellular proteolytic factors or activators of proteolytic 
factors, following a 21-day efficacy trial in Caki-1 xenograft tumor bearing NOD.CB17-Prkdc 
SCID/J mice. And, in vitro changes in expression levels of proteolytic factors of oncological 
interest, following treatment of Caki-1 cells in vitro with IC20 concentrations of each compound 
for 72h. Analysis of 150µg of protein extracted from cell or tumor lysate. The values indicate the 
percentage of change in expression relative to DMSO treated cells.  
 
In the context of potential anticancer therapeutic agents, these results suggest that RANCE-
1 would be a good antimetastatic candidate as it inhibits a series of key proteolytic factors (MMPs, 
ADAMs, Cts) associated with metastasis whose inhibitions have been reported to curb metastasis. 
Also, the compound potentiated the expression of immune factors, IL-2-R and GM-CSF, known 
to be associated with optimal host anti-cancer immune responses and their presence is correlated 
with good prognosis 33,34,43.  RANCE-1’s inhibitory capacities towards five key growth factors 
also adds to its therapeutic potential. It is a single molecule multi-drug of sorts, as it promotes 
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antitumorigenic immune responses, blocks prometastatic proteolytic factors and inhibits key 
growth factors.  
 
4.2.2.6.  Pathology 
Finally, we report on our study to determine any pathological effects that might be caused by 
treatment with RANCE-1. Access to expertise in cancer histopathology is critical in making a 
definitive determination of the safety, and therefore clinical viability of a compound for potential 
use in humans. A complete pathology study was performed in collaboration with Dr. Adam Michel 
from Memorial Sloan Kettering Cancer Center. This study revealed that no significant adverse 
effects were observed after histological evaluation related to the RANCE-1 treatment (Table 4.9, 
Figure 4.20). We found no notable difference in total body weight or organ weight between the 
treated and control mice at the end of the trial, the data in Table 4.9 also suggest there were no 
enlargements or atrophy as a result of treatment. While there were no significant or visible changes 
to the spleen, we observed a drastic increased in percentages of blood circulating neutrophils 
(NEUT), white blood cells (WBC) and monocytes (MONO) that were above the normal range 
which would indicate changes in splining activity which can be reconciled with the observed 
increase in GM-CSF (Table 4.10). Because this change was only observed in RANCE-1 treated 
animals, the effect was drug induced or the result of a response to an unrelated infection. 
Clinical indicators of liver, kidney and spleen function (Table 4.10) complete blood counts 
(Table 4.11), and clinical chemistry (Table 4.12) of all mice treated with RANCE-1 were compared 
to vehicle treated mice. While levels of liver function indicators such as aspartate aminotransferase 
(AST) (indicative of either an inflamed or injured liver (REF)) and Alanine transaminase (ALT) 
were elevated in RANCE-1 treated mice, they were also elevated in the Veh treated mice, 
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suggesting the effect did not result from the drug treatment 44  (Table 4.10). The pathology report 
also indicated extramedullary hematopoiesis in the liver, which is the formation of blood cells 
outside of the bone, and results from microvacuolar changes. The pathology report gave no 
indication that these responses were a serious health concern. 
From stained histological samples, we observed no lesions, or signs of pathologic tissue distension, 
discoloration, necrosis, or structural abnormalities (Figure 4.20). The histological data is supported 
by hematologic data on the levels of key clinical indicators of liver, kidney through clinical 
chemistry (Table 4.10A) and spleen function as measured by complete blood count (CBC) (Table 
4.10B). All kidney health indicators were within normal values.  Finally, we found that no 
differences in the clinical chemistry of the treated or control animals (Table 4.14), indicating 
normal production and excretion of physiological fluids and metabolic markers whose 
deregulation are indicators of pathology or drug side effects.  
 
Table 4. 9. Summary of histological data 
 RANCE-1 DMSO 
Body weight (g) 21.31 ± 5.1 22.82  ± 2.14 
Liver weight (g) 1.15 ± 0.37 1.17  ± 0.28 
Spleen weight (g) 0.04 ± 0.017 0.05  ± 0.01 
Heart weight (g) 0.11 ± 0.05 0.13  ± 0.02 
Average Kidney weight 
(g) 0.17 ± 0.06 0.16  ± 0.06 
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Figure 4.20. RANCE-1 treatment does not induce histological changes in liver, spleen or kidney 
tissue of mice at the end of the 21 day efficacy trial. Histopathology on H&E staining of paraffin 
sections magnification 20x. Sections are representative of 3 mice of each treatment. 
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Table 4.10. Summary of key clinical indicators of (A) liver, kidney through clinical chemistry and 
(B) spleen function though complete blood count (CBC). 
 
A.  
 Clinical chemistry RANCE-1 DMSO NSG Reference Range 
K
id
ne
y BUN (mg/dL)  18.33 ± 5.51 23 ± 2.65 5.0-28 
CREA (mg/dL)  0.12 ± 0.04 0.17 ± 0.04 0.2-0.5 
ALB (g/dL) 2.56 ± 0.02 2.83 ± 0.11 2.4-4.3 
L
iv
er
 
 AST (U/L) 394.66 ± 456 372.33 ± 27.94 54-77 
TBIL (mg/dL) 0.23 ± 0.06 0.2 ± 0.003 0.2-0.6 
DBIL (mg/dL) 0.03 ± 0.06 0 - 
IBIL (mg/dL) 0.2 0.2 ± 0.04 - 
ALT (U/L)  170.66 ±  248.03 163.33 ± 156.69 27-195 
 
B. 
 
Complete Blood 
Count RANCE-1 DMSO 
NSG Reference 
Range 
Sp
le
en
 
RBC (M/uL) 10.31  ± 1.05 8.11 ± 2.51  7.84-10.84 
WBC# (K/ul) 9.39  ± 7.06 2.39 ± 0.30 0.94-4.68 
Neut# (K/uL) 8.21  ± 7.18 1.37 ± 0.19 0.54-3.16 
LYMPH# (K/uL) 0.52  ± 0.32 0.57 ± 0.30 0.23-1.56 
MONO# (K/uL) 0.57  ± 0.45 0.36 ± 0.25 0.03-0.26 
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Table 4.11. Complete blood count report 
  DMSO RANCE- 1 NSG Reference Range 
RBC (M/uL) 8.11 ± 2.51 10.31  ± 1.05 7.84-10.84 
HGB (g/dL) 12.6 ± 3.81 15.8  ± 1.55 11.8-17.6 
HCT (%) 40.93 ± 14.32 52.8  ± 4.45 44.1-58.3 
MCV (fL) 49.93 ± 2.72 51.3  ± 1.84 51.1-58.6 
MCH (pg) 15.57 ± 0.23 15.37  ± 0.057 13.7-17.2 
MCHC (g/dL) 31.27 ± 2.04 29.9  ± 0.96 25.1-31.3 
RDW-SD (fL) 29.77 ± 3.23 31.03  ± 1.46 - 
RDW-CV (%) 21.30 ± 3.49 23.5  ± 0.72 17.3-20.3 
RET# (K/uL) 440.95 ± 4.88 192.67  ± 214.33 294-444 
RET (%) 4.62 ± 0.001 2.03  ± 2.43 2.56-4.56 
PLT (K/uL) 626.67 ± 60.07 1056.66  ± 149.94 651-2055 
PDW (fL) 6.85 ± 0.49 7.5  ± 0.44 - 
MPV (fL) 6.15 ± 0.35 6.53  ± 0.38 4.2-6.3 
WBC# (K/ul) 2.39 ± 0.30 9.39  ± 7.06 0.94-4.68 
Neut# (K/uL) 1.37 ± 0.19 8.21  ± 7.18 0.54-3.16 
LYMPH# (K/uL) 0.57 ± 0.30 0.52  ± 0.32 0.23-1.56 
MONO# (K/uL) 0.36 ± 0.25 0.57  ± 0.45 0.03-0.26 
EO# (K/uL) 0.1 ± 0.03 0.08  ± 0.04 0.00-0.39 
BASO # (K/ul) 0.01 0.006  ± 0.01 0.00-0.15 
NEUT (%) 58.3 ± 14.01 77.37  ± 21.06 44.21-79.92 
LYMPH (%) 22.57 ± 9.14 13.93  ± 18.8 13.51-42.61 
 
Complete Blood Count (CBC)  
NOD scid gamma mice (NSG mice) 
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Table 4.12. Clinical chemistry 
 
RANCE-1 DMSO NSG Reference Range 
BUN (mg/dL) 18.33 ± 5.51 23 ± 2.65 5.0-28 
CREA (mg/dL) 0.12 ± 0.04 0.17 ± 0.04 0.2-0.5 
BUN/CREA 
ratio 183.33 ± 117.87 143.14 ± 32.51 - 
ALP (U/L) 39.33  ± 7.37 62 ± 19.97 105-370 
ALT (U/L) 170.66 ±  248.03 163.33 ± 156.69 27-195 
AST (U/L) 394.66 ± 456 372.33 ± 279.43 54-77 
GGT (U/L) 0 0 - 
TBIL (mg/dL) 0.23 ± 0.06 0.2 ± 0.003 0.2-0.6 
DBIL (mg/dL) 0.03 ± 0.06 0 - 
IBIL (mg/dL) 0.2 0.2 ± 0.04 - 
TP (g/dL) 5.2 ± 0.17 5 4.8-7.2 
ALB (g/dL) 2.56 ± 0.02 2.83 ± 0.11 2.4-4.3 
GLOB (g/dL) 2.63 ± 0.31 2.17 ± 0.06 1.7-2.2 
A/G ratio 0.99 ± 0.19 1.31 ± 0.08 - 
P (mg/dL) 10.37 ± 2.92 10.1 ± 1.68 7.3-14.5 
Ca (mg/dL) 9.67 ± 0.56 9.43 ± 0.42 9.5-12.5 
GLU (mg/dL) 165 ± 69.47 190 ± 33.51 172-372 
CHOL (mg/dL) 87.67 ± 10.26 82.67 ± 9.81 55-169 
TRIG (mg/dL) 116 ± 48.51 93.67 ± 34.59 67-289 
CK (U/L) 368.67 ± 174.37 689 ± 471 428-1609 
TCO2 (mEq/L) 18 ± 7 18.67 ± 2.31 - 
Na (mEq/L) 150.67 ± 4.04 155 ± 3.46 145-181 
K (mEq/L) 10.97 ± 1.43 9.73 ± 1.96 7.3-11.1 
Cl (mEq/L) 106 ± 6.56 114.33 ± 1.53 111-134 
Na/K ratio 13.89 ± 1.89 16.37 ±  3.39 - 
Anion Gap 37.63 ± 9.41 31.73 ± 2.1 - 
 
4.2.2.7. Considerations about the xenograft model used for this study.  
The cells used are Caki-1 ccRC which are adherent epithelial cells. The Caki-1 cells express 
wildtype von Hippel-Lindau (VHL) tumor-suppressor protein and are known to form tumors in 
immunocompromised mice. These cells were isolated in 1971 from a metastatic site (skin) in a 49-
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year-old Caucasian male with ccRC.  While exploring changes in immune populations in the tumor 
microenvironment might have been very informative, because the NOD genetic background 
contains alleles that reduce the function of the innate branch of the immune system, macrophages 
and dendritic cells are defective 45. Thus, readouts of immune changes in the immunocompromised 
NOD SCID model would not necessarily be highly informative as when studying an immune 
competent organism. 
 
4.2.3. CONCLUSIONS 
We have shown that the heterobimetallic ruthenium-gold complex RANCE-1 drastically 
inhibits growth in an efficacy trial using mice bearing xenografted metastasis-derived clear cell 
renal carcinoma tumors without prediction of grave clinical side effects as indicated by the 
pathology study. In vivo, the inhibition of tumor growth coincided with a significant decrease in 
proliferation, and a reduction in the expression of growth factors known to drive malignant tumor 
progression phenotypes including angiogenesis such as VEGF, PDGF, FGF, EGFR, and HGRF. 
Overall, we have also identified changes in expression levels of 30 factors some known to 
modulate tumor growth, immune recruitment (i.e. CCL7, CCL8, ICAM) resistance to death 
(i.e.TrxR, Trx, HIF-1), and metastasis (i.e. MMPs, ADAMs, ILs, Cts) and others, changes that 
may drive the efficacy observed.  
Moreover, in vitro at doses below that of cytotoxicity, the novel compound significantly 
inhibited proteolytic factors critical to metastasis such as members of the ADAM, MMP, and Cts 
families and other associated malignant factors. While we observed great inhibition of angiogenic 
tube formation in vitro, were unable to detect blood vessels in vivo. 
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There is a salient distinction between in vivo RANCE-1 efficacy profile in vitro and in 
vivo, which is their effect on cancer cell behavior. Cytotoxic drugs act by stimulating cell death by 
triggering apoptosis, which is the efficacy profile of RANCE-1 in vitro. Whereas, cytostatic drugs 
act by inhibiting the hyperproliferation of cancerous cells thus blocking cell growth, which seems 
to be the in vivo profile of RANCE-1. Because, notwithstanding the great complexity of cancer its 
core definition is often simplified as the abnormal and deregulated and uncontrollable proliferation 
of cells. Since RANCE-1 seems able to block this phenotype and inhibit tumor growth, it still holds 
clinical potential as effective, curative, alternatives are lacking. An added asset of RANCE-1 in 
addition to tumor growth inhibition is its favorable pathology profile which would suggest no 
significant clinical side effects. The efficacy of RANCE-1 seems to be linked to reduction of 
activity of protumorigenic growth factors, the modulation of immune cell markers and the 
inhibition of proteins whose expression is associated with chemoresistance all of those features 
might make RANCE-1 a good candidate for combination therapy. Most interestingly, since 
RANCE-1 inhibit factors that often drive chemoresistance, it might be a valuable addition to 
therapies effective in other cancers but for which ccRCC are resistant such a cisplatin or other 
compounds to which ccRCC are non-responsive. The inhibition of key growth factors might be a 
potentiating addition to other growth factor inhibitors as to create a pan-growth-factor inhibitor 
cocktail. In the event of inoperable cancers, controlling the growth of is critical, thus an agent such 
as RANCE-1 might be a good candidate. The tumor model used is one of metastasis derived cells 
Caki-1, thus RANCE-1’s effect are against a cell line with inherent metastatic phenotype, and 
because ccRCC are often diagnosed after the tumor has spread to the liver or lung, in such scenario, 
a drug that can stop growth would be of great interest in the absence of drug alternatives that can 
kill the tumors and metastasis.  
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It is worth reiterating that, the indications that RANCE-1 is likely to cause no or minimal 
side effects as predicted by the pathology report make is an appealing compound to potentiate 
drugs whose efficacy is associated with significant AE.  
The landscape of ccRCC treatment is terse. Currently available pharmaceutical 
interventions are associated with limited efficacy since neither cytotoxic chemotherapies, nor 
targeted or immunotherapies have to date successfully cured advance renal cancer or brought DFS 
past 30 months and that with significant side effects. Therefore, there is an urgent need for novel 
effective, non-toxic clinical alternatives to the currently available pharmaceutical arsenal to 
improve survival and quality of life. Life can be extended by inhibiting further tumor growth. 
Therefore, we are making a case for exploration of this compound towards clinical trials in humans 
perhaps in combination therapy. As we work toward an ideal cure, there is merit to clinical 
interventions that can prevent malignant evolution of solid tumors.  
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CHAPTER 5 
MATERIALS AND METHODS 
(for work described in Chapters 3 and 4) 
 
Unless otherwise indicated, the experiments were carried out in the Contel (Brooklyn College, 
CUNY) or Hubbard (City College of New York, CUNY) laboratories.  
 
5.1 In vitro assays 
5.1.1 Metallic compounds 
Compounds used in these studies: Cisplatin, titanocene dichloride, and auranofin (AF) were 
purchased from Strem Chemicals (Newburyport, MA) and used without further purification. [Ru(p-
cymene)Cl2(dppm-κP)] Ru-dppm 1; [Cl2(p-cymene)Ru(μ-dppm)Au(IMes)]ClO4 (RANCE-1),  
[AuCl(IMes)] ANCE-1 2, [(η-C5H5)2TiMe(µ-mba)Au(PPh3)], cref [Au(Hmba)(PR3)] (PR3 = PPh3)] 
, fin [Au(Hmba)(PEt3)] 3 and were prepared as described previously. Titanofin [(η-C5H5)2TiMe(µ-
mba)Au(PR3)] is a new compound described in a recently submitted manuscript 4 . (Chart 5.1) 
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Chapter 4 
 
Chart 5.1. Structure of compounds studied in Chapter 3 in vitro and structure of compounds 
studied in Chapter 4 in vitro. 
 
5.1.2 Cells  
Caki-1, a human epithelial clear cell renal cell carcinoma (ccRCC) line derived from a metastasis 
to the skin was newly obtained for these studies from the American Type Culture Collection 
(ATCC) (Manassas, VA) and cultured in Roswell Park Memorial Institute (RPMI-1640) 
(Mediatech Inc., Manassas, VA) media containing 10% fetal bovine serum (FBS, Life 
Technologies, Grand Island, NY), 1% Minimum Essential Media (MEM) nonessential amino acids 
(NEAA, Mediatech) and 1% penicillin-streptomycin (PenStrep, Mediatech) and incubated at 37°C 
and 5% CO2 in a humidified incubator. IMR90 (human fetal lung fibroblast) cells were purchased 
from ATCC and maintained in Dulbecco's modified Eagle's medium (DMEM) (Mediatech) 
supplemented with 10% FBS, 1% NEAA and 1% penicillin-streptomycin. HUVEC (human 
umbilical vein endothelial) cells were obtained from ATCC and cultured in Medium 200PRF 
(Gibco, Gaithersburg, MD) 
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5.1.3 Cell Viability Analysis  
Cytotoxic profiles (IC50) of bimetallic, monometallic, and control compounds (Chapters 3 
and 4) were obtained by assessing the viability of Caki-1 and IMR90 control cells treated with the 
appropriate culture medium containing 0.01 μM, 0.1 μM, 1 μM, 10 μM and 100 μM of compound 
for 24h and 72h using the colorimetric cell viability assay PrestoBlue (Invitrogen, Carlsbad, CA). 
All compounds were dissolved in DMSO, except Cisplatin, which was dissolved in H2O with a 
final DMSO concentration of 1%.  
 
5.1.4 Caspase 3 and 7 activity 
Cells were treated with the bimetallic test compounds Titanocref and Titanofin as well as 
Auranofin at doses ranging from 0.001 µM to 10 µM and incubated for 72h (Chapter 3). To 
evaluate apoptosis and necrosis induced because of treatment, we used an ApoTox-Glo Triplex 
Assay kit (Promega, Madison, WI). Apoptosis studies were conducted by measuring caspase 3/7 
activity. Caspase 3/7 activity was analyzed using a bioluminescent indicator and detected by a 
BioTek Microplate Reader (BioTek U.S., Winooski, VT) according to the manufacturer’s 
protocol. Apoptosis induced by Staurosporine treatment was used as control. Necrosis was studied 
by measuring dose-dependent increase in cytotoxicity in the absence of caspase-3/7 activation a 
cellular behavior associated with primary necrosis.  
 
5.1.5 Cell Death Assay 
The cell death profile was determined in Caki-1 cells cultured in appropriate media 
containing IC50 concentrations of bimetallic Ti-Au Titanocref or Titanofin, or monometallic Au 
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control AF (Chapter 3); or IC50 concentrations of bimetallic Ru-Au RANCE-1 or monometallic 
Au control AF (Chapter 4) for 24h was analyzed by flow cytometry stained with Annexin V (FITC) 
dye (Invitrogen). Staurosporine and Ionomycin treated cells were also stained with Annexin V dye 
and served as positive controls for apoptosis and cell death.  FITC fluorescence intensity was 
detected by flow cytometry analysis using a BD LSR II flow cytometer (Franklin Lakes, NJ). 
10*105 events per sample were recorded. The flow cytometer was calibrated prior to use.  
 
5.1.6 Cell Cycle Profile 
The cell cycle profile was determined in Caki-1 cells cultured in appropriate media 
containing IC20 concentrations of bimetallic Ti-Au Titanocref, or Titanofin, or monometallic Au 
control AF (Chapter 3); or IC50 concentrations of bimetallic Ru-Au RANCE-1 or monometallic 
Au control AF (Chapter 4) for 24h was analyzed by flow cytometry wherein total DNA was stained 
with FxCycle Violet (FCV; DAPI) dye (Invitrogen). DAPI fluorescence intensity was detected by 
flow cytometry, theanalysis was conducted using BD FACSDiva 8.0.2 10*105 events per sample 
were recorded. The flow cytometer was calibrated prior to use.  
 
5.1.7 Cell Migration and Invasion Analysis  
The anti-migratory profile of bimetallic Ti-Au Titanocref, or Titanofin, or monometallic 
Au fin, cref, or Au control AF (Chapter 3); or that of bimetallic Ru-Au RANCE-1, monometallic 
Au ANCE-1, monometallic Ru control R or monometallic Au control AF (Chapter 4) was assessed 
by an in vitro scratch assay using Caki-1 cells cultured in appropriate media and treated under 
serum-free conditions with IC20 concentration of the compounds. The diluting agent (0.1% DMSO) 
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served as a control. Briefly, cells were seeded in 6-well collagen-coated plates for 24h, followed 
by 4 hours of serum starvation, and scratching with 200 μL pipette tips. 24 hours after injury, cells 
were photographed using a Moticam (Kowloon, Hong Kong) camera mounted on a Zeiss inverted 
microscope (Oberkochen, Germany) at 20X magnification. The area invaded was measured then 
averaged in five randomly selected segments from three photos from each sample. Data were 
collected from two independent experiments. 
The anti-invasion profiles of bimetallic of bimetallic, monometallic, and control 
compounds (Chapters 3 and 4) were assessed by transwell assay by determining the invasion of 
Caki-1 cancerous cells treated with the appropriate serum-free culture medium containing IC20 
concentration of the compounds. The diluting agent (0.1% DMSO) served as a control.  Briefly, 
Geltrex® a Reduced Growth Factor Basement Membrane Matrix (Invitrogen) was thawed and 
added to a 24-well transwell insert and solidified in a 37°C incubator for 30 minutes to form a thin 
gel layer. 5*105 cells in serum-free media were then added on top of the Geltrex® coating to 
simulate invasion through an extracellular matrix. The insert was then mounted into a well 
containing complete media. 24 hours later, the membrane was fixed and stained with hematoxylin 
and eosin to assess the extent of cell invasion. The invaded cells were captured with a Moticam 
camera mounted on a Zeiss inverted microscope at 20X magnification. Cell numbers were counted 
from views randomly selected field of views from three photos for each sample then averaged. 
Data were collected from at least two independent experiments. 
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5.1.8 Angiogenesis Analysis  
96 well plates were coated with Geltrex®, Reduced Growth Factor Basement Membrane 
Matrix (Invitrogen) (50μl/well) and incubated at 37ºC for 30 minutes to allow gelation to solidify. 
HUVECs were added and the antiangiogenic profiles of bimetallic, monometallic, and control 
compounds (Chapters 3 and 4) were determined by assessing their effect on endothelial tube 
formation by Human umbilical vein endothelial cells (HUVECs).  We measured the ability of 
HUVECs to form tubes and reach the top of the gel at a density of 6,000 cells/well in the presence 
or absence of the bimetallic test compounds or monometallic control (1 μM) 1% DMSO served as 
a control. Cells were incubated at 37ºC with 5% CO2 for 24h and pictures were captured with a 
Moticam camera mounted on a Zeiss inverted microscope at 10X magnification. Quantification of 
tube formation was assisted by SCORE, a web-based image analysis system (S.CO 
BioLifescience). Tube formation was quantified by determining the number of branching points 
(tube nodes, TN) and total length of skeleton (tube length, TL). Data presented are an average of 
three wells per treatment condition. 
 
5.1.9 Thioredoxin reductase activity assay 
  Caki-1 cells treated in vitro with IC50 concentrations bimetallic, monometallic, and control 
compounds (Chapters 3 and 4) or 0.1% DMSO were lysed after 24 hours of treatment. TrxR 
activity was measured using a kit (Abcam ab843463). Briefly, lysate was inclubated for 20 minutes 
with DTNB (5, 5′-dithiobis (2-nitrobenzoic) acid), mixed with Thioredoxin Reductase Assay 
buffer, then TrxR levels were detected according to the manufacturer's instructions using a BioTek 
Microplate Reader (BioTek U.S., Winooski, VT) at λ = 412 nm. Tests were conducted in duplicate. 
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TrxR activity was measured relative to the linear quantity of TNB produced per mg of total protein. 
Background activity from non TrxR enzymes in the lysates were adjusted. 
 
5.1.10 VEGF protein blotting assay 
Caki-1 cells treated in vitro with either IC20 concentrations of bimetallic, monometallic, 
and control compounds (Chapters 3 and 4) or 0.1% DMSO were lysed after 72 hours of treatment, 
cell culture supernatant was collected, and VEGF expression was assessed by a VEGF human 
ELISA kit (100663 Abcam) following manufacturer’s instructions. 
 
5.1.11 Cytokine Expression 
Caki-1 cells treated in vitro with IC20 concentrations of bimetallic, monometallic, and 
control compounds (Chapters 3 and 4) or 0.1% DMSO. After 72 hours of treatment, cell culture 
supernatant was collected, and interleukin expression was determined using a Multi-Target ELISA 
array kit (PathScan Cytokine Antibody Array Kit, Cell Signaling, Danvers, MA). The relative 
expression levels were determined according to the manufacturer’s protocol, and signal intensities were 
compared using HLImage++ software (Western Vision Software, Layton, UT).  
 
5.1.12 Protein array  
Caki-1 cells treated in vitro with IC20 concentrations of bimetallic, monometallic, and 
control compounds (Chapters 3 and 4) or 0.1% DMSO were lysed after 72 hours of treatment. 
Before application to the array, protein concentration was determined by BCA. 150 μg of lysate was 
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then incubated for 24 h with the Proteome Profiler Human Protease Array Kit (ARY025) [in vitro 
samples] or Proteome Profiler Human XL Oncology Array (ARY026) [ in vitro and in vivo samples] 
(R&D Systems, Minneapolis, MN). The relative expression levels of the proteases were determined 
according to the manufacturer’s protocol, and signal intensities were compared using HLImage++ 
software.  
 
5.1.13 Data collection and statistical analysis 
Results for all experiments were expressed as mean ± Standard Error of the Mean. 
Experiments were conducted in duplicate or triplicate. For all other parameters, statistical 
significance was determined using an independent two-tailed Student t-test and one-way ANOVA 
for independent data. p < 0.05 was considered as significant for all statistical analyses. All 
statistical analysis was done using GraphPad Prism® software (La Jolla, CA). 
 
5.2 In Vivo Assays 
5.2.1 Animals 
Five to eight-week-old male and female non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) mice NOD.CB17-Prkdc SCID/J mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME). The NOD.CB17-Prkdc SCID/J strain of mice is routinely 
used in safety evaluation studies, is recommended for xenograft studies, and is often used for 
preclinical efficacy studies of novel cancer chemotherapeutic leads 5,6. The mice weighed 18–20 g 
when they arrived to vivarium of the City University of New York (CUNY), City College of New 
York (CCNY), where they were housed in pathogen-free rooms in clear polycarbonate plastic 
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cages and acclimated for at least 72h prior to use. Mice were observed daily for signs of illness. 
The vivarium housing the mice was set to a cycle of 12 hour of darkness and 12 hours of light.  
The number of animals, animal use protocols and experimental design, were evaluated and 
approved by the CUNY, CCNY Institutional Animal Care and Use Committee (IACUC). All 
procedures of this study followed the CCNY IACUC and the USDA Animal Welfare Act. 
Treatment to prevent or assuage pain, including the administration of analgesics or 
recommendation for euthanasia was the responsibility of the veterinary staff in consultation with 
the principal investigator and study coordinator. In the event of toxicity, the decision to proceed 
with treatment or euthanize was made by the veterinary staff. Mice were randomly assigned to 
dose treatment group, or assigned based on body weight, sex, and tumor size where applicable.   
 
5.2.2 Xenograft  
Naïve male and female NOD.CB17-Prkdc SCID/J mice received 5x106 tumor cells via 
subcutaneous injection. Exponentially growing human clear cell renal carcinoma Caki-1 cells were 
suspended at a 1:1 ratio in 50 μL phosphate-buffered saline (PBS; pH 7.4) plus 50 μL of MMatrigel 
(BD Biosciences) were injected subcutaneously on both the left and right flanks. Within two 
weeks, the cells grew into a solid tumor, the diameter of which was measured twice a week using 
an electronic digital caliper. Tumor volume (TV) was calculated according to the empirical 
equation TV = (a)(b2) x π/6 where a = longest dimension; b = largest dimension orthogonal to a. 
The median volumes for each group were normalized to the initial tumor volume to determine the 
relative tumor volume.  Xenograft mice were then used for pharmacokinetic, efficacy and 
pathology studies; treatment began once the tumors reached a volume of  t 93mm3, and throughout 
the studies the tumor burden was measured at least once a week. Based on weekly external digital 
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caliper measurements, tumor burden was determined for each mouse and averaged for each 
treatment. Sex-matched mice were randomized to treatment groups [Titanofin, Titanocref or 
vehicle control (Chapter 3); RANCE-1 or vehicle control (Chapter 4)] based on their starting tumor 
burden to ensure equivalent distribution between the three groups. 
 
5.2.3 Test and control articles.  
5.2.3.1 Test articles 
Titanocref  (MW: 807.1g/mol) and Titanofin (MW: 660.1g/mol) (Chapter 3) and Ru-Au 
RANCE-1 (MW: 1291.4g/mol) (Chapter 4) were synthesized in the Contel Laboratory at Brooklyn 
College, CUNY as previously reported 2–4. The purity of the compounds was greater than 99%. 
Data on handling and disposal instructions along with any available safety information were 
provided by the Contel Laboratory and approved by the CCNY laboratory animal study director.  
 
 
     
 
Chart 5.2. Structure of compounds studied in Chapters 3 (Titanocref and Titanofin) and 4 
(RANCE-1) in vivo. 
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5.2.3.2 Control articles 
The control agent was the vehicle (Veh.) solution of 0.5% Dimethyl sulfoxide (DMSO) 
99.5% (GC) (Sigma-Aldrich St. Louis, MO) and 99.5% normal saline (NS) (0.9% NaCl) (G-
Biosciences, St. Louis, MO). (Table 5.1) 
 
5.2.4 Route of administration 
All the compounds were administered by intraperitoneal (i.p.) injection. The location of 
the i.p. injection was alternated between the lower left and lower right abdomen. 
 
Table 5.1. Compound information 
 
 
5.2.5 Acute Toxicity and MTD Study Design  
22 naïve males and 22 naïve female NOD.CB17-Prkdc SCID/J mice were assigned to 
either the acute toxicity (Part A) or MTD study (Part B). The animals received dose formulations 
containing Titanocref, Titanofin, or RANCE-1 suspended in vehicle solution (0.5% DMSO + 
99.5% normal saline) at various dosages by i.p. injection (Part A), then six sub-acute doses spaced 
by 48h followed by a two-week recovery period (Part B).  The location of the i.p. injection was 
alternated between lower left and lower right abdomen.  
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Table 5.2. Detailed design of dose range finding study (A) Titanocref and Titanofin (Chapter 
3) (A) Titanocref and Titanofin (Chapter 3). (B) RANCE-1 (Chapter 4) 
   Dose range finding study (escalating dose design) 
    No. of animals  Dose 
 
Compound 
  
Female Male (mg/kg/48h) 
 
 
Ti
ta
no
cr
ef
 Cohort 1 2 2 10 
  Cohort 2 2 2 15 
  Cohort 3 2 2 20 
  Cohort 4 2 2 25 
 
Ti
ta
no
fin
 Cohort 5 2 2 30 
  cohort 6 2 2 35 
  Cohort 7 2 2 40 
  Cohort 8 2 2 45 
  Cohort 9 1 1 50 
Veh.    Cohort 10 2 2 0.5% DMSO + 99.5% NS* 
 
(A) RANCE-1 
  Dose range finding study (escalating dose design) 
   No. of animals  Dose 
Compound   Female Male (mg/kg/48h) 
 
R
A
N
C
E-
1 
Cohort 1 2 2 30 
 Cohort 2 2 2 35 
 Cohort 3 2 2 40 
 Cohort 4 2 2 45 
 Cohort 5 2 2 50 
Veh.  Cohort 6 2 2 0.5% DMSO + 99.5% NS* 
 
*Dose level was determined based on the result in consultation with drug trial pharmacologists. 
**NS = normal saline.  
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The MTD dose for this study was defined as the highest dose that tolerated without 
inducing significant debilitating side effects for the 24 days of the study. The starting dose for the 
dose range finding study was 15 mg/kg/48h, which was been selected based upon the findings of 
previous studies (Table 5.2). 
The dose range finding study (escalating dose design) was used to determine acute toxic 
dose and MTD. The following parameters and end points were evaluated in this study: mortality, 
clinical signs of distress, body weight; post mortem procedures included, gross examination of the 
i.p. cavity, liver, kidney, and spleen for each animal at the terminal necropsy. 
 
5.2.6 Pharmacokinetics  
The pharmacokinetics of Titanocref, Titanofin (Chapter 3), and RANCE-1 (Chapter 4) were 
investigated in a xenograft mouse model. Female (n=2/compound or control) and male 
(n=2/compound or control) NOD.CB17-Prkdc SCID/J mice bearing subcutaneous Caki-1 tumors 
(t 93mm3 in volume at start of trial) (Table 5.3). Following a single injection of Titanocref 
(5mg/kg),Titanofin (10mg/kg), RANCE-1 (10mg/kg), or vehicle control [40μl (0.5% DMSO +  
99.5%  normal saline)], mice were gently anesthetized by isoflurane, and 200 μL of blood was 
collected from the submandibular vein over the course of 72h (at 1h, 2h, 6h, 12h,  24h, 48h, and 
72h post-infection)  into blood collection tubes coated with sodium heparin and mixed briefly by 
gentle inversion three to four times, then kept on ice. Within 1 hour after collection, whole blood 
was centrifuged for 10 minutes at 4000 rpm at 4 oC to separate the plasma, it was then stored at − 
80 oC.  
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Table 5.3. Design of pharmacokinetic study  
 
(The samples were then sent for pharmacokinetic analysis were performed by the Laboratory of 
Swayam Prabha, at the University of Minnesota’s Department of Experimental and Clinical 
Pharmacology). 
 
Gold and titanium content was determined using inductively coupled plasma mass 
spectrometry (ICP-MS). Standards were prepared in untreated mouse plasma prepared identically 
to that of treated animals. In brief, 50μl of plasma was transferred into a glass vial and 1ml of 
concentrated acid mix (comprising of 75% of 16 N nitric acid and 25% of 12 N hydrochloric acid) 
was added. The mixture was heated at 90°C for 5 hours. After cooling, the samples were diluted 
with water, 40 ppb of Indium internal standard was added, and then samples were analyzed in a 
Thermo Scientific XSERIES 2 ICP-MS with ESI PC3 Peltier cooled spray chamber with SC-FAST 
injection loop and SC-4 autosampler. All the elements were analyzed using He/H2 collision-
reaction mode. Plasma from control mice was spiked with the test compounds to determine the 
extraction efficiency of gold and titanium.  
For measurement of metal content in organs (liver, kidney, and tumor), tissues were 
harvested, weighed, and transferred into glass vials. One ml of water was added to each sample 
and subjected to ultrasonic tissue disruption at 15W power for 1 minute. The tissue homogenates 
were frozen at -80°C for 2 hours and lyophilized. The lyophilized product was heated at 90°C with 
the concentrated acid mix (described above) for 5 hours, cooled, diluted with water and analyzed 
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for titanium and gold by ICP-MS. Pharmacokinetic estimates were obtained from the plasma 
concentration–time profiles by non-compartmental analysis. 
 
5.2.7 Pharmacokinetic parameters 
The pharmacokinetic parameters quantified were the maximum plasma drug concentration 
(Cmax), the time to reach Cmax (Tmax), the area under the plasma concentration–time curve from 0 
h to last measurable concentration (AUClast), elimination rate constant (ke), plasma half-life (t1/2), 
apparent total clearance of the drug from plasma (Cl/F), and apparent volume of distribution 
(Vd/F). Pharmacokinetic parameters were obtained from the plasma concentration–time profiles 
by noncompartmental analysis using Phoenix WinNonlin 6.4 version 6.4 (Pharsight Corporation, 
Mountain View, CA). All the measurements were normalized to blood and tissue samples from 
Veh. treated mice. 
 
5.2.8 Termination 
 5.2.8.1 Unscheduled sacrifices and deaths 
Animals exhibiting signs of acute pain or distress, which were unable to eat, walk, or groom 
normally, or were moribund, or exhibited other signs of severe systemic toxicity were euthanized 
immediately. Animals found dead were refrigerated and necropsied. Animals sacrificed at an 
unscheduled point were weighed and euthanized followed by a gross necropsy. 
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5.2.9 Scheduled sacrifice 
5.2.9.1 Dose range finding study.  
The endpoint of Part A was death because of acute toxic effects at some point during the 
six rounds of doses of the test compound spaced by 48h. This was followed by a gross necropsy. 
For Part B, following 6 doses spaced by 48h and a two-week recovery period, blood was collected 
from each surviving animal; then all surviving animals were euthanized, tissues were collected, 
and a gross necropsy was performed. 
 
5.2.9.2 Efficacy and pathology study.  
The preclinical experimental endpoint is to determine therapeutic responses to drugs. In 
this investigation, a reduction in tumor growth after seven doses within a 21-day period was used 
as a study end-point. At trial endpoint, mice were sacrificed, and tissue and blood were collected.  
 
5.2.10 Tumor analysis 
Mice were anesthetized, followed by heart perfusion using 10 ml of 1x PBS, then 10 ml 
4% Paraformaldehyde Solution (Affymetrix, In., Santa Clara, CA). The tumors, liver, and spleen 
of the mice were collected. The diameter of the tumors was measured once weekly, and after 
excision from the euthanized mice using an electronic digital caliper, the tumor volume (TV) was 
calculated according to the equation TV = (a)(b 2) × π/6 where a = longest dimension; b = largest 
dimension orthogonal to a.  
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5.2.11 Preparation of samples for pathology 
The clinical pathology core facility at Memorial Sloan Kettering Cancer Center (New York, US) 
carried out the histology, clinical chemistry and complete blood count analysis of mice treated 
with Titanofin, Titanocref, RANCE-1, or vehicle control.  
 
5.2.12 Preparation of histological samples and immunohistochemistry 
Tissues were prepared by embedding in OCT (Thermo Fisher Scientific, Waltham, MA ) 
followed by freezing at −80°C. Vessel leakiness was evaluated following tail-vein injection of 100 
μL of Dextran Texas Red (Invitrogen). Vessel integrity was assessed after tail-vein injection of 50 
μL of lectin labelled with FITC (Vector Labs, Burlingame, CA). The Dextran and Lectin labeling 
was visualized using a fluorescent microscope at 20X magnification (CCNY). Apoptotic cells were 
visualized using an anti-rabbit cleaved caspase 3 primary antibody (Cell Signaling Technology, 
Danvers, MA) and an goat-anti-rabbit Alexa Fluor 594 secondary antibody (Cell Signaling 
Technology); proliferating cells were visualized using an anti-mouse Ki67 primary antibody (Cell 
Signaling Technology) and an goat-anti-mouse Alexa Fluor 488 secondary antibody (Cell 
Signaling Technology); DAPI containing ProLong Gold Antifade Mounting Medium (Cell 
Signaling Technology) was used to visualize the nuclei and mount the slide.  
 
5.2.13 Analysis of cell proliferation, apoptosis, angiogenic coverage. 
For all histological analyses, tumors from treated mice were compared to those of the 
vehicle control of the intervention trial. Samples from four mice per treatment group were 
analyzed.  Stained samples were imaged at 20X magnification (ZEISS LSM 700); samples injected 
with Dextran and Lectin were imaged using a fluorescent microscope at 20X magnification (ZEISS 
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Axioplan-2). Cell proliferation and apoptosis were quantified one channel at a time using ImageJ 
and were calculated as the percentage of Ki67 positive or cleaved caspase 3 positive cells per DAPI 
positive cells per field of view. Vessel area as defined by lectin-covered area and vessel leakiness 
was determined by dextran-covered area and was determined using ImageJ imaging software 
(NIH, open access software). All the image analyses were performed treatment-blind. 
 
5.2.14 Analysis of changes in protein expression 
Whole tumors were extracted at the trial endpoint and lysed. Before application to the array, 
protein concentration was determined by BCA. Then 150 µg of lysate was incubated for 24 h with the 
Proteome Profiler Human XL Oncology Array (ARY026, R&D Systems) and Human Cell Stress Array 
(ARY018, R&D Systems). The relative expression levels of the proteases were determined according 
to the manufacturer’s protocol, and signal intensities were compared using HLImage++ software.  
 
This section contains methods from four publications of which I was the contributing author 
for all the biological assay 3,7–9 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
We have identified three potent cytotoxic and selective agents against metastatic renal 
cancer cell line Caki-1in vivo and in a xenograft mouse model of ccRCC. 
 
Figure 6.1. Visual summary of in vitro trend of Titanocref, Titanofin and RANCE-1. After 
incubation with the IC20 concentration of the respective compound, in all instances there is a 
significant reduction in proliferation and angiogenesis and a marked increase in apoptosis (see 
Chapter 3 and 4 for details).  
 The initial assessment of a large series of gold based heterobimetallic titanium-gold and 
ruthenium-gold compounds and the preliminary investigation of anticancer-profile beyond 
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cytotoxicity led to the selection of Titanocref, Titanofin and RANCE-1 for further studies. Prior 
to the selection of these three compounds, the initial screen revealed two important patterns. First, 
that the compounds were most effective against urogenital cancer cell lines (kidney and prostate 
cancer). Second, that heterobimetallic complexes outperformed their individual monometallic 
moieties or metal matched pairs (i.e. 1:1, gold moiety + titanium moiety or gold moiety + 
ruthenium moiety), which suggested that indeed there might be synergistic potentiation of each 
metal moiety when mounted onto a single molecule. This initial work (introduced in Chapter 2) 
has been published and strongly suggests that our gold-based heterobimetallic compounds have 
potential medicinal relevance.  
We then evaluated Titanocref, Titanofin and, RANCE-1 in vitro, and in vivo in a mouse 
model to determine their efficacy and their mechanism of action. We observed that the all three 
compounds at subtoxic doses inhibited proteolytic factors and growth factors key to angiogenesis 
and metastasis in vitro and in vivo.  
Though all three compounds were cytotoxic in vitro,in vivo, Titanocref and Titanofin 
appear to retain their cytotoxic profile wherein they induced apoptotic cell death which lead to a 
drastic decrease in tumor size (Figures 6.2, 6.3), while RANCE-1 exhibited cytostatic properties 
and inhibited tumor growth by curbing cell proliferation without increasing the rate of apoptosis 
(Figure 6.4). The rate of increase in apoptosis and the concurrent decrease in proliferation in 
response to Titanocref and Titanofin can explain why we observe such significant shrinkage of 
tumor mass: while fewer cells are dividing twice as many cells are dying. 
The staticity in tumor size of mice treated with RANCE-1 does not void RANCE-1 of 
clinical potential because owing to its lack of systemic toxicity, and its inhibition of many key 
tumorigenic growth factors, RANCE-1 might be well suited for combination therapy.  
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Figure 6.2. In response to treatment with Titanocref the tumor burden decreased by 51% from its 
volume at the beginning of the trial, the number of apoptotic cells increased by 270%, the number 
of proliferating cells dropped by 47% while angiogenesis decreased by 28%.  
 
Figure 6.3. In response to treatment with Titanofin the tumor burden decreased by 60% from its 
volume at the beginning of the trial, the number of apoptotic cells increased by 312%, the number 
of proliferating cells dropped by 38% while angiogenesis decreased by 54%.  
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Figure 6.4. In response to treatment with RANCE-1 the tumor burden did not change from its 
volume at the beginning of the trial, though re observed the tumor became less dense upon 
histological analysis. This compound seems to possess chemo static properties wherein it inhibits 
growth (100%). 
Also, in a proteomic profile study, aimed at detecting changes in expression levels of 
proteins of oncological interest in response to treatment, it appeared that RANCE-1 lead to a 
significant decrease in the production of five growth factors, which was not the case for Titanocref 
or Titanofin.  
From the studies presented in this thesis we can conclude that ruthenium(II)-gold(I) 
compounds display a synergistic effect for biological effects and mode of action due to the 
combination of both metallic fragments. For titanocene-based heterometallic complexes it seems 
that the mode of action is mainly due to the second metal (gold). However, in these heterometallic 
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complexes the titanocene fragments seem to have a non-negligible role in the modification of some 
of the chemicophysical properties of the compounds with remarkable improvement of their 
pharmacological profile. Assessing the effects of each individual metal in the mode of action is not 
an easy task and more in-depth follow-up studies will be necessary in the future. It can be asserted 
that the addition of a second metal to the monometallic Ti compounds does significantly improve 
efficacy, and the addition of a second metal to the monometallic Au compounds also improves 
anticancer properties. 
Titanocref, Titanofin, and RANCE-1 caused no changes in tissue or blood in the mouse 
model that would be indicative of serious side effects in humans. Though preclinical animal data 
is not an absolute predictor of human response, the results obtained here are encouraging, 
especially given the bare landscape of viable non-toxic agents.  
 
6.2 Future directions 
The results of this body of work gave rise to questions that have yet to be addressed and 
will be the object of the next experimental venture on this project.  
As previously discussed, the tumor microenvironment’s diverse and unique cellular 
composition plays a key role in the malignant progression of cancer. This investigation did not 
include a determination of the composition of the cellular ecosystem of the tumor 
microenvironment. Some of the drastic changes in protein levels were suggested to result from the 
presence of immune cells (such as the increased immune marker presence or factors associated 
with increased immune presence) or from other cell types in the tumor microenvironment. Such 
information could be obtained through detailed flow cytometric analysis of tumor samples and/or 
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through histological analysis using immunological markers.  These experiments will indicate if 
there are any differences in intratumoral cell populations in response to treatment with a given 
compound, as compared to the vehicle treated mice. There are however some considerations to be 
given to the meaning of such results given the animal model used is immunocompromised and 
thus will have a tumor microenvironment populated in a manner drastically dissimilar to that of an 
immunocompetent individual. While much is learned from preclinical trials carried out in 
immunocompromised mice, this model is rather artificial and, the lack of immunocompetence is 
an important consideration especially when our observations indicate immune markers are chiefly 
modulated by our three compounds. Also, the fact that tumors are implanted subcutaneously 
creates another dimension of artificiality because in this model the tumor does not interact with 
the kidney tissue’s microenvironment removing which is a signaling rich variable. Therefore, it 
would be informative to test the compound in a spontaneous ccRCC mouse model that is 
immunocompetent. 
The proteome profiling data was informative but failed to capture more profound changes 
that might be induced at the gene level in response to treatment. Much could be learned from 
investigating gene expression changes in cells responsive to our compound (e.g. Caki-1 cells) in 
comparison to non-responsive cells (e.g. MDA-MB-231 triple negative breast cancer cell line). 
Gene expression analysis in combination with the protein profile will help to generate more refined 
picture of the compounds' mechanisms of action.  
Finally, to advance the compounds’ clinical relevance, a univariate genomic analysis will 
be performed on wide array of cancerous cells from different tissue types to identify and prioritize 
predictive genomic biomarkers from drug response data by analysis of several hundreds of 
genomic features clustered by cancer subtypes and tissue classification. This work will be 
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performed by a commercial service. The genomic attributes that will be analyzed include mRNA 
over expression, amplifications, deletions, coding and non-coding mutations, and gain/loss of 
function lesion categories.  
The mechanistic understanding of the mode of action of the compounds will help the 
synthetic research group in the optimization of lead drugs.  
There is still lot of progress to be made in search for a cure for ccRCC. With the work 
presented in this thesis, the Contel laboratory is contributing to that search, and we believe our 
findings hold great potential for further preclinical exploration and potential clinical applications.  
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